<SEC-DOCUMENT>0001213900-22-025580.txt : 20220511
<SEC-HEADER>0001213900-22-025580.hdr.sgml : 20220511
<ACCEPTANCE-DATETIME>20220511160557
ACCESSION NUMBER:		0001213900-22-025580
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220511
DATE AS OF CHANGE:		20220511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TFF Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001733413
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824344737
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39102
		FILM NUMBER:		22913683

	BUSINESS ADDRESS:	
		STREET 1:		2600 VIA FORTUNA, SUITE 360
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78746
		BUSINESS PHONE:		737-802-1973

	MAIL ADDRESS:	
		STREET 1:		2600 VIA FORTUNA, SUITE 360
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78746
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0322_tffpharma.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 05:01:33 UTC 2022 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pf0="http://fasb.org/srt/2022" xmlns:tffp="http://tffp.com/20220331" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric> QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Quarterly Period Ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">March 31, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-39102</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>TFF PHARMACEUTICALS, Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="vertical-align: bottom; width: 2%; text-align: center; font-size: 10pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>82-4344737</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(State or other jurisdiction of</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">incorporation or organization)</p></td> <td style="text-align: center; font-size: 10pt">&#160;</td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(I.R.S. Employer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Identification no.)</p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">1751 River Run</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Suite 400</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Fort Worth</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">76107</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, including
zip code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(817)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">438-6168</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name, former address and former fiscal
year, if changed since last report)</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Act:</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock: Par value $0.001</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TFFP</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Global Market</span></td></tr> </table><div>
</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746; &#160;No&#160;&#9744;</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company (as defined in Rule 12b-2 of the Act):</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 16%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 31%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 20%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="padding-right: 0.8pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt">&#160;</td> <td style="padding-right: 0.8pt; text-align: center">&#160;</td> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="padding-right: 0.8pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The number of shares of
the registrant&#8217;s common stock outstanding as of May&#160;9, 2022 was <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">25,373,818</ix:nonFraction>.</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 81%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART I - FINANCIAL INFORMATION</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></a></td>
    <td>&#160;</td>
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated
    Balance Sheets</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited Condensed Consolidated
    Statements of Operations and Comprehensive Loss</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited Condensed Consolidated
    Statements of Stockholders' Equity</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited Condensed Consolidated
    Statements of Cash Flows</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Unaudited Condensed
    Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></a></td>
    <td>&#160;</td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion
    and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></a></td>
    <td>&#160;</td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative
    Disclosures about Market Risk</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">16<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></a></td>
    <td>&#160;</td>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">16</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II - OTHER INFORMATION</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">17</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></a></td>
    <td>&#160;</td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_013">Item 5.</a></td>
    <td>&#160;</td>
    <td><a href="#a_013">Other Information</a></td>
    <td>&#160;</td>
    <td style="text-align: center">17</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></a></td>
    <td>&#160;</td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">18</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">26,414,170</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">33,794,672</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Receivable due from collaboration agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tffp:ReceivableDueFromCollaborationAgreement" scale="0" unitRef="usd">1,776,583</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tffp:ReceivableDueFromCollaborationAgreement" scale="0" unitRef="usd">1,628,703</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development tax incentive receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tffp:ResearchAndDevelopmentTaxIncentiveReceivable" scale="0" unitRef="usd">1,168,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tffp:ResearchAndDevelopmentTaxIncentiveReceivable" scale="0" unitRef="usd">966,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid assets and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">2,164,451</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">2,447,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">31,524,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">38,837,951</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">2,258,738</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,859,860</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">33,782,772</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">40,697,811</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">2,028,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">1,493,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tffp:AccruedCompensationLiabilities" scale="0" sign="-" unitRef="usd">416,910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Deferred research grant revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">168,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,196,779</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">1,960,752</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Commitments and contingencies (see Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Common stock; $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">45,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">25,371,781</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">25,372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">25,372</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">105,256,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">104,078,968</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">1,687</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">48,921</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">73,694,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">65,318,360</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">31,585,993</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">38,737,059</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">33,782,772</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">40,697,811</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Grant revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">67,435</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">24,315</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,261,604</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,278,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">3,246,195</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">2,647,415</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">8,507,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">7,925,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">8,440,364</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">7,901,352</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">57,177</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">231,278</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd">7,185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd">15,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">64,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">246,777</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">8,376,002</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">7,654,575</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.33</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.33</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">25,371,781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">23,140,607</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">8,376,002</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">7,654,575</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:ForeignCurrencyTranslationAdjustments" scale="0" sign="-" unitRef="usd">47,234</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:ForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">37,958</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="0" sign="-" unitRef="usd">8,328,768</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="0" sign="-" unitRef="usd">7,692,533</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional <br/>
Paid in</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated <br/>
Other <br/>
Comprehensive</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total <br/>
Stockholders&#8217;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%">Balance, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,371,781</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">25,372</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">104,078,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">48,921</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">65,318,360</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">38,737,059</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">1,177,702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">1,177,702</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="tffp:ForeignCurrencyTranslationAdjustment" scale="0" unitRef="usd">47,234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:ForeignCurrencyTranslationAdjustment" scale="0" unitRef="usd">47,234</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">8,376,002</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">8,376,002</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance, March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,371,781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">25,372</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">105,256,670</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">1,687</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">73,694,362</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">31,585,993</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance, January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,534,874</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">22,535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">71,648,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">51,538</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">34,279,648</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">37,339,802</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">2,140,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">2,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">28,021,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">28,023,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for stock option exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockForStockOptionExercisesShares" scale="0" unitRef="shares">244,656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockForStockOptionExercises" scale="0" unitRef="usd">245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockForStockOptionExercises" scale="0" unitRef="usd">655,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockForStockOptionExercises" scale="0" unitRef="usd">655,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#160;Issuance of common stock for warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" scale="0" unitRef="shares">444,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" scale="0" unitRef="usd">444</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" scale="0" unitRef="usd">179,768</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" scale="0" unitRef="usd">180,212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">1,030,415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">1,030,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="tffp:ForeignCurrencyTranslationAdjustment" scale="0" sign="-" unitRef="usd">37,958</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:ForeignCurrencyTranslationAdjustment" scale="0" sign="-" unitRef="usd">37,958</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">7,654,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">7,654,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance, March 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,364,281</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">25,364</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">101,535,068</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">89,496</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">41,934,223</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">59,536,713</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;Three Months&#160;Ended<br/> March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;Three Months&#160;Ended<br/> March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash flows from operating activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">8,376,002</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">7,654,575</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Adjustment to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensation" scale="0" unitRef="usd">1,177,702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensation" scale="0" unitRef="usd">1,030,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">77,028</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">1,495</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left">Receivable due from collaboration agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:ReceivableDueFromCollaborationsAgreement" scale="0" unitRef="usd">147,880</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left">Research and development tax incentive receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:ResearchAndDevelopmentTaxIncentiveReceivables" scale="0" unitRef="usd">108,097</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left">Prepaid assets and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">237,646</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">534,612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">192,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">521,114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="0" sign="-" unitRef="usd">416,910</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:IncreaseDecreaseDeferredResearchGrantRevenue" scale="0" sign="-" unitRef="usd">118,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:IncreaseDecreaseDeferredResearchGrantRevenue" scale="0" unitRef="usd">24,315</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">7,246,302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">5,591,254</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">137,231</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">476,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">137,231</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">476,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Net proceeds from issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:ProceedsFromIssuanceOfCommonStockValue" scale="0" unitRef="usd">28,023,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from issuance of common stock for stock option exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises" scale="0" sign="-" unitRef="usd">655,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of common stock for warrant exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" scale="0" sign="-" unitRef="usd">180,212</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">28,859,029</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent" scale="0" unitRef="usd">3,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent" scale="0" sign="-" unitRef="usd">37,330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">7,380,502</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">22,754,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">33,794,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">35,300,805</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">26,414,170</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">58,055,122</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Purchases of equipment included in accounts payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd">338,674</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Cashless exercise of warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:CashlessExerciseOfWarrants" scale="0" unitRef="usd">416</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For The Three Months Ended March 31, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 1 &#8211; ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TFF Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated in the State of Delaware on January 24, 2018. The Company&#8217;s initial focus is on the development of inhaled dry
powder drugs to enhance the treatment of pulmonary diseases and conditions. In December 2019, the Company established a wholly-owned Australian
subsidiary, TFF Pharmaceuticals Australia Pty Ltd (&#8220;TFF Australia&#8221;), in order to conduct clinical research. TFF Pharmaceuticals,
Inc., along with TFF Australia, are collectively referred to as the &#8220;Company&#8221;. The Company is in the development stage and
is devoting substantially all of its efforts toward technology research and development and the human clinical trials of its initial product
candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_3" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">COVID-19</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this report, the COVID-19 pandemic
has had a relatively insignificant impact on the Company&#8217;s operations and has not caused the Company to forego, abandon or materially
delay any proposed activities. While the Company believes it has been able to effectively manage the disruption caused by the COVID-19
pandemic to date, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted
or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak
of COVID-19.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LiquidityAndManagementsPlansTextBlock-c0_cont_1" escape="true" name="tffp:LiquidityAndManagementsPlansTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 2 - LIQUIDITY AND MANAGEMENT&#8217;S PLANS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LiquidityAndManagementsPlansTextBlock-c0_cont_2" id="_LiquidityAndManagementsPlansTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had cash and
cash equivalents of approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tffp:CashAndCashEquivalents" scale="0" unitRef="usd">26,414,000</ix:nonFraction> and a working capital of approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SurplusNotes" scale="0" unitRef="usd">29,327,000</ix:nonFraction>. The Company has not generated revenues
from commercial operations since inception and has incurred recurring operating losses. The Company expects to continue incurring losses
for the foreseeable future and may need to raise additional capital to continue the pursuit of its product development.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LiquidityAndManagementsPlansTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to further increase its research
and development activities, which will increase the amount of cash utilized subsequent to March 31, 2022. Specifically, the Company expects
increased spending on research and development activities and higher payroll expenses as it increases its professional and scientific
staff and continues to prepare for anticipated manufacturing activities. If the Company encounters unforeseen delays or expenses, it has
the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and cash equivalents
will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of
issuance of these condensed consolidated financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;)
for interim financial statements and with Form 10-Q&#160;and Article&#160;10 of Regulation S-X&#160;of the United States Securities and
Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial
statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain
all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March&#160;31,
2022 and the results of operations, changes in stockholders&#8217; equity and cash flows for the periods presented. The results of operations
for the three months ended March&#160;31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any
future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December
31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and transactions
have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation id="_ForeignCurrencyDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of TFF Australia, the Company&#8217;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars
using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using the average exchange
rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities is included as a separate
component of stockholders&#8217; equity in accumulated other comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For The Three Months Ended March 31, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its operating accounts in
financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&#8217;s cash is maintained
in checking accounts and money market funds with maturities of less than three months when purchased, which are readily convertible to
known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value. As of March 31, 2022
and December 31, 2021, the Company had cash in Australia of AUD$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="aud">308,824</ix:nonFraction> (US$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="usd">231,447</ix:nonFraction>) and AUD$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="aud">831,984</ix:nonFraction> (US$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="usd">604,944</ix:nonFraction>), respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into feasibility and material
transfer agreements (&#8220;Feasibility Agreements&#8221;) with third parties that provide the Company with funds in return for certain
research and development activities. Revenue from the Feasibility Agreements is recognized in the period during which the related qualifying
services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility Agreements have been met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Feasibility Agreements are on a best-effort
basis and do not require scientific achievement as a performance obligation. All fees received under the Feasibility Agreements are non-refundable.
The costs associated with the Feasibility Agreements are expensed as incurred and are reflected as a component of research and development
expense in the accompanying condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funds received from the Feasibility Agreements
are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility Agreements
are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of
providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying
services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company
records a grant receivable. During the three months ended March 31, 2022 and 2021, the Company rendered the related services and recognized
revenue and research and development expenses of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="0" unitRef="usd">67,435</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="0" unitRef="usd">24,315</ix:nonFraction>, respectively. As of March 31, 2022 and December 31, 2021, the Company
had receivables due related to Feasibility Agreements of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">55,435</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">11,996</ix:nonFraction>, respectively, which is included in prepaid assets and other
current assets in the accompanying condensed consolidated balance sheets, and deferred grant revenue of approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">168,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">50,000</ix:nonFraction>,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_CollaborativeArrangementsPolicyTextBlock-c0_cont_1" escape="true" name="tffp:CollaborativeArrangementsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Collaborative Arrangements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation continuedAt="_CollaborativeArrangementsPolicyTextBlock-c0_cont_2" id="_CollaborativeArrangementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the nature and contractual
terms of arrangements and assesses whether an arrangement involves a joint operating activity pursuant to which the Company is an active
participant and is exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company is an
active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts
for such arrangement as a collaborative arrangement under Accounting Standards Codification (&#8220;ASC&#8221;) 808, <i>Collaborative
Arrangements</i>. ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition
matters subjected to other authoritative guidance, in certain cases by analogy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation continuedAt="_CollaborativeArrangementsPolicyTextBlock-c0_cont_3" id="_CollaborativeArrangementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For arrangements determined to be within the scope
of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments
received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. This reflects
the joint risk sharing nature of these activities within a collaborative arrangement. The Company classifies payments owed or receivables
recorded as other current liabilities or prepaid expenses and other current assets, respectively, in the Company&#8217;s consolidated
balance sheets. Please refer to Note 5, &#8220;Joint Development Agreement&#8221; for additional details regarding the Company&#8217;s
joint development agreement (&#8220;JDA&#8221;) with Augmenta Bioworks, Inc. (&#8220;Augmenta&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation id="_CollaborativeArrangementsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If payments from the collaborative partner to
the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for
those payments within the scope of ASC 606, <i>Revenue from Contracts with Customers</i>. The Company does not currently have any collaborative
arrangements that are accounted for under ASC 606.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For The Three Months Ended March 31, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentTaxIncentivePolicyTextBlock-c0_cont_1" escape="true" name="tffp:ResearchAndDevelopmentTaxIncentivePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Tax Incentive</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="_ResearchAndDevelopmentTaxIncentivePolicyTextBlock-c0_cont_2" id="_ResearchAndDevelopmentTaxIncentivePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to obtain a cash refund
from the Australian Taxation Office for eligible research and development expenditures under the Australian R&amp;D Tax Incentive Program
(the &#8220;Australian Tax Incentive&#8221;). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that
the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. During the
year ended December 31, 2021, the Company received its first cash refund under the Australian Tax Incentive, which was for expenditures
incurred during 2020. Therefore, the Company recorded amounts received, or that it expects to receive, for expenditures incurred during
2020 as other income in the condensed consolidated statements of operations during the period ended March 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_ResearchAndDevelopmentTaxIncentivePolicyTextBlock-c0_cont_3" id="_ResearchAndDevelopmentTaxIncentivePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company has determined that it has reasonable
assurance that it will receive the cash refund for eligible research and development expenditures, beginning with expenditures incurred
during the year ended December 31, 2021, the Company records the Australian Tax Incentive as a reduction to research and development expenses
as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company&#8217;s ongoing tax status,
or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information
at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="tffp:ResearchAndDevelopmentTaxPercentage" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="tffp:ResearchAndDevelopmentTaxPercentage" scale="-2" unitRef="pure">43.5</ix:nonFraction></ix:nonFraction>% for
the three months ended March 31, 2022 and 2021. In addition, the Company is also eligible to receive amounts from the United States Internal
Revenue Service (&#8220;IRS&#8221;) related to research and development tax credits for expenditures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation id="_ResearchAndDevelopmentTaxIncentivePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research and development incentive receivable
represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development
tax incentive receivable of $<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd">1,168,830</ix:nonFraction> and $<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd">966,646</ix:nonFraction> as of March 31, 2022 and December 31, 2021, respectively, in the condensed consolidated
balance sheets. The Company has recorded other income of $<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">57,177</ix:nonFraction> and $<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">231,278</ix:nonFraction>, in the condensed consolidated statements of operations
for the three months ended March 31, 2022 and 2021, respectively, related to refundable IRS and Australian research and development incentive
program payments for expenditures incurred during 2020. The Company recorded a reduction to research and development expenses of $<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">108,098</ix:nonFraction>
during the three months ended March 31, 2022 for expenditures incurred during 2022 and $<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">0</ix:nonFraction> during the three months ended March 31, 2021
for expenditures incurred during 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basic and Diluted Earnings per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed
by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined
using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive
securities are anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2022 and
2021, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted
net loss per common share because inclusion thereof would be anti-dilutive:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,976,090</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,375,839</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c37" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">389,233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c38" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">389,233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">3,365,323</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,765,072</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>




</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>On
an as-converted basis</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial
statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation and
warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Accounting Standards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the three months ended March 31, 2022 that are of
significance or potential significance to the Company.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For The Three Months Ended March 31, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 4 - COMMITMENTS AND CONTINGENCIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2018, the Company entered into a lease
agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018 and expires on October 31, 2022, as amended.
The lease has an additional one-year option for renewal, and the base rent is $<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="0" unitRef="usd">36,000</ix:nonFraction> per year. The Company has determined that the lease
agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The Company rents another
office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease as well. Short-term lease
expense for the three months ended March 31, 2022 and 2021 was approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">21,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">15,000</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate future minimum lease payments required
under the operating leases are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -8.1pt; padding-left: 8.1pt">Year Ending December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="0" unitRef="usd">21,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Legal</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may be involved, from time to time,
in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes
and are not predictable with assurance. While management believes that such matters are currently insignificant, matters arising in the
ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its
business and financial condition. To the Company&#8217;s knowledge, neither the Company nor any of its properties are subject to any pending
legal proceedings.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_1" escape="true" name="tffp:LicenseAndAgreementDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 5 - LICENSE AND AGREEMENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_2" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2015, the University of Texas at Austin
(&#8220;UT&#8221;) granted to the Company&#8217;s former parent, LTI, an exclusive worldwide, royalty bearing license to the patent rights
for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide, royalty bearing license
to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all of its interest to the TFF platform,
including the patent license agreement with UT, at which time the Company paid UT an assignment fee of $<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" unitRef="usd">100,000</ix:nonFraction> in accordance with the
patent license agreement. In November 2018, the Company and UT entered into an amendment to the patent license agreement pursuant to which,
among other things, the Company&#8217;s exclusive patent rights to the TFF platform were expanded to all fields of use. The patent license
agreement requires the Company to pay royalties and milestone payments and conform to a variety of covenants and agreements, and in the
event of the Company&#8217;s breach of agreement, UT may elect to terminate the agreement. For the period ended December 31, 2018, the
Company did not achieve any of the milestones and, as such, was not required to make any milestone payments. During the ended December
31, 2019, the Company achieved one milestone by gaining IND approval on first indication of a licensed product on November 24, 2019 and
the Company satisfied the milestone payment of $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="tffp:MilestoneFee" scale="0" unitRef="usd">50,000</ix:nonFraction> and issuance of shares in accordance with the agreement. As of the date of these
condensed consolidated financial statements, the Company is in compliance with the patent license agreement as all required amounts have
been paid in accordance with the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_3" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2018, the Company entered into a master
services agreement and associated individual study contracts with ITR Canada, Inc. (&#8220;ITR&#8221;) to provide initial contract pre-clinical
research and development services for the Company&#8217;s drug product candidates. In January 2019, <ix:nonNumeric contextRef="c42" name="tffp:AgreementTremDescription">the Company cancelled all of the individual
study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba
Strategy Point Innovations (&#8220;SPI&#8221;)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits.</ix:nonNumeric> The services related to the contract with
SPI were sub-contracted to ITR and others under substantially the same terms as the initial contract with ITR. Desire Ventures, LLC facilitates
the invoicing for the various affiliates. The accounts payable due in connection with this agreement was approximately $<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">472,000</ix:nonFraction> and $<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">0</ix:nonFraction>
as of March 31, 2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded
research and development costs of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">1,585,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">1,812,000</ix:nonFraction>, respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_4" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2019, the Company entered into a master
services agreement with Irisys, LLC to provide contract manufacturing services for one of the Company&#8217;s drug product candidates,
Voriconazole. The accounts payable due in connection with this agreement was approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">35,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">21,000</ix:nonFraction> as of March 31, 2022 and
December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">446,000</ix:nonFraction> and $<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">494,000</ix:nonFraction>, respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For The Three Months Ended March 31, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 5 - LICENSE AND AGREEMENTS, continued</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_5" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, TFF Australia entered into a
master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) <ix:nonNumeric contextRef="c47" name="tffp:AgreementDescription">to provide initial
contract clinical research and development services for the Company&#8217;s drug product candidates. The accounts payable due in connection
with this agreement was approximately AUD$179,000 (US$134,000) and AUD$138,000 (US$100,000) as of March 31, 2022 and December 31, 2021,
respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
AUD$347,000 (US$251,000) and AUD$705,000 (US$545,000), respectively, pertaining to this agreement.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_6" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2020, TFF Australia entered into an amended
clinical trial research agreement with Nucleus Network Pty Ltd. <ix:nonNumeric contextRef="c48" name="tffp:AgreementDescription">to provide a Phase I study of one of the Company&#8217;s drug candidates,
Tacrolimus. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of March 31,
2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $0 and AUD$244,000 (US$188,000), respectively, pertaining to this agreement.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_7" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2020, the Company entered into a
licensing and collaboration agreement with UNION therapeutics A/S in which UNION acquired an option to obtain a worldwide exclusive license
for the TFF technology in combination with niclosamide. Pursuant to the terms of the license agreement, UNION can exercise its option
to obtain the license within 45 days after the complete data has been received by UNION from investigator-initiated trials. Upon exercise
of the option, UNION shall be responsible to pay all expenses incurred in the development of any licensed product. The Company will be
eligible to receive milestone payments upon the achievement of certain milestones in the development the licensed products, based on completion
of clinical trials, pre-marketing approvals and/or the receipt of at least $<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="tffp:PremarketingApprovals" scale="0" unitRef="usd">25,000,000</ix:nonFraction> of grant funding. The Company will receive a single-digit
tiered royalty on net sales. The Company will also be entitled to receive sales-related milestone payments based on the commercial success
of the licensed products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_8" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2021, the Company entered into a master
services agreement with Experic to provide contract manufacturing services for one of the Company&#8217;s drug product candidates, Voriconazole.
The accounts payable due in connection with this agreement was approximately $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">87,000</ix:nonFraction> and $<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">313,000</ix:nonFraction> as of March 31, 2022 and December 31,
2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
$<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">318,000</ix:nonFraction> and $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">196,000</ix:nonFraction>, respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_9" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2022, the Company entered into a Letter
of Intent with Synteract, Inc. to provide contract research and development services while negotiating a Master Services Agreement for
one of the Company&#8217;s drug product candidates, Voriconazole. The accounts payable due in connection with this agreement was approximately
$<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" unitRef="usd">14,000</ix:nonFraction> as of March 31, 2022. During the three months ended March 31, 2022, the Company recorded research and development costs of approximately
$<ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">226,000</ix:nonFraction> pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_10" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Joint Development Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_11" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2020, the Company and Augmenta
entered into the JDA pursuant to which the Company and Augmenta (collectively the &#8220;Parties&#8221;) agreed to work jointly to develop
one or more novel commercial products incorporating Augmenta&#8217;s human derived monoclonal antibody for the treatment of patients with
COVID-19 and the Company&#8217;s patented Thin Film Freezing technology platform. Each party retains full ownership over its existing
assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_12" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties will share development costs with
each party funding its fifty-percent-share at specified times. In the event that one of the Parties fails to make its pro rata share payment,
the other party may terminate the JDA. In lieu of terminating the JDA, the non-defaulting party may elect to continue the JDA by paying
the delinquent amount and each party&#8217;s pro rata share of the JDA will automatically adjust by the amount paid. In addition, in the
event Augmenta experiences a default on its required payment, Augmenta will have the one-time right to elect to require the Company to
purchase Augmenta&#8217;s interest in the JDA (&#8220;Put Right&#8221;) for a one-time fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:InterstFee" scale="0" unitRef="usd">500,000</ix:nonFraction>. Upon exercise of the Put Right
and payment by the Company, Augmenta will grant the Company an exclusive, worldwide, royalty-free, transferable, sublicensable license
to the Augmenta antibody and Augmenta&#8217;s rights to the property developed under the JDA. The Company has determined that the likelihood
of the Put Right being exercised to be remote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LicenseAndAgreementDisclosureTextBlock-c0_cont_13" id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JDA is within the scope of ASC 808 as the
Company and Augmenta are both active participants in the research and development activities and are exposed to significant risks and
rewards that are dependent on commercial success of the activities of the arrangement. The research and development activities are a unit
of account under the scope of ASC 808 and are not promises to a customer under the scope of ASC 606.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LicenseAndAgreementDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records its portion of the research
and development expenses as the related expenses are incurred. All payments received or amounts due from Augmenta for reimbursement of
shared costs are accounted for as an offset to research and development expense. During the three months ended March 31, 2022 and 2021,
the Company recorded research and development expenses of $<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">147,880</ix:nonFraction> and $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">76,200</ix:nonFraction>, respectively, and has recorded a receivable of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd">1,776,583</ix:nonFraction>
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd">1,628,703</ix:nonFraction> for reimbursement due from Augmenta as of March 31, 2022 and December 31, 2021, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For The Three Months Ended March 31, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 6 &#8211; STOCK BASED COMPENSATION</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2018, the Company&#8217;s board of
directors approved its 2018 Stock Incentive Plan (&#8220;2018 Plan&#8221;). The 2018 Plan provides for the grant of non-qualified stock
options and incentive stock options to purchase shares of the Company&#8217;s common stock, the grant of restricted and unrestricted share
awards and grant of restricted stock units. The Company initially reserved <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="tffp:ReservedShares" scale="0" unitRef="shares">1,630,000</ix:nonFraction> shares of its common stock under the 2018 Plan; however,
upon completion of the Company&#8217;s IPO the number of shares reserved for issuance under the 2018 Plan increased to <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares">3,284,480</ix:nonFraction>, representing
<ix:nonFraction contextRef="c59" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PercentageOfWeightedAverageCostInventory" scale="-2" unitRef="pure">15</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock calculated on a fully diluted basis upon the close of the IPO. All of the
Company&#8217;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the
Company&#8217;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible
to receive incentive awards under the 2018 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, the Company&#8217;s board of
directors approved its 2021 Stock Incentive Plan (&#8220;2021 Plan&#8221;), which was also approved by the stockholders of the Company
at the Company&#8217;s annual meeting of stockholders held on November 4, 2021. The 2021 Plan provides for the grant of non-qualified
stock options and incentive stock options to purchase shares of the Company&#8217;s common stock, the grant of restricted and unrestricted
share awards and grant of restricted stock units. The Company has <ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="tffp:ReservedShares" scale="0" unitRef="shares">4,200,000</ix:nonFraction> shares of its common stock reserved under the 2021 Plan. All
of the Company&#8217;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all
of the Company&#8217;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will
be eligible to receive incentive awards under the 2021 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the stock-based
compensation expense recorded in the Company&#8217;s results of operations during the three months ended March 31, 2022 and 2021 for stock
options and warrants:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three<br/> Months<br/> Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three<br/> Months<br/> Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensationExpenses" scale="0" unitRef="usd">205,809</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensationExpenses" scale="0" unitRef="usd">67,279</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensationExpenses" scale="0" unitRef="usd">971,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensationExpenses" scale="0" unitRef="usd">963,136</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensationExpenses" scale="0" unitRef="usd">1,177,702</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockBasedCompensationExpenses" scale="0" unitRef="usd">1,030,415</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, there was approximately
$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd">8,135,000</ix:nonFraction> of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected to
vest. This cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm">2.4</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records compensation expense for awards
with graded vesting using the straight-line method. The Company recognizes compensation expense over the requisite service period applicable
to each individual award, which generally equals the vesting term. The Company estimates the fair value of each option award using the
Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value stock options
using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite
service periods of the respective awards. The fair value of stock options issued was estimated using the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Three&#160;Months<br/> March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Weighted average exercise price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assumptions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">96</ix:nonFraction>%-<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">97</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.3</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<ix:nonFraction contextRef="c65" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.79</ix:nonFraction>%-<ix:nonFraction contextRef="c66" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.41</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate was obtained from
U.S. Treasury rates for the applicable periods. The Company&#8217;s expected volatility was based upon the historical volatility for industry
peers and used an average of those volatilities. The expected life of the Company&#8217;s options was determined using the simplified
method as a result of limited historical data regarding the Company&#8217;s activity for employee awards and the contractual term for
nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and does not expect to pay dividends
in the foreseeable future. The Company uses the closing stock price on the date of grant as the fair value of the common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TFF PHARMACEUTICALS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For The Three Months Ended March 31, 2022 and
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 6 &#8211; STOCK BASED COMPENSATION,
continued</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock option activity
during the three months ended March 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term (In&#160;Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" scale="0" unitRef="shares">2,893,839</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="tffp:SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">8.05</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">9,932,413</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tffp:StockIssuedDuringPeriodSharesStockOptionesExercised" scale="0" unitRef="shares">17,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">11.09</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" scale="0" unitRef="shares">2,976,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="tffp:WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" scale="0" unitRef="usdPershares">6.47</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="tffp:WeightedAverageRemainingContractualTermOutstandingEndingBalance">7.87</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">4,435,685</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,411,441</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.00</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.24</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="tffp:AggregateIntrinsicValueExercisables" scale="0" unitRef="usd">3,196,095</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock options
is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock
for those stock options that had strike prices lower than the fair value of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Option Modification</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 21, 2022, one of the members of
the Company&#8217;s board of directors, Dr. Brian Windsor, resigned. As part of his resignation from the board of directors, modifications
were made to Dr. Windsor&#8217;s vested and non-vested stock option awards including acceleration of certain non-vested option awards
and the extension of the post-termination exercise period of certain stock option awards. During the three months ended March 31, 2022,
in accordance with ASC Topic 718, <i>Compensation&#8212;Stock Compensation,</i> the Company recorded a one-time, non-cash incremental
compensation expense net of the required reversal of previously recognized compensation attributed to non-vested shares in the amount
of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd">339,000</ix:nonFraction>, which is included in general and administrative expense in the accompanying condensed consolidated statements
of operations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 7 &#8211; SUBSEQUENT EVENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has performed an evaluation of events
occurring subsequent to March 31, 2022 through the filing date of this Quarterly Report. Based on its evaluation, there are no events
that need to be disclosed.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cautionary Statement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion
and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto
contained elsewhere in this report. The information contained in this quarterly report on Form 10-Q is not a complete description of our
business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures
made by us in this report and in our other filings with the Securities and Exchange Commission, or SEC, including our 2021 Annual Report
on Form 10-K filed with the SEC on March&#160;24, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this report we make, and
from time to time we otherwise make written and oral statements regarding our business and prospects, such as projections of future performance,
statements of management&#8217;s plans and objectives, forecasts of market trends, and other matters that are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements containing
the words or phrases &#8220;will likely result,&#8221; &#8220;are expected to,&#8221; &#8220;will continue,&#8221; &#8220;is anticipated,&#8221;
&#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221;
&#8220;target,&#8221; &#8220;goal,&#8221; &#8220;plans,&#8221; &#8220;objective,&#8221; &#8220;should&#8221; or similar expressions identify
forward-looking statements, which may appear in our documents, reports, filings with the SEC, and news releases, and in written or oral
presentations made by officers or other representatives to analysts, stockholders, investors, news organizations and others, and in discussions
with management and other of our representatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future results, including
results related to forward-looking statements, involve a number of risks and uncertainties, including those risks included in Part I,
Item 1 &#8220;Risk Factors&#8221; in our 2021 Annual Report on Form 10-K filed with the SEC on March&#160;24, 2022. No assurance can be
given that the results reflected in any forward-looking statements will be achieved. Any forward-looking statement speaks only as of the
date on which such statement is made. Our forward-looking statements are based upon assumptions that are sometimes based upon estimates,
data, communications and other information from suppliers, government agencies and other sources that may be subject to revision. Except
as required by law, we do not undertake any obligation to update or keep current either (i) any forward-looking statement to reflect events
or circumstances arising after the date of such statement or (ii) the important factors that could cause our future results to differ
materially from historical results or trends, results anticipated or planned by us, or which are reflected from time to time in any forward-looking
statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TFF Pharmaceuticals, Inc.
(NASDAQ: TFFP) is a clinical stage biopharmaceutical company focused on developing and commercializing innovative drug products based
on our patented Thin Film Freezing, or TFF technology platform. We believe, and early testing confirms, that our TFF platform can significantly
improve the solubility of poorly water-soluble drugs, a class of drugs that makes up approximately 33% of the major pharmaceuticals worldwide,
thereby improving the pharmacokinetic effect of those drugs. We believe that in the case of some new drugs that cannot be developed due
to poor water-solubility, our TFF platform has the potential to increase the pharmacokinetic effect of the drug to a level allowing for
its development and commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
we have three product candidates under development, TFF Voriconazole Inhalation Powder, or TFF Vori; TFF Tacrolimus Inhalation Powder,
or TFF Tac-Lac; and TFF Niclosamide Inhalation Powder, or TFF Niclo. In July 2020, we completed Phase I human clinical trials of our lead
product, TFF Vori, and completed the enrollment of a Phase 1b clinical trial of TFF Vori in asthma patients in December 2021. Dosing of
TFF Vori in patients with invasive pulmonary aspergillosis in a Phase 2 clinical trial is expected to begin in 2022. Dosing of a patient
in a Compassionate Use Study commenced in the first quarter of 2022 for a lung transplant patient with a pulmonary fungal infection. In
September 2021, we completed Phase 1 human clinical trials of our TFF Tac-Lac product in Australia. Dosing of TFF Tac-Lac in lung transplant
patients in a Phase 2 clinical trial is expected to begin in 2022. In November 2021, we commenced dosing of TFF Niclosamide in a Phase
1 human clinical trial in Canada and completed dosing the Phase 1 trial in January 2022. We have not progressed the development of any
other of our drug candidates to human clinical trials and our efforts have focused on the formulation, early-stage animal testing and
formal toxicology studies of our initial drug candidates in preparation for our first clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also focused on the joint
development of dry powder formulations of proprietary drugs owned or licensed by other pharmaceutical companies. As of the date of this
report, we are engaged in the joint development of an inhaled SARS-CoV2 Monoclonal Antibody in collaboration with Augmenta BioWorks and
a dry powder formulation of niclosamide in collaboration agreement with UNION therapeutics A/S. We are also actively engaged in the analysis
and testing of dry powder formulations of several drugs and vaccines through topical, ocular and nasal applications pursuant to feasibility
studies and material transfer agreements with U.S. and international pharmaceutical companies and certain government agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to initially focus
on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. While the TFF platform was designed
to improve solubility of poorly water-soluble drugs generally, the researchers at University of Texas at Austin, or UT, found that the
technology was particularly useful in generating dry powder particles with properties which allow for superior inhalation delivery, especially
to the deep lung, which is an area of extreme interest in respiratory medicine. We believe that our TFF platform can significantly increase
the number of pulmonary drug products that can be delivered by way of breath-actuated inhalers, which are generally considered to be the
most effective and patient-friendly means of delivering medication directly to the lungs. Our dry powder drug products will be designed
for use with dry powder inhalers, which are generally considered to be the most effective of all breath-actuated inhalers. We plan to
focus on developing inhaled dry powder formulations of existing off-patent drugs intended for lung diseases and conditions, which we believe
includes dozens of potential drug candidates, many of which have a potential market ranging from $100 million to over $500 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to initially focus on the
development of the following product candidates:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TFF
Vori</b> is an inhaled dry powder version of Voriconazole, generally considered to be the best antifungal drug used to treat and prevent
invasive pulmonary aspergillosis, or IPA, a severe fungal pulmonary disease with a mortality rate that can reach 90% in some patient
populations. In October 2019, we submitted to the U.S. Food and Drug Administration, or FDA, an Investigational New Drug Application,
or IND, for our TFF Vori product and initiated our Phase I human clinical trials in November 2019. In July 2020, we completed Phase I
human clinical trials of TFF Vori, and completed the enrollment of a Phase 1b clinical trial of TFF Vori in asthma patients in December
2021. Dosing of TFF Vori in patients with invasive pulmonary aspergillosis in a Phase 2 clinical trial is expected to begin in 2022.
We believe, and our clinical testing to date confirms, that our TFF platform can be used to formulate a dry powder version of Voriconazole,
which is no longer subject to patent protection. Voriconazole is currently marketed in Australia, Europe and the U.S. as Vfend&#174;.
As of the date of this report, the Clinical Practice Guidelines released by the Infectious Diseases Society of America recommend Voriconazole
as first-line monotherapy for IPA. However, since the registration of Vfend in Europe and the U.S. in 2002, several studies have examined
the exposure-response relationship with Voriconazole, identifying a relationship between low Voriconazole exposure and higher rates of
treatment failure, as well as a higher propensity for neurotoxicity at higher exposures. We believe a TFF prepared dry powder formulation
of Voriconazole administered directly to the lungs can maximize both the prophylactic value for immunocompromised patients susceptible
to IPA and the treatment value of patients suffering from acute and chronic IPA. We also believe our dry powder drug formulation would
benefit patients by providing the drug at the &#8220;port of entry&#8221; of invasive fungal infections, while also reducing or eliminating
the unpleasant and potentially fatal side effects associated with Voriconazole and other last line antifungals.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TFF
Tac-Lac</b> is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine. Prograf&#174; tacrolimus
is currently the second most commonly administered immunosuppressive drug used in solid organ transplants, despite what we believe to
be the many challenges for patients and physicians when used for extended periods. Prograf tacrolimus can cause toxicity in the kidneys,
particularly when used in high doses that are required for effective immunosuppression in the lung. Tacrolimus is no longer under patent
protection, and we intend to develop a dry powder version suitable for use with a dry powder inhaler. Because our dry powder version
would provide for a high local lung concentration without the typical systemic toxicity frequently experienced with oral dosage form
immunosuppressants, we believe our drug candidate should have a high likelihood of success in competing in the immunosuppressant market
for lung and heart/lung transplants. In September 2021, we completed Phase 1 human clinical trials of our TFF Tac-Lac product in Australia.
As of the date of this report, dosing of TFF Tac-Lac in lung transplant patients in a Phase 2 clinical trial is expected to begin in
2022, and we intend to submit to the FDA an IND for TFF Tac-Lac in 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TFF
Niclosamide</b>&#160;is an inhaled dry powder formulation of Niclosamide. Niclosamide has been used to treat tapeworm infections in humans
since the 1960s and was recently reported to be one of the most potent approved drugs in screens for antiviral activity against the SARS-CoV2
virus that causes the COVID-19 disease, including the UK B.1.1.7 and South African B.1.351 variants. Early testing confirmed that our
TFF platform can be used to formulate a dry powder version of Niclosamide, which is no longer subject to patent protection. We believe
a TFF prepared dry powder formulation of Niclosamide administered directly to the lungs can maximize both the prophylactic value for
persons exposed to COVID-19 and for the treatment of patients with COVID-19 infections at risk for serious disease complications. TFF
has also obtained the rights to a novel formulation that may enhance the bioavailability of Niclosamide through oral delivery under our
license from the University of Texas. Orally delivered Niclosamide has shown promise for the treatment of COVID -19 and various forms
of cancer.&#160;&#160;On August 12, 2020, we entered into a licensing and collaboration agreement with UNION therapeutics A/S in which
UNION acquired an option to obtain a worldwide exclusive license for the TFF technology in combination with niclosamide In November 2021,
we commenced dosing of TFF Niclosamide in a Phase 1 human clinical trial in Canada and completed dosing subjects in the Phase 1 trial
in January 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TFF
mAb therapies</b>&#160;is intended to be a dry powder formulation of a COVID-19 monoclonal antibody therapy. On November 1, 2020, the
Company entered into a joint development and collaboration agreement (the &#8220;Agreement&#8221;) with Augmenta Bioworks, Inc. (&#8220;Augmenta&#8221;)
pursuant to which the parties have agreed to collaborate on the joint development of novel commercial products incorporating Augmenta&#8217;s
human-derived monoclonal antibodies (&#8220;mAbs&#8221;) for potential COVID-19 therapeutics. Under the terms of the Agreement, both
companies will collaborate to develop one or more commercial therapeutics utilizing the Company&#8217;s Thin-Film Freezing technology
to manufacture dry powder formulations of Augmenta&#8217;s mAbs for inhalation delivery directly to the lungs of patients.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have identified a number
of additional drug candidates that show promise upon initial evaluation, including dry powder formulations of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cannabidiol</b>,
or CBD, a controlled substance as defined in the federal Controlled Substances Act of 1970 that is reported to be used by some for the
treatment of various epilepsy syndromes as well as anxiety, insomnia, and different types of pain. We are in the early stages of developing
an inhaled dry powder form of CBD that could be used to support or to treat a variety of health issues that may benefit from CBD administration.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vaccines
</b>containing aluminum salts, which make up approximately 35% of all vaccines. Aluminum salts are incorporated into many vaccine formulations
as an adjuvant, which is a substance added to vaccines to enhance the immune response of vaccinated individuals. A major limitation with
these vaccines is that they are fragile and to maintain their efficacy they must be formulated as liquid suspensions and kept in a cold
chain (2 &#8211; 8&#176;C) during transport and storage, which is burdensome and expensive. We have conducted drug and performance characterization
activities of certain TFF formulated salt containing vaccines, which suggest that the salt containing vaccines can be successfully converted
from liquid suspension into dry powder, and then later be reconstituted at the time of use without causing a decrease in efficacy. Furthermore,
TFF has evaluated formulation and delivery of vaccines that do not contain aluminum salts and reported positive animal data for a universal
influenza candidate vaccine formulation in collaboration with the University of Georgia. In addition, TFF and USAMRIID have a CRADA agreement
to evaluate monoclonal antibody vaccines to prevent a number of viral infections. We are also collaborating with Albert Einstein College
of Medicine on certain VSV vaccine candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
we intend to focus on the development of dry powder formulations of CBD and salt containing vaccines in partnership with pharmaceutical
companies.&#160;&#160; Our intent is for TFF to be involved only through performance characterization of the formulations and early animal
efficacy trials.&#160; Beyond that work, if successful, we will transfer further development and commercialization responsibility to the
partner as part of a negotiated licensing transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also focused on the
joint development of dry powder formulations of proprietary drugs owned or licensed by other pharmaceutical companies. As of the date
of this report, we are at various stages of different feasibility studies of new chemical entities owned by international pharmaceutical
companies. In addition, we recently commenced preliminary analysis and testing of dry powder formulations of certain drugs and vaccines
through topical, ocular and nasal applications in connection with our participation in submissions made to certain government agencies
for government contracts. Also, in May 2020, we authorized a third party to conduct feasibility studies and market testing of dry powder
formulations of cannabis and cannabis-derived products. These efforts have resulted in refinement of specific formulations that we believe
could achieve a positive position in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business model is to
develop proprietary innovative drug product candidates that offer commercial or functional advantages, or both, to currently available
alternatives. In our initial evaluation of the market, we have identified a number of potential drug candidates that show promise upon
initial assessment. In most cases, these are off-patent drugs for which we would directly pursue the development of a dry powder formulation,
however, we do not expect any dry powder formulation of a CBD drug product to be off-patent and our dry powder formulation of aluminum
salt vaccines may not be off-patent. In those cases where our initial dry powder drug candidate will be established drugs that are off-patent,
such as TFF Vori and TFF Tac-Lac, we believe that our drug product candidates may qualify for approval by the FDA through the FDA&#8217;s
505(b)(2) regulatory pathway and in corresponding regulatory paths in other foreign jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 505(b)(2) pathway sometimes
does not require clinical trials other than a bioequivalence trial. Our dry powder formulation of a CBD drug candidate will likely require
a full NDA through the FDA&#8217;s 505(b)(1) regulatory pathway, however, a non-pharmaceutical CBD dry formulation, such as a dietary
supplement, may not require FDA approval. We expect that our dry powder formulation of aluminum salt vaccines will require a biological
license application, or BLA, which is very similar to a full NDA through the FDA&#8217;s 505(b)(1) regulatory pathway. In addition, to
the extent we claim that any of our off-patent drug product candidates target a new indication or offer improved safety compared to the
existing approved products, and it is our present expectation that we will in many cases, it is likely that we will be required to conduct
additional clinical trials in order to obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the February 2019 pre-Investigational New Drug Application,
or IND, meeting with the FDA, and a March 2022 post-Phase 1 meeting with the FDA concerning TFF Vori, we believe we will need to conduct
one Phase 2 study and may need a second Phase 2 or a Phase 2b/3a study prior to filing for marketing approval for TFF Vori. Concerning
TFF Tac-Lac, based on a pre-IND meeting with the FDA, we believe we will need to conduct Phase 1 and Phase 2b/3a studies prior to filing
for marketing approval for TFF Tac-Lac. However, there can be no assurance that the FDA will not ask for additional clinical data for
either TFF Vori or TFF Tac-Lac.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also believe that in
some cases our dry powder drug products may qualify for the FDA&#8217;s orphan drug status, such as designated for TFF Tac-Lac. Upon and
subject to receipt of the requisite approvals, we intend to commercialize our drug products through a combination of our internal direct
sales and third-party marketing and distribution partnerships. In some cases, such as the development of combination drugs or the development
of dry powder formulations of patented drugs, we intend to pursue the licensing of our TFF platform or a joint development arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated under
the laws of the state of Delaware on January 24, 2018. Our principal executive offices are located at 1751 River Run, Suite 400, Fort
Worth, Texas 76107 and our telephone number is (817) 438-6168. Our website address is www.tffpharma.com. The information contained in,
or accessible through, our website is not incorporated by reference into this report, and you should not consider any information contained
in, or that can be accessed through, our website as part of this report or in deciding whether to purchase our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed in January
2018 and have not commenced revenue-producing operations. To date, our operations have consisted of the development and early-stage testing
and Phase 1 human clinical trials of our initial product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, we established
a wholly-owned Australian subsidiary, TFF Pharmaceuticals Australia Pty Ltd. in order to conduct clinical research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
the COVID-19 pandemic has had a relatively insignificant impact on our operations and has not caused us to forego, abandon or materially
delay any proposed activities. While we believe we have been able to effectively manage the disruption caused by the COVID-19 pandemic
to date, there can be no assurance that our operations, including the development of our drug candidates, will not be disrupted or materially
adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak of COVID-19.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations with respect to the items set forth below for the three months ended March 31, 2022 and 2021 together with the
percentage change for those items.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Favorable<br/> (Unfavorable)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Grant revenue</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">67,435</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">24,315</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">43,120</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">177</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,261,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,278,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,246,195</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,647,415</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(598,780</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total operating expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,507,799</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,925,667</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(582,132</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into feasibility
and material transfer agreements with third parties that provide us with funds in return for certain research and development activities.
During the three months ended March 31, 2022 and 2021, we recognized $67,435 and $24,315, respectively, of grant revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
March 31, 2022 and 2021, we incurred $5.3 million and $5.3 million of research and development expenses and $3.2 million and $2.6 million
of general and administrative expenses, respectively. The change in research and development expenses during 2022 was mainly due to increased
manufacturing costs of approximately $299,000, which includes approximately $72,000 related to the Augmenta monoclonal antibody, clinical
expenses of approximately $990,000 related to Niclosamide, TFF Vori and TFF Tac-Lac, payroll and related expense of approximately $292,000
and stock-based compensation of approximately $139,000, offset by a decrease in preclinical expenses of approximately $1.8 million. The
change in research and development expenses also includes our preliminary analysis and testing of dry powder formulations of several drugs
and vaccines owned or licensed by third parties we believe may lead to the out-licensing of our TFF technology for the development of
dry powder product candidates. We expect our spending on research and development activities to increase in upcoming quarters due primarily
to clinical trial activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in general and
administrative expenses in 2022 from the prior year was mainly a result of increases in insurance and investor relation expenses of approximately
$523,000 and payroll and related expenses of approximately $90,000, offset by decreased consulting and business development expenses of
approximately $148,000. While we expect our general and administrative expenses to continue to increase over the next few years, we anticipate
the rate of increase has begun to decrease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our other income and interest income for the three months ended March 31, 2022 and 2021 together with the percentage change for those
items.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Favorable<br/> (Unfavorable)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Other income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">231,278</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(174,101</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(75</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(54</td><td style="text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income consists of
refundable United States Internal Revenue Services and Australian research and development incentive program payments for expenditures
incurred during 2020. Interest income decreased during fiscal 2022 due to lower balances in interest-bearing accounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incurred a net loss of
$8.4 million and $7.7 million for the three months ended March 31, 2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financial Condition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2022, we
had total assets of approximately $33.8 million and working capital of approximately $29.3 million. As of March 31, 2022, our liquidity
included approximately $26.4 million of cash and cash equivalents. We believe that our cash on-hand as of the date of this report is sufficient
to fund our proposed operating plan for, at least, the 12 months following the date of this report. However, as of the date of this report,
we believe that we will need additional capital to fund our operations through to the marketing approval for TFF Vori and TFF Tac-Lac,
assuming such approval can be obtained at all, and to engage in the substantial development of any other of our drug candidates, such
as formulation, early-stage animal testing and formal toxicology studies. If we encounter unforeseen delays or expenses, we may require
additional capital in order to fund our current level of ongoing costs over the next twelve months. We intend to seek additional funds
through various financing sources, including the sale of our equity and debt securities, licensing fees for our technology and co-development
and joint ventures with industry partners, with a preference towards licensing fees for our technology and co-development and joint ventures
with industry partners. In addition, we will consider alternatives to our current business plan that may enable to us to achieve revenue
producing operations and meaningful commercial success with a smaller amount of capital. However, there can be no guarantees that such
funds will be available on commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may
be unable to further pursue our business plan and we may be unable to continue operations, in which case you may lose your entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Critical Accounting Policies </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the three months ended March 31, 2022, there were no material changes to our critical accounting policies previously disclosed in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Critical Accounting Estimates </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Our management's discussion and
analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared
in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires
us to make judgments and estimates that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent
assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events,
and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under
different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances,
facts and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements
prospectively from the date of change in estimates. There were no material changes to our critical accounting estimates as reported in
our Annual Report on Form 10-K for the year ended December&#160;31, 2021, which was filed with the SEC on March 24, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. Quantitative and Qualitative Disclosures
about Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the
participation of our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our
disclosure controls and procedures pursuant to Rule 13a-15 of the Securities Exchange Act of 1934. Based upon their evaluation, our chief
executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control Over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in
our internal control over financial reporting that occurred during the three-month period ended March 31, 2022 that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II - OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1A. Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on
Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and
Section&#160;21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include our expectations, beliefs,
intentions and strategies regarding the future. You should carefully consider the risk factors discussed in Part I, Item 1A. &#8220;Risk
Factors&#8221; in our 2021 Annual Report on Form 10-K filed with the SEC on March&#160;24, 2022 as, in light of those risks, the forward-looking
events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated
or implied in our forward-looking statements. There have been no material changes in the risk factors included in our 2021 Annual Report
on Form 10-K. The risk factors described in our 2021 Annual Report on Form 10-K are not the only risks facing our company. Additional
risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our
business, financial condition or future results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5. Other Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 9, 2022, we entered
into an Amended and Restated Patent License Agreement, or the Amended PLA, with <span>University of Texas
at Austin, or UT. The Amended PLA is an amendment to the Patent License Agreement, or the Original PLA, originally entered into in July
2015 and pursuant to which we hold the exclusive rights to approximately 127 patents held by UT concerning the TFF technology. We initiated
the discussions leading to the Amended PLA for purposes of strengthening our licensed rights to the TFF technology and patents held by
UT. </span> The principal changes to the Original PLA made by way of the <span style="font-family: Times New Roman, Times, Serif">Amended
PLA are to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Grant
us the exclusive license rights to any future UT patents relating to the TFF technology;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Grant
us the license rights to the know-how developed by UT concerning the TFF technology; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Allow
us to assign the Amended PLA, without the consent of UT, in the event of a sale of our company.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except as
set forth above, the material terms</span> of the Original PLA remain unchanged and in effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. Exhibits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>Exhibit No.</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 55%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Method of Filing</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-1_tffpharm.htm">Second Amended and Restated Certificate of Incorporation of the Registrant</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Registration Statement on Form S-1 filed on August 20, 2019.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-3_tffpharm.htm">Amended and Restated Bylaws of the Registrant</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Registration Statement on Form S-1 filed on August 20, 2019.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">10.1</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="f10q0322ex10-1_tffpharma.htm">Amended and Restated Patent License Agreement dated April 20, 2022 between the Registrant and The University of Texas at Austin</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Filed electronically herewith</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0322ex31-1_tffpharma.htm">Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0322ex31-2_tffpharma.htm">Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0322ex32-1_tffpharma.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).</a></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed electronically herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Cover Page Interactive Data File (formatted as Inline XBRL and contained
in Exhibit 101)</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">In accordance with the requirements
of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TFF PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 11, 2022 &#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/&#160;Glenn Mattes</i></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glenn Mattes,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">President and Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">(Principal Executive Officer)</p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 11, 2022 &#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/&#160;Kirk Coleman</i></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirk Coleman,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">19</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="tffp:AccruedCompensationLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-3" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-4" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-5" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-6" name="tffp:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-7" name="tffp:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-8" name="tffp:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-9" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-10" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-11" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-14" name="tffp:IssuanceOfCommonStockForStockOptionExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-15" name="tffp:IssuanceOfCommonStockForStockOptionExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-16" name="tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-17" name="tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-18" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-19" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-20" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-21" name="tffp:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-22" name="tffp:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-23" name="tffp:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-24" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-27" name="tffp:ReceivableDueFromCollaborationsAgreement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-28" name="tffp:ResearchAndDevelopmentTaxIncentiveReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-29" name="us-gaap:IncreaseDecreaseInAccruedSalaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-30" name="tffp:ProceedsFromIssuanceOfCommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-31" name="tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-32" name="tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-33" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-34" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-35" name="tffp:CashlessExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001733413</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="tffp-20220331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0cRffbuw4EmArolVL7JcutiDhHh5xiitTb/y8TaDQcUHL6I7rOA4HAM+CZSIX8sCdNA7WoMzgTreBxRK0VvULUeJI0bHvVrHP4bLHH5F4kzimwS8DhAizu4Ie3GM3/Gun214xsWeJHSs=] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tffp:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tffp:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2018-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-11-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterConsultancyAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-03</xbrli:startDate>
    <xbrli:endDate>2020-08-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">tffp:ContractManufacturingServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">tffp:ContractManufacturingServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001733413</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="aud">
  <xbrli:measure>iso4217:AUD</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f10q0322ex10-1_tffpharma.htm
<DESCRIPTION>AMENDED AND RESTATED PATENT LICENSE AGREEMENT DATED APRIL 20, 2022 BETWEEN THE REGISTRANT AND THE UNIVERSITY OF TEXAS AT AUSTIN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED PATENT LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT No. PM 2202501</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amended and Restated Patent License Agreement
(the &ldquo;Patent License Agreement&rdquo;) is made and entered into as of April 20, 2022 (&ldquo;Amendment Effective Date&rdquo;) by
and between TFF Pharmaceuticals, Inc. (&ldquo;Licensee&rdquo;) and The University of Texas at Austin, on behalf of the Board of Regents
of the University of Texas System (&ldquo;Licensor&rdquo;), an agency of the State of Texas (collectively referred to as &ldquo;<B>Parties</B>&rdquo;
or separately as &ldquo;<B>Party</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensor and Lung Therapeutics, Inc. entered
into a Patent License Agreement (UTA Agreement No. PM1504101-A) with an Effective Date of July 8, 2015, which was assigned by Lung Therapeutics,
Inc. to Licensee on January 24, 2018 and consented to by Licensor on March 9, 2018, and was amended by Amendment #1 to the Patent License
Agreement with an effective date of November 30, 2018, by Amendment # 2 to the Patent License Agreement with an effective date of September
6, 2019, by Amendment #3 to the Patent License Agreement with an effective date of May 5, 2020, by Amendment #4 to the Patent License
Agreement with an effective date of June 12, 2020, by Amendment #5 to the Patent License Agreement with an effective date of July 27,
2020, and further amended by Amendment #6 to the Patent License Agreement with an effective date of November 13, 2020 (as amended, the
&ldquo;Original Patent License Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensor and Licensee entered into a second
Patent License Agreement (UTA Agreement No. PM1908501) with an Effective Date of August 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties now wish to further amend the Original
Patent License Agreement as set forth below and terminate the UTA Agreement No. PM1908501. UTA Agreement PM1908501 terminates automatically
upon execution of this Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No new binding agreement between the Parties
will exist until this Patent License Agreement has been signed by all Parties. Unsigned drafts of this Patent License Agreement shall
not be considered offers. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, therefore, in consideration of the mutual
covenants and premises herein contained, the Parties hereby amend and restate the Original Patent License Agreement in its entirety as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensor owns or controls Patent Rights. Licensee
desires to secure the right and license to use, develop, manufacture, market, and commercialize the TFF Technology. Licensor has determined
that such use, development, and commercialization of the TFF Technology is in the public&rsquo;s best interest and is consistent with
Licensor&rsquo;s educational and research missions and goals. Licensor desires to have the Patent Rights developed and used for the benefit
of Licensee, the inventors, Licensor, and the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Terms and Conditions of Patent License attached
hereto as Exhibit A are incorporated herein by reference in their entirety (the &ldquo;Terms and Conditions&rdquo;). In the event of a
conflict between provisions of this Patent License Agreement and the Terms and Conditions, the provisions in this Patent License Agreement
shall govern. Unless defined in this Patent License Agreement, capitalized terms used in this Patent License Agreement shall have the
meanings given to them in the Terms and Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The section numbers used in the left hand column
in the table below correspond to the section numbers in the Terms and Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #E6E6E6">
    <TD STYLE="width: 100%; border: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;Definitions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD ROWSPAN="7" STYLE="padding: 2pt; background-color: rgb(230,230,230); width: 6%; border: gray 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt; width: 16%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Date </FONT></TD>
    <TD STYLE="padding: 2pt; width: 78%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of last signature</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensor</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-size: 10pt">The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas System, an agency of the State of Texas, whose address is 3925 W. Braker Lane, Suite 1.9A (R3500), Austin, Texas 78759. </FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Licensee</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TFF Pharmaceuticals, Inc., a Delaware Corporation, with its principal place of business at 1751 River Run, Suite 400, Fort Worth, Texas 76107.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Year and Contract Quarters</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Year is 12-month period ending on December 31 and Contract Quarters are 3-month periods ending on March 31, June 30, Sept. 30, Dec. 31.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Territory </FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Worldwide</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Field</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All fields</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent Rights</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(See Exhibit B)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; background-color: rgb(230,230,230); border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TFF Technology</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Thin film freezing or ultra rapid freezing technology that cannot be practiced without infringing any issued patents listed in</FONT> Patent Rights. </TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; background-color: rgb(230,230,230); border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Know-how</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Information and materials, including protocols, methods, processes, techniques, devices, models, designs, libraries and trade secrets owned by Licensor that (a) are necessary or advantageous for use in commercializing the technology described in the Patent Rights; and (b) University is not legally prevented from licensing; and (c) are either (1) developed pursuant to the Sponsored Research Agreement in the lab of Dr. Robert O. Williams III at the University of Texas at Austin, or (2) are learned or developed in the labs of Dr. Robert O. Williams III or Dr. Zhengrong Cui at the University of Texas at Austin or any successor lab. </FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; background-color: rgb(230,230,230); border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mandatory Sublicensing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt; background-color: rgb(230,230,230); border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USPTO Entity Status as of Effective Date</FONT></TD>
    <TD STYLE="padding: 2pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check one box:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
    </FONT>Small</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif">Large</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="width: 100%; border: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4.&nbsp;&nbsp;Diligence Milestones</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="11" STYLE="width: 6%; border: gray 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD ROWSPAN="11" STYLE="width: 17%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestones and deadlines</FONT></TD>
    <TD STYLE="width: 56%; border-top: gray 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone Events</FONT></TD>
    <TD STYLE="width: 21%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deadlines</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive $14 million in aggregate financing.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enter into a sponsored research agreement with the lab of Dr. Robert O. Williams III for $129,000.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enter into a sponsored research agreement with the lab of Dr. Robert O. Williams III for $200,000 with a start date after May 1, 2019.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IND submission for TFF-VORI Licensed Product.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enter into a sponsored research agreement with the lab of Dr. Robert O. Williams III for $200,000,&nbsp;&nbsp;with a start date after May 1, 2020.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enroll first patient in Phase I FDA clinical trial for TFF-TAC Licensed Product.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enroll first patient in Phase II FDA clinical trial for TFF-VORI Licensed Product.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fund least $200,000 in research in the lab of Dr. Robert O. Williams III in the period between October 1, 2021 and December 31, 2022 under the Sponsored Research Agreement. </FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enroll first patient in Phase III FDA clinical trial for TFF-VORI Licensed Product.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;&nbsp;FDA regulatory approval for TFF-VORI Licensed Product.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="width: 100%; border: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;Compensation</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD ROWSPAN="10" STYLE="vertical-align: top; width: 7%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-left: gray 1pt solid; border-bottom: #999999 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1(a)</B></FONT></TD>
    <TD ROWSPAN="10" STYLE="vertical-align: top; width: 20%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: #999999 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Milestone Fees</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 53%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone Events</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone Fees</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND Approval on first indication of Licensed Product.</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$50,000 (paid)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submit IND (or foreign equivalent) on a first indication for a thin film freezing vaccine Licensed Product</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$50,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enroll first patient in Phase II clinical trial for first Licensed Product (FDA or foreign equivalent).</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$100,000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enroll first patient in a Phase II clinical trial for a TFF-Vaccine Licensed Product (FDA or foreign equivalent)</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enroll first patient in Phase III clinical trial for first Licensed Product (FDA or foreign equivalent).</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$250,000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enroll first patient in Phase III clinical trial for a thin film freezing vaccine Licensed Product (FDA or foreign equivalent).</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory approval for a thin film freezing vaccine Licensed Product (FDA or foreign equivalent).</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory approval for first Licensed Product (FDA or foreign equivalent).</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$500,000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory approval for second Licensed Product or second indication of first Licensed Product (FDA or foreign equivalent).</FONT></TD>
    <TD STYLE="border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$500,000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1(b)</B></FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sublicense Fees</B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: gray 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7.5% of Non-Royalty Sublicense Consideration from a Sublicense Agreement
    executed before FDA regulatory approval of Licensed Product.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5% of Non-Royalty Sublicense Consideration from a Sublicense Agreement
    executed after FDA Regulatory approval of Licensed Product.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: gray 1pt solid; border-bottom: #999999 1pt solid; border-right: gray 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2</B></FONT></TD>
    <TD STYLE="border-bottom: #999999 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Running royalty rate (applies to Net Sales by Licensee, Affiliates and Sublicensees)</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: #999999 1pt solid; border-right: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2% </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border-top: Black 1pt solid; border-right: Gray 1pt solid; border-bottom: Black 1pt solid; border-left: Gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.&nbsp;&nbsp;&nbsp;Contact Information</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; width: 7%; border: gray 1pt solid; background-color: #E6E6E6; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 44%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee Contacts</FONT></TD>
    <TD STYLE="width: 49%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensor Contacts</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact for Notice:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">Attn: Glenn Mattes</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">1751 River Run, Suite 400, Fort Worth, Texas 76107</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">Phone: 215-880-2632</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">E-mail: gmattes@tffpharma.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting contact:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">Attn: Kirk Coleman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">1751 River Run, Suite 400, Fort Worth, Texas 76107</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">Fax: N/A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">Phone: 817-989-6358</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">E-mail: kcoleman@tffpharma.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent prosecution contact:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">Attn: Kirk Coleman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1751 River Run, Suite 400, Fort Worth, Texas 76107</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax: N/A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Phone: 817-989-6358</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">E-mail: kcoleman@tffpharma.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.7pt">Attn: Chris Cano</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1751 River Run, Suite 400, Fort Worth, Texas 76107</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax: N/A</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Phone: 609.933.3938</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">E-mail: ccano@tffpharma.com</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact for Notice:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Attn: Contract Manager</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">3925 W. Braker Lane, Suite 1.9A (R3500)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Austin, TX 78759</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Fax: 512.475.6894</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Phone: 512.471.2995</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">E-mail: licensing@otc.utexas.edu</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment and reporting contact:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Checks payable to &ldquo;The University of Texas at Austin&rdquo;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Attn: Accounting/Compliance</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">3925 W. Braker Lane, Suite 1.9A (R3500)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Austin, TX 78759</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Fax: 512.475.6894</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">Phone: 512.471.2995</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt">E-mail: accounting@otc.utexas.edu; compliance@otc.utexas.edu</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent prosecution contact:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Patents</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">3925 W. Braker Lane, Suite 1.9A (R3500)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Austin, TX 78759</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax: 512.475.6894</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Phone: 512.471.2995</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">E-mail: patents@otc.utexas.edu</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>20.</B></TD><TD STYLE="text-align: justify"><B>Related Future Intellectual Property</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If Licensor receives an invention disclosure
for an invention (i) developed pursuant to the Sponsored Research Agreement in the lab of Dr. Robert O. Williams III at the University
of Texas at Austin, or (ii) that is jointly owned by Licensor and TFF Pharmaceuticals, Inc., or (iii) that could not be practiced without
a license to any issued or pending claim within the Patent Rights, or (iv) that is developed in the lab of Dr. Robert O. Williams III
at the University of Texas at Austin and directly related to thin film freezing or ultra rapid freezing technology, then Licensor shall
provide a copy of such disclosure to Licensee for review, subject to the terms of the Sponsored Research Agreement, if applicable, and
appropriate confidentiality restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">After receiving such a disclosure, Licensee shall have thirty
(30) days (&ldquo;<B>Election Period</B>&rdquo;) to provide written notice to University of Licensee&rsquo;s election to add Board&rsquo;s
rights to such disclosed invention(s) to Patent Rights under this Agreement.&nbsp;If Licensee elects to add such disclosed invention,
Licensor, provided that it is not legally prevented from doing so, shall provide Licensee with an executable amendment to this Agreement
to add Board&rsquo;s rights to such disclosed invention(s) to the Patent Rights under this Agreement, and all other terms of this Agreement
shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If Licensee does not elect to add the
disclosed invention(s) within thirty (30) days, Licensor shall have no further obligation to Licensee with respect to such disclosed invention(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>21.</B></TD><TD STYLE="text-align: justify"><B>No Other Promises and Agreements; Representation by Counsel</B>. Licensee expressly warrants and represents
and does hereby state and represent that no promise or agreement which is not herein expressed has been made to Licensee in executing
this Patent License Agreement except those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not relying
upon any statement or representation of Licensor or its representatives. Licensee is relying on Licensee&rsquo;s own judgment and has
had the opportunity to be represented by legal counsel. Licensee hereby warrants and represents that Licensee understands and agrees to
all terms and conditions set forth in this Patent License Agreement and said Terms and Conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>22.</B></TD><TD STYLE="text-align: justify"><B>Deadline for Execution by Licensee</B>. If this Patent License Agreement is executed first by the Licensor
and is not executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms
and Conditions within 30 days of the date of signature set forth under the Licensor&rsquo;s signature below, then this Patent License
Agreement shall be null and void and of no further effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized
representatives to execute this Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-decoration: none; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">LICENSOR:
    The University of Texas at Austin on behalf of the Board of Regents of the University of Texas System</FONT></TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">LICENSEE:
    TFF Pharmaceuticals, Inc</FONT></TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: top">
    <TD STYLE="text-decoration: none; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">By: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-decoration: none; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><I>/s/ Les Nichols&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
    <TD STYLE="text-decoration: none; width: 20%"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD>
    <TD STYLE="text-decoration: none; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-decoration: none; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">/s/ Glenn Mattes&#9;</FONT></TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">Les Nichols</FONT></TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">Glenn Mattes</FONT></TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">Director, Office of Technology
    Commercialization</FONT></TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">CEO, TFF Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR STYLE="text-decoration: none; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">Date:
May 9, 2022</FONT></TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="text-decoration: none">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">Date:
May 6, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Terms and Conditions of Patent License</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These Terms and Conditions of Patent License (&ldquo;Terms
and Conditions&rdquo;) are incorporated by reference into the Patent License Agreement to which they are attached. All Section references
in these Terms and Conditions shall be references to provisions in these Terms and Conditions unless explicitly stated otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Definitions</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; means
any business entity more than 50% owned by Licensee, any business entity which owns more than 50% of Licensee, or any business entity
that is more than 50% owned by a business entity that owns more than 50% of Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Agreement</B>&rdquo; means
collectively (i)&nbsp;these Terms and Conditions, and (ii)&nbsp;the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Contract Quarter</B>&rdquo;
means the three-month periods indicated as the Contract Quarter in Section 1 of the Patent License Agreement, or any stub period thereof
at the commencement of the Agreement or the expiration or termination of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Contract Year</B>&rdquo; means
the 12-month periods indicated as the Contract Year in Section&nbsp;1 of the Patent License Agreement, or any stub period thereof at the
commencement of the Agreement or the expiration or termination of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Effective Date</B>&rdquo;
means the date indicated as the Effective Date in Section 1 of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Fair Market Value</B>&rdquo;
means the cash consideration an unaffiliated, unrelated buyer would pay in an arm&rsquo;s length sale of a substantially identical item
sold in the same quantity, under the same terms, and at the same time and place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Field</B>&rdquo; means all
fields.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Government</B>&rdquo; means
any agency, department or other unit of the United States of America or the State of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Gross Consideration</B>&rdquo;
means all cash and non-cash consideration (e.g., securities).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Licensed Process</B>&rdquo;
means a method or process whose practice or use is covered by a Valid Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Licensed Product</B>&rdquo;
means any product or component (i) whose manufacture, use, sale, offer for sale or import is covered by any Valid Claim, or (ii) which
is made using a Licensed Process or another Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Licensed Service</B>&rdquo;
means performance of a service for any consideration using a Licensed Product, or the practice of a Licensed Process. For clarity, research
and development of Licensed Products by Licensee, its Affiliates, or a Sublicensee does not constitute a Licensed Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Licensee</B>&rdquo; means
the Party identified as the Licensee in Section 1 of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Licensor</B>&rdquo; means
the Party identified as the Licensor in Section 1 of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Milestone Fees</B>&rdquo;
means all fees identified as Milestone Fees in Section&nbsp;3.1(a) of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Net Product Sales</B>&rdquo;
means the Gross Consideration from the Sale of Licensed Products less the following items directly attributable to the Sale of such Licensed
Products that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as the seller:
(a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding
income taxes; (c) import and export duties actually paid; (d) freight, transport, packing and transit insurance charges actually paid
or allowed; and (e) other amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the original
invoiced amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Additionally, if Licensee, its Affiliates
or Sublicensees use a Licensed Product or a Licensed Process for its own internal purposes or otherwise in a situation that does not involve
a Sale for which a royalty is paid under Section 3.2, then Net Product Sales shall also include an amount equal to the customary sale
price charged to a third party for the same Licensed Product or Licensed Process, except for a reasonable quantity used internally solely
for testing or quality control purposes, marketing or demonstration purposes, or seeking governmental approval (e.g., U.S. Food and Drug
Administration clinical trial). If there is no customary sale price, then the Net Product Sales shall be an amount equal to the Fair Market
Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Net Sales</B>&rdquo; means
the total of Net Product Sales and Net Service Sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Net Service Sales</B>&rdquo;
means the Gross Consideration received from the Sale of Licensed Services less the following items, directly attributable to the Sale
of such Licensed Services that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees
as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government charges actually
paid, excluding income taxes; and (c) other amounts actually refunded, allowed or credited due to rejections or re-works, but not exceeding
the original invoiced amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Non-Royalty Sublicensing Consideration</B>&quot;
means the Gross Consideration received by the Licensee or its Affiliate from a Sublicensee in consideration of the grant of a sublicense
under the Patent Rights (including, without limitation, license or option or distribution fees, fees to maintain license rights, and bonus/milestone
payments), but excluding amounts received as running royalties, a profit share, or other revenue sharing based on Net Product Sales or
Net Service Sales for which Licensor receives a running royalty under Section 3.2. For the avoidance of doubt, Non-Royalty Sublicensing
Consideration shall not include bona fide: (a) running royalties received by Licensee or an Affiliate based on Net Product Sales or Net
Service Sales that are royalty-bearing to Licensor under Section 3.2, (b) purchase price for Licensee&rsquo;s stock or other securities
not in excess of Fair Market Value, and (iii) amounts paid and used exclusively for research and development of Licensed Products or Licensed
Services by Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Patent License Agreement</B>&rdquo;
means the particular Patent License Agreement to which these Terms and Conditions are attached and incorporated into by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Patent Rights</B>&rdquo; means
the Licensor&rsquo;s rights in (a) the patents and patent applications listed in Section 1 of the Patent License Agreement; (b) all non-provisional
patent applications that claim priority to any provisional application listed in Section 1 of the Patent License Agreement; and (c) all
divisionals, continuations, and such claims of continuations-in-part as are entitled to claim priority to the aforesaid patents and/or
patent applications, and all reissues, reexaminations, extensions of, and foreign counterparts; and (d) any patents that issue with respect
to the aforesaid patent applications. From time to time during the term of the Agreement, upon written agreement by both parties, Licensee
and Licensor shall update the list of all patent applications and patents within the Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Phase I</B>&rdquo; means a
human clinical trial of a Licensed Product, including the initial introduction into humans, the principal purpose of which is to obtain
sufficient information about the Product&rsquo;s pharmacokinetics and pharmacological effects to permit the design of further clinical
trials, and be generally consistent with 21 CFR &sect; 312.21(a). Said trial may be conducted in any country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Phase II</B>&rdquo; means
a human clinical trial of a Licensed Product the principal purpose of which is to make a preliminary determination that such Product is
safe in a patient population for its intended use and to obtain sufficient information about such Product's efficacy to permit the design
of further clinical trials, and be generally consistent with 21 CFR &sect; 312.21(b). Said trial may be conducted in any country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Phase III</B>&rdquo; means
a human clinical trial of a Licensed Product, which trial is designed to: (a) establish that a Licensed Product is safe and efficacious
for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage
range to be prescribed; (c) support regulatory approval of such Licensed Product; and (d) be generally consistent with 21 CFR &sect; 312.21(c).
Said trial may be conducted in any country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Prosecution Counsel</B>&rdquo;
means the law firm or attorney who is handling the prosecution of the Patent Rights. Prosecution Counsel as of the Effective Date is identified
in Section 1 of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Quarterly Payment Deadline</B>&rdquo;
means the day that is 30 days after the last day of any particular Contract Quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Regulatory Approval</B>&rdquo;
means the approval by the Regulatory Authority needed for a particular national jurisdiction to market, sell and use a Licensed Product
in that national jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Regulatory Authority</B>&rdquo;
means the governmental authority responsible for granting any necessary licenses or approvals for the marketing, sale and use of a Licensed
Product or Licensed Service in a particular national jurisdiction, including without limitation, the FDA, European Medicines Agency or
Koseisho (i.e. the Japanese Ministry of Health and Welfare)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Sell, Sale or Sold</B>&rdquo;
means any transfer or other disposition of Licensed Products or Licensed Services for which consideration is received by Licensee, its
Affiliates or Sublicensees. A Sale of Licensed Products or Licensed Services will be deemed completed at the time Licensee or its Affiliate
or its Sublicensee receives such consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Sponsored Research Agreement</B>&rdquo;
means that certain Sponsored Research Agreement UTA18-000556 dated May 17, 2018, as the same may be amended from time to time, between
Licensor and Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Sublicense Agreement</B>&rdquo;
means any agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to any third party any license rights
of Licensee under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Sublicense Fee</B>&rdquo;
means the fee specified in Section&nbsp;3.1(b) of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Sublicensee</B>&rdquo; means
any entity to whom an express sublicense has been granted under the Patent Rights. For clarity, a third party wholesaler or distributor
who has no significant responsibility for marketing and promotion of the Licensed Product or Licensed Services within its distribution
territory or field (i.e., the third party simply functions as a reseller), and who does not pay any consideration to Licensee or an Affiliate
for such wholesale or distributor rights, shall not be deemed a Sublicensee; and the resale by such a wholesaler or distributor shall
not be treated as royalty bearing Net Sales by a Sublicensee provided that a royalty is being paid by Licensee for the initial transfer
to the wholesaler or distributor pursuant to Section 3.2. This definition does not limit Licensee&rsquo;s rights to grant or authorize
sublicenses under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Territory</B>&rdquo; means
the territory so indicated as the Territory in Section&nbsp;1 of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Valid Claim</B>&rdquo; means
a claim of (i)&nbsp;an issued and unexpired patent included within the Patent Rights unless the claim has been held unenforceable or invalid
by the final, un-reversed, and un-appealable decision of a court or other government body of competent jurisdiction, has been irretrievably
abandoned or disclaimed, or has otherwise been finally admitted or determined to be invalid, un-patentable or unenforceable, whether through
reissue, reexamination, disclaimer or otherwise, or (ii)&nbsp;a pending patent application within the Patent Rights to the extent the
claim continues to be prosecuted in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">License Grant and Commercialization</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>2.1</U></TD><TD STYLE="text-align: justify"><U>Grant</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Licensor grants to Licensee a royalty-bearing exclusive license under the Patent Rights to manufacture,
have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field in
the Territory and to perform Licensed Services in the Field in the Territory. Licensor grants to Licensee a non-exclusive royalty-bearing
license under the Know-How to manufacture, have manufactured, offer for sale, sell, lease and/or import Licensed Products in the Licensed
Field in the Licensed Territory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">This grant is subject to (i)&nbsp;the payment by Licensee to Licensor of all consideration required under
the Agreement, (ii) any rights of, or obligations to, the Government as set forth in Section 11.2 (Government Rights), and (iii) rights
retained by Licensor to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Publish the scientific findings from research related to the Patent Rights in compliance with the confidentiality
and pre-publication review provisions of any other agreements between the Parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Make and use the technology claimed in the Patent Rights solely for non-commercial purposes limited to
teaching, research, and education, except to the extent consented to by Licensee; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Grant rights to, and transfer material embodiments of, the Patent Rights to other academic institutions
or non-profit research institutions for the purposes identified in clauses (1) and (2) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensor reserves all rights
not expressly granted in the Agreement and disclaims the grant of any implied rights to Licensee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>2.2</U></TD><TD STYLE="text-align: justify"><U>Affiliates</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee may extend the license granted
herein to any Affiliate provided that the Affiliate agrees in writing to be bound by the Agreement to the same extent as Licensee.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>2.3</U></TD><TD STYLE="text-align: justify"><U>Sublicensing</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee has the right to grant Sublicense
Agreements under the Patent Rights and Know-how consistent with the terms of the Agreement, subject to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">A Sublicense Agreement shall not exceed the scope and rights granted to Licensee hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.3pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Sublicense Agreements shall be consistent with the terms and conditions of this Agreement, including,
but not necessarily limited to;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">All payments, fees, and royalties under Section 3.1 and 3.2.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Sublicensee&rsquo;s acknowledgment of the disclaimer of warranty and limitation on Licensor&rsquo;s liability,
as provided by Section 11.3 and 12 below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Provisions under which the Sublicensee accepts duties at least equivalent to those accepted by the Licensee
in the following Sections: Section 11.3 (Licensor Disclaimers); Section 12 (Limitation of Liability); Section 13 (Indemnification); Section
14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">In the event of termination of the Agreement, continued sublicense rights shall be governed by Section
7.5(a) (Effect of Termination).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.3pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Licensee may grant a Sublicensee the right to grant further sub-Sublicense Agreements, in which case such
sub-Sublicense Agreements shall be treated as &ldquo;Sublicense Agreements&rdquo; and such sub-Sublicensees shall be treated as &ldquo;Sublicensees&rdquo;
for purposes of the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.3pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Licensee shall deliver to Licensor a true, complete, and correct copy of each Sublicense Agreement granted
by Licensee, Affiliate or Sublicensee, and any modification or termination thereof, within 30 days following the applicable execution,
modification, or termination of such Sublicense Agreement. If the Sublicense Agreement is not in English, Licensee shall provide Licensor
an accurate English translation in addition to a copy of the original agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor for all
of the Licensee&rsquo;s duties and obligations contained in the Agreement, including without limitation the payment of running royalties
due under Section 3.2 whether or not paid to Licensee by a Sublicensee. Any act or omission of a Sublicensee that would be a breach of
the Agreement if performed by Licensee will be deemed to be a breach by Licensee unless Licensee complies with the remaining provisions
of this paragraph. Each Sublicense Agreement will contain a right of termination by Licensee in the event that the Sublicensee breaches
the payment or reporting obligations affecting Licensor or any other terms and conditions of the Sublicense Agreement that would constitute
a breach of the Agreement if such acts were performed by Licensee. In the event of a Sublicensee breach, and if after a reasonable opportunity
to cure as provided in any such Sublicense Agreement, such Sublicensee fails to cure such Sublicensee breach, then the Licensee shall
in Licensee&rsquo;s discretion either terminate the Sublicense Agreement or shall continue to be responsible for all payments and reports
owed to Licensor as a result of Sublicensee&rsquo;s activities under such Sublicense Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.3pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">If a Sublicensee initiates any proceeding or action to challenge the validity, enforceability, or scope
of one or more of the Patent Rights, Licensor shall provide written notice of such action to Licensee, and Licensee shall immediately
terminate such Sublicense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>2.4</U></TD><TD STYLE="text-align: justify"><U>Diligent Commercialization</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee by itself or through its Affiliates
and Sublicensees will use diligent efforts to make Licensed Products or Licensed Services commercially available in the Field in the Territory.
Without limiting the foregoing, Licensee will (a) maintain a reasonably funded, ongoing and active research, development, manufacturing,
regulatory, marketing or sales program required to make License Products or Licensed Services commercially available, and (b) fulfill
the milestone events specified in Section 2.4 of the Patent License Agreement by the deadlines indicated therein and (c) use diligent
and commercially reasonable efforts to perform and complete the plans described in the annual report submitted pursuant to Section 4.2
(Annual Written Progress Report). If the obligations under this Section 2.4 are not fulfilled, Licensor may treat such failure as a breach
in accordance with Section 7.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Compensation</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In consideration of rights granted to
Licensee, Licensee will pay Licensor the following fees and royalties. All fees and royalties are not refundable and are not creditable
against other fees and royalties except as explicitly set forth herein. Each payment will reference the Patent License Agreement number
and will be sent to Licensor&rsquo;s payment and accounting contact in Section 18 (Notices) of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>3.1</U></TD><TD STYLE="text-align: justify"><U>Non-Royalty Payments due from Licensee</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Milestone Fees</I></FONT>. Licensee will pay
the Milestone Fees indicated in Section 3.1(a) of the Patent License Agreement by the Quarterly Payment Deadline for the Contract Quarter
in which the milestone events set forth in Section 3.1(a) of the Patent License Agreement are achieved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.3pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Sublicense Fees</I></FONT>. Licensee will
pay the Sublicense Fees indicated in Section 3.1(b) of the Patent License Agreement on or before the Quarterly Payment Deadline for the
Contract Quarter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>3.2</U></TD><TD STYLE="text-align: justify"><U>Royalties</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee will pay a running royalty at
the rate set forth in Section 3.2 of the Patent License Agreement on Net Sales in each Contract Quarter, payable on or before the Quarterly
Payment Deadline for such Contract Quarter, subject to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">No more than one royalty shall be paid to Licensor hereunder with respect to the Sale of any one unit
of Licensed Product or Licensed Service, whether or not more than one patent or Valid Claim is applicable to the Licensed Product or Licensed
Service, or the development, manufacture, or performance thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">No royalty shall be payable under this Section 3.2 with respect to (i) Sales to an Affiliate or Sublicensee
of a particular unit of Licensed Product that is used by such Affiliate or Sublicensee to perform a Licensed Service if Licensor is paid
a royalty on the Sale of such Licensed Service, (ii) the Sale of Licensed Products between or among Licensee, its Affiliates, and Sublicensees
for re-sale purposes, provided Licensor is paid a royalty with respect to the re-sale, or (iii) payments that constitute Non-Royalty Sublicensing
Consideration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>3.3</U></TD><TD STYLE="text-align: justify"><U>Non-cash Consideration</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If Licensee receives or anticipates receipt
of non-cash consideration from Sales or Sublicenses, the manner in which Licensor will receive its compensation under the Agreement with
respect to such non-cash consideration will be negotiated in good faith and timely agreed to by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">Reports and Plans</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The reports specified in this Section
4 will be sent to Licensor&rsquo;s payment and reporting contact identified in Section 18 (Notices) of the Patent License Agreement. If
Licensor requests to have information submitted in a particular format, Licensee will use reasonable efforts to comply with such request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>4.1</U></TD><TD STYLE="text-align: justify"><U>Quarterly Payment and Milestone Reports</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On or before each Quarterly Payment Deadline,
Licensee will deliver to Licensor a true and accurate report, certified by an officer of Licensee, giving such particulars of the business
conducted by Licensee, its Affiliates and its Sublicensees (including copies of reports provided by Sublicensees and Affiliates to Licensee)
during the preceding Contract Quarter under the Agreement as necessary for Licensor to account for Licensee&rsquo;s payments hereunder,
even if no payments are due. The reports shall continue to be delivered after the termination or expiration of the Agreement until such
time as all Licensed Products permitted to be Sold after termination or expiration have been Sold or destroyed. Licensee shall provide
information in sufficient detail to enable the royalties payable hereunder to be determined and to calculate all of the amounts payable
under the Agreement. The report shall include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The name of the Licensee, the Patent License Agreement number, and the period covered by the report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The name of any Affiliates and Sublicensees whose activities are also covered by the report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Identification of each Licensed Product and Licensed Service for which any royalty payments have become
payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Net Product Sales and Net Service Sales segregated on a product-by-product basis, and a country-by-country
basis, or an affirmative statement that no Sales were made. The report shall also itemize the permitted deductions from the Gross Consideration
used to arrive at the resulting Net Product Sales and Net Service Sales, on a product-by-product and country-by-country basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The applicable royalty rate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">An affirmative statement of whether any milestones with deadlines in that Contract Quarter under Section
2.4 and any milestones under Section 3.1(a) were met or not, and the resulting Milestone Fee payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.3pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Non-Royalty Sublicensing Consideration received by Licensee segregated on a Sublicense-by-Sublicense basis,
or an affirmative statement that none was received;<BR>
<BR>
</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">If any consideration was received in currencies other than U.S. dollars, the report shall describe the
currency exchange calculations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Any changes in accounting methodologies used to account for and calculate the items included in the report
since the previous report.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>4.2</U></TD><TD STYLE="text-align: justify"><U>Annual Written Progress Report and Commercialization Plan</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Within 45 days following the end of each
Contract Year, Licensee will deliver to Licensor a true and accurate written progress report and commercialization plan, certified by
an officer of Licensee, that summarizes (i) Licensee&rsquo;s efforts and accomplishments during the Contract Year to diligently commercialize
Licensed Products and Licensed Services, and (ii) Licensee&rsquo;s development and commercialization plans with respect to Licensed Products
and Licensed Services for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees. The report
shall contain the following information to the extent relevant to the activities under the Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.4pt">(a)</TD><TD STYLE="text-align: justify">The name of the Licensee, the Patent License Agreement number, the names of any Affiliates and Sublicensees,
and the products and services being developed and/or commercialized;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 107.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.4pt">(b)</TD><TD STYLE="text-align: justify">The progress toward completing and the plans for completing the applicable milestone events pursuant to
Section 2.4, Section 3.1(a) and Exhibit C;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The research and development activities, including status and plans for obtaining any necessary governmental
approvals, performed during the past year, and the plans for research and development activities for the next year; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The marketing activities for the past year and planned for the next year, and Licensee&rsquo;s internal
estimate for Sales for the next year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>4.3</U></TD><TD STYLE="text-align: justify"><U>Government and Economic Development Reporting</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If Licensor requests, Licensee will provide
information required by the Government for Licensor&rsquo;s Government and economic development reporting purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Payment, Records, and Audits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>5.1</U></TD><TD STYLE="text-align: justify"><U>Payments</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">All amounts referred to in the Patent
License Agreement are expressed in U.S. dollars without deductions for taxes, assessments, fees, or charges of any kind. Each payment
will reference the agreement number set forth at the beginning of the Patent License Agreement. All payments to Licensor will be made
in U.S. dollars by check or wire transfer (Licensee to pay all wire transfer fees) payable to the payee identified in Section 18 of the
Patent License Agreement and sent to the payment and reporting contact in Section 18 (Notices) of the Patent License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>5.2</U></TD><TD STYLE="text-align: justify"><U>Sales Outside the U.S.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If any currency conversion shall be required
in connection with the calculation of payments hereunder, such conversion shall be made using the rate used by Licensee for its financial
reporting purposes in accordance with Generally Accepted Accounting Principles (or foreign equivalent) or, in the absence of such rate,
using the average of the buying and selling exchange rate for conversion between the foreign currency and U.S. Dollars, for current transactions
as reported in <I>The Wall Street Journal</I> on the last business days of the Contract Quarter to which such payment pertains. Licensee
may not make any tax withholdings from payments to Licensor, but Licensor agrees to supply to Licensee, upon written request, appropriate
evidence from appropriate U.S. governmental agencies showing that&nbsp;Licensor is a resident of the United States of America for purposes
of the U.S. income tax laws and is tax-exempt under such income tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>5.3</U></TD><TD STYLE="text-align: justify"><U>Late Payments</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Amounts that are not paid when due will
accrue a late charge from the due date until the date paid, at a rate equal to 1.0% per month (or the maximum allowed by law, if less).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>5.4</U></TD><TD STYLE="text-align: justify"><U>Records</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For a period of six years after the Contract
Quarter to which the records pertain, Licensee agrees that it and its Affiliates and Sublicensees will each keep complete and accurate
records of their Sales, Net Product Sales, Net Service Sales, Milestone Fees, and Non-Royalty Sublicensing Consideration in sufficient
detail to enable such payments to be determined and audited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>5.5</U></TD><TD STYLE="text-align: justify"><U>Auditing</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee and its Affiliates will permit
Licensor or its representatives, at Licensor&rsquo;s expense, to annually examine books, ledgers, and records during regular business
hours, at Licensee&rsquo;s or its Affiliate&rsquo;s place of business, on at least 30 days advance written notice, to the extent necessary
to verify any payment or report required under the Agreement. For each Sublicensee, Licensee shall obtain such audit rights for itself,
and will, within 30 days of Licensor&rsquo;s written request, conduct an audit of the Sublicensee&rsquo;s records, and Licensee will furnish
to Licensor a copy of the findings from such audit. No more than one audit of Licensee, each Affiliate, and each Sublicensee shall be
conducted under this Section&nbsp;5.5 in any calendar year. If any amounts due Licensor have been underpaid, then Licensee shall immediately
pay Licensor the amount of such underpayment plus accrued interest due in accordance with Section&nbsp;5.3. If the amount of underpayment
is equal to or greater than 5% of the total amount due for the records so examined, Licensee will pay the cost of such audit. Such audits
may, at Licensor&rsquo;s sole discretion, consist of a self-audit conducted by Licensee at Licensee&rsquo;s expense and certified in writing
by an authorized officer of Licensee. All information examined pursuant to this Section&nbsp;5.5 shall be deemed to be the Confidential
Information of the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">Patent Expenses and Prosecution</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>6.1</U></TD><TD STYLE="text-align: justify"><U>Patent Expenses</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee shall pay for all past documented,
out-of-pocket expenses incurred by Licensor for filing, prosecuting, enforcing, defending and maintaining Patent Rights and related patent
searches through the Effective Date of the Agreement. Licensee shall pay all expenses incurred by Licensor for actions instructed or approved
by Licensee, or that are otherwise necessary for the maintenance of the Patent Rights after the effective date, for so long as, and in
such countries as the Agreement remains in effect. Licensee will pay all patent expenses within 30 days after Licensee&rsquo;s receipt
of an invoice. Patent expense payment delinquencies (whether owed directly to Prosecution Counsel or to Licensor) will be considered a
payment default under Section 7.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>6.2</U></TD><TD STYLE="text-align: justify"><U>Direction of Prosecution</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensor will confer with Licensee to
develop a strategy for the prosecution and maintenance of Patent Rights. Licensor will request that copies of all documents prepared by
the Prosecution Counsel for submission to governmental patent offices be provided to Licensee for review and comment prior to filing.
At its discretion, Licensor may allow Licensee to instruct Prosecution Counsel directly, provided, that (a) Licensor will maintain final
authority in all decisions regarding the prosecution and maintenance of the Patent Rights, (b) Licensor may revoke this authorization
to instruct Prosecution Counsel directly at any time, and (c) the Prosecution Counsel remains counsel to the Licensor with an appropriate
contract (and shall not jointly represent Licensee unless requested by Licensee and approved by Licensor, and an appropriate engagement
letter and conflict waiver are in effect). If Licensee wishes to instruct Prosecution Counsel directly or change Prosecution Counsel,
Licensee may request to do so by following the Licensor&rsquo;s procedures for such. Licensor reserves in its sole discretion the ability
to change Prosecution Counsel and to approve or disapprove any requested changes by Licensee. The Parties agree that they share a common
legal interest to get valid enforceable patents and that Licensee will maintain as privileged all information received pursuant to this
Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>6.3</U></TD><TD STYLE="text-align: justify"><U>Ownership</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The ownership of all patent applications
and patents filed after the effective date will be determined in accordance with U.S. patent law. No payments due under the Agreement
will be reduced as the result of co-ownership interests in the Patent Rights by Licensee or any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>6.4</U></TD><TD STYLE="text-align: justify"><U>Foreign Filings</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition to the U.S., the Patent Rights
shall, subject to applicable bar dates, be pursued in such foreign countries as Licensee so designates in writing to Licensor in sufficient
time to reasonably enable the preparation of such additional filings, and in those foreign countries in which Licensor has filed applications
prior to the Effective Date. If Licensee does not choose to pursue patent rights in a particular foreign country and Licensor chooses
to do so, Licensor shall provide written notice to Licensee and thereafter said patent application or patent shall no longer be included
in the Patent Rights and Licensee shall have no further rights thereto. Licensor shall have the right to make alternative arrangements
with Licensee for upfront payment of foreign patent expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>6.5</U></TD><TD STYLE="text-align: justify"><U>Withdrawal from Paying Patent Costs</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If at any time Licensee wishes to cease
paying for any costs for any particular Patent Rights or for patent prosecution in a particular jurisdiction, Licensee must give Licensor
at least 90 days prior written notice (the &ldquo;Notice Period&rdquo;) and Licensee will continue to be obligated to pay for the patent
costs which reasonably accrue during said Notice Period. Thereafter, said patent application or patent shall no longer be included in
the Patent Rights and Licensee shall have no further rights thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>6.6</U></TD><TD STYLE="text-align: justify"><U>U.S. Patent and Trademark Office Entity Size Status</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee represents that as of the Effective
Date the entity size status of Licensee in accordance with the regulations of the U.S. Patent and Trademark Office is as set forth in
Section 1 of the Patent License Agreement. Licensee will inform Licensor in writing on a timely basis of any change in its U.S. Patent
and Trademark Office entity size status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>6.7</U></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Extension
of Patent Term</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If a Licensed Product is eligible for
extending the term of any patent in the Patent Rights under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or
any European, Japanese, or other foreign counterparts of this law, then Licensee shall take all necessary steps with the appropriate regulatory
authorities to apply in a timely manner for such an extension of the term for such patent. For example, such application must be made
to the USPTO within sixty (60) days after the US FDA approves a commercial marketing application for said Licensed Product. Licensee shall
prepare and file all documents needed for the application; and Licensee shall take all reasonable actions as may be appropriate to further
obtain patent term extension. Licensor shall cooperate and sign such documents as may be reasonably requested by Licensee for the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee shall keep Licensor informed
as to Licensee&rsquo;s efforts to prepare and file said application, including giving a written report within thirty (30) days after Licensee
obtains the applicable marketing approval from the FDA (or foreign counterpart). If Licensee fails to make this required application,
then Licensor shall have the option but not the obligation to do so; and if Licensor does elect to file the application, then Licensee
shall cooperate and sign such documents as may be needed; and Licensee shall reimburse Licensor&rsquo;s costs incurred for said application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">Term and Termination</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>7.1</U></TD><TD STYLE="text-align: justify"><U>Term</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Unless earlier terminated as provided
herein, the term of the Agreement as to Patent Rights will commence on the Effective Date and continue until the last date of expiration
or termination of the Patent Rights, but shall continue for another ten years as to the Know-How with the running royalty rate being reduced
by half during that period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>7.2</U></TD><TD STYLE="text-align: justify"><U>Termination by Licensee</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee, at its option, may terminate
the Agreement by providing Licensor written notice of intent to terminate, which such termination effective will be 90 days following
receipt of such notice by Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>7.3</U></TD><TD STYLE="text-align: justify"><U>Termination by Licensor</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensor, at its option, may immediately
terminate the Agreement, or any part of Patent Rights, or any part of Field, or any part of Territory, or the exclusive nature of the
license grant, upon delivery of written notice to Licensee of Licensor&rsquo;s decision to terminate, if any of the following occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Licensee becomes more than $5,000 in arrears in any payments due under the Agreement, and Licensee fails
to make the required payment within 60 days after delivery of written notice from Licensor; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Licensee is in material breach of any non-payment provision of the Agreement, and does not cure such breach
within 60 days after delivery of written notice from Licensor; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Licensee or its Affiliate initiates any proceeding or action to challenge the validity, enforceability,
or scope of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding or action.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>7.4</U></TD><TD STYLE="text-align: justify"><U>Other Conditions of Termination</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Agreement will terminate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Immediately without the necessity of any action being taken by Licensor or Licensee, (i) if Licensee becomes
bankrupt or insolvent, or (ii) Licensee&rsquo;s Board of Directors elects to liquidate its assets or dissolve its business, or (iii) Licensee
ceases its business operations, or (iv) Licensee makes an assignment for the benefit of creditors or (v) if the business or assets of
Licensee are otherwise placed in the hands of a receiver, assignee or trustee, whether by voluntary act of Licensee or otherwise; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">At any time by mutual written agreement between Licensee and
Licensor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>7.5</U></TD><TD STYLE="text-align: justify"><U>Effect of Termination</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If the Agreement is terminated
for any reason:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">All rights and licenses of Sublicensees shall continue in force provided that the Sublicensee is in good
standing and agrees in writing to assume all of the obligations of Licensee, provided however if there is more than one Sublicense that
survives the termination of this Agreement, the patent cost reimbursement obligations may be shared among the Sublicenses in proportions
agreed by Licensor, and such Sublicensee provides Licensor with written notice thereof within 30 days after termination of the Agreement,
then such Sublicense Agreement shall survive; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -35.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Licensee shall cease making, having made, distributing, having distributed, using, selling, offering to
sell, leasing, loaning and importing any Licensed Products and performing Licensed Services by the effective date of termination; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Licensee shall tender payment of all accrued royalties and other payments due to Licensor as of the effective
date of termination; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Nothing in the Agreement will be construed to release either Party from any obligation that matured prior
to the effective date of termination; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The provisions of Sections 8 (Confidentiality), 9 (Infringement and Litigation), 11 (Representations and
Disclaimers), 12 (Limit of Liability), 13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General Provisions)
will survive any termination or expiration of the Agreement. In addition, the provisions of Sections 3 (Compensation), 4.1 (Quarterly
Payment and Milestone Reports), 5 (Payment, Records and Audits), 6.1 (Patent Expenses) of the Patent License Agreement shall survive with
respect to all activities and payment obligations accruing prior to the termination or expiration of the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Confidentiality</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.1</U></TD><TD STYLE="text-align: justify"><U>Definition</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo;
means all information that is of a confidential and proprietary nature to Licensor or Licensee and provided by one Party to the other
Party under the Agreement. Licensor&rsquo;s Confidential Information includes unpublished information related to novel drug formulations,
formulation technologies including thin film freezing technology and its applications, including information related to subject of patent
filings and applications listed in Exhibit B, and also data, Know-How, and information related to thin film freezing technology and its
applications that is not described in the patents and patent applications in Exhibit B or that are the subject of sponsored research,
feasibility studies, or technology validations between the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.2</U></TD><TD STYLE="text-align: justify"><U>Protection and Marking</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensor and Licensee each agree that
all Confidential Information disclosed in tangible form, and marked &ldquo;confidential&rdquo; and forwarded to one by the other, or if
disclosed orally, is designated as confidential at the time of disclosure: (i) is to be held in strict confidence by the receiving Party,
(ii) is to be used by and under authority of the receiving Party only as authorized in the Agreement, and (iii) shall not be disclosed
by the receiving Party, its agents or employees without the prior written consent of the disclosing Party or as authorized in the Agreement.
Licensee has the right to use and disclose Confidential Information of Licensor reasonably in connection with the exercise of its rights
under the Agreement, including without limitation disclosing to Affiliates, Sublicensees, potential investors, acquirers, and others on
a need to know basis, if such Confidential Information is provided under conditions which reasonably protect the confidentiality thereof.
Each Party&rsquo;s obligation of confidence hereunder includes, without limitation, using at least the same degree of care with the disclosing
Party&rsquo;s Confidential Information as it uses to protect its own Confidential Information, but always at least a reasonable degree
of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.3</U></TD><TD STYLE="text-align: justify"><U>Confidentiality of Terms of Agreement</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Each Party agrees not to disclose to any
third party the terms of the Agreement without the prior written consent of the other Party hereto, except each Party may disclose the
terms of the Agreement: (a) to advisors, actual or potential Sublicensees, acquirers or investors, and others on a need to know basis,
in each case, under appropriate confidentiality obligations substantially similar to those of this Section 8; and (b) to the extent necessary
to comply with applicable laws and court orders (including, without limitation, The Texas Public Information Act, as may be amended from
time to time, other open records laws, decisions and rulings, and securities laws, regulations and guidance). Notwithstanding the foregoing,
the existence of the Agreement shall not be considered Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.4</U></TD><TD STYLE="text-align: justify"><U>Disclosure Required by Court Order or Law</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If the receiving Party is required to
disclose Confidential Information of another Party hereto, or any terms of the Agreement, pursuant to the order or requirement of a court,
administrative agency, or other governmental body or applicable law, the receiving Party may disclose such Confidential Information or
terms to the extent required, provided that the receiving Party shall use reasonable efforts to provide the disclosing Party with reasonable
advance notice thereof to enable the disclosing Party to seek a protective order and otherwise seek to prevent such disclosure. To the
extent that Confidential Information so disclosed does not become part of the public domain by virtue of such disclosure, it shall remain
Confidential Information protected pursuant to Section 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.5</U></TD><TD STYLE="text-align: justify"><U>Copies</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Each Party agrees not to copy or record
any of the Confidential Information of the other Party, except as reasonably necessary to exercise its rights or perform its obligations
under the Agreement, and for archival and legal purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.6</U></TD><TD STYLE="text-align: justify"><U>Continuing Obligations</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Subject to the exclusions listed in Section
8.7, the Parties&rsquo; confidentiality obligations under the Agreement will survive termination of the Agreement and will continue for
a period of five years thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.7</U></TD><TD STYLE="text-align: justify"><U>Exclusions</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Information shall not be considered Confidential
Information of a disclosing Party under the Agreement to the extent that the receiving Party can establish by competent written proof
that such information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Was in the public domain at the time of disclosure; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Later became part of the public domain through no act or omission of the recipient Party, its employees,
agents, successors or assigns in breach of the Agreement; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Was lawfully disclosed to the recipient Party by a third party having the right to disclose it not under
an obligation of confidentiality; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Was
already known by the recipient Party at the time of disclosure; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Was independently developed by the recipient Party without use of the disclosing Party&rsquo;s Confidential
Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>8.8</U></TD><TD STYLE="text-align: justify"><U>Copyright Notice</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The placement of a copyright notice on
any Confidential Information will not be construed to mean that such information has been published and will not release the other Party
from its obligation of confidentiality hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Infringement and Litigation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>9.1</U></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notification</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If either Licensee or Licensor&rsquo;s
designated office for technology commercialization becomes aware of any infringement or potential infringement of Patent Rights in the
Field in the Territory, such Party shall give prompt written notice to the other Party of such infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>9.2</U></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Enforcement
Against Infringer</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee shall have the right, but no
obligation, to enforce the Patent Rights against any infringement by a third party in all fields licensed exclusively to Licensee. Licensee
shall confer with Licensor and give due consideration to Licensor&rsquo;s input concerning any such enforcement action. If an enforcement
action results in a sublicense to the alleged infringer, any consideration received by Licensee shall be shared with Licensor according
to the terms of this Agreement (e.g., non-royalty sublicensing consideration and/or royalties on sales going forward). If an enforcement
action results in Licensee obtaining an award of damages for infringement, such damages shall be treated as non-royalty sublicensing consideration
for purposes of sharing such damages with Licensor. If an enforcement action is commenced, both Parties agree to cooperate fully with
each other and to permit reasonable access to all relevant personnel, records, papers, information, samples, specimens, etc., relevant
to the action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>9.3</U></TD><TD STYLE="text-align: justify"><U>Cooperation between Licensor and Licensee</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In any infringement suit or dispute, the
Parties agree to cooperate fully with each other. At the request of the Party bringing suit, the other Party will permit reasonable access
after reasonable advance notice to all relevant personnel, records, papers, information, samples, specimens, etc., during regular business
hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If it is necessary to name Licensor as
a party in such action, then Licensee must first obtain Licensor&rsquo;s prior written permission, which permission shall not be unreasonably
withheld, provided that Licensor shall have reasonable prior input on choice of counsel on any matter where such counsel represents Licensor,
and Licensee and such counsel agree to follow all required procedures of the Texas Attorney General regarding retention of outside counsel
for state entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">10.</TD><TD STYLE="text-align: justify">Export Compliance</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Licensee understands that the Arms Export
Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the Export Administration Act (EAA),
including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export
laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (a) ITAR
and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements; (c) ITAR and EAR end
user-specific requirements; (d) Foreign Corrupt Practices Act; and (e) anti-boycott laws and regulations. Licensee will comply with all
then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining
to the Licensed Products and Licensed Services (including any associated products, items, articles, computer software, media, services,
technical data, and other information). Licensee certifies that it will not, directly or indirectly, export (including any deemed export),
nor re-export (including any deemed re-export) the Licensed Products and Licensed Services (including any associated products, items,
articles, computer software, media, services, technical data, and other information) in violation of applicable U.S. laws and regulations.
Licensee will include a provision in its agreements, substantially similar to this Section 10, with its Sublicensees, third party wholesalers
and distributors, and physicians, hospitals or other healthcare providers who purchase a Licensed Product, requiring that these parties
comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">11.</TD><TD STYLE="text-align: justify">Representations and Disclaimers</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>11.1</U></TD><TD STYLE="text-align: justify"><U>Licensor Representations</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Except for the rights, if any, of the
Government as set forth in Section 11.2, Licensor represents and warrants to Licensee that to the knowledge of Licensor&rsquo;s designated
office for technology commercialization (i) Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights
and TFF Technology (other than the right, title and interest of any joint owner identified in Section 1 of the Patent License Agreement),
(ii) Licensor has the right to grant licenses hereunder, and (iii) Licensor has not knowingly granted and will not knowingly grant licenses
or other rights under the Patent Rights that are in conflict with the terms and conditions in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>11.2</U></TD><TD STYLE="text-align: justify"><U>Government Rights</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee understands that Patent Rights
may have been developed under a funding agreement with Government and, if so, that Government may have certain rights relative thereto.
The Agreement is made subject to the Government&rsquo;s rights under any such agreement and under any applicable Government law or regulation.
To the extent that there is a conflict between any such agreement, such applicable law or regulation and the Agreement, the terms of such
Government agreement, and applicable law or regulation, shall prevail. Licensee agrees that, to the extent required by U.S. laws and regulations,
Licensed Products used or Sold in the U.S. will be manufactured substantially in the U.S., unless a written waiver is obtained in advance
from the U.S. Government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>11.3</U></TD><TD STYLE="text-align: justify"><U>Licensor Disclaimers</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">EXCEPT AS SPECIFICALLY SET FORTH IN SECTION
11.1, LICENSEE UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING,
WITHOUT LIMITATION, AS TO THE LICENSED PRODUCTS OR LICENSED SERVICES, OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE,
MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT, PATENTABILITY, AND/OR BREADTH
OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE
ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY LICENSOR THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN FIELD. NOTHING
IN THE AGREEMENT WILL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY
OF LICENSOR OTHER THAN THE PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>11.4</U></TD><TD STYLE="text-align: justify"><U>Licensee Representation</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">By execution of the Agreement, Licensee
represents, acknowledges, covenants and agrees (a) that Licensee has not been induced in any way by Licensor or its employees to enter
into the Agreement, and (b) that Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items
and issues pertaining to this Section 11 (Representations and Disclaimers) and all other matters pertaining to the Agreement; and (c)
that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due
diligence, and (c) that Licensee accepts all risks inherent herein. Licensee represents that it is a duly organized, validly existing
entity of the form indicated in Section 1 of the Patent License Agreement, and is in good standing under the laws of its jurisdiction
of organization as indicated in Section 1 of the Patent License Agreement, and has all necessary corporate or other appropriate power
and authority to execute, deliver and perform its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">12.</TD><TD STYLE="text-align: justify">Limit of Liability</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">IN NO EVENT SHALL LICENSOR, THE UNIVERSITY
SYSTEM IT GOVERNS, ITS MEMBER INSTITUTIONS, INVENTORS, REGENTS, OFFICERS, EMPLOYEES, STUDENTS, AGENTS OR AFFILIATED ENTERPRISES, BE LIABLE
FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS
OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY
KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">OTHER THAN FOR ANY CLAIMS AGAINST LICENSEE
FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT OF LICENSOR&rsquo;S INTELLECTUAL PROPERTY RIGHTS, LICENSEE WILL NOT BE LIABLE TO LICENSOR
FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING
OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE KNOWS OR SHOULD HAVE KNOWN OF THE POSSIBILITY
OF SUCH DAMAGES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">13.</TD><TD STYLE="text-align: justify">Indemnification</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>13.1</U></TD><TD STYLE="text-align: justify"><U>Indemnification Obligation</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Subject to Section 13.2, Licensee agrees
to hold harmless, defend and indemnify Licensor, the university system it governs, its member institutions, its Regents, officers, employees,
students and agents (&ldquo;Indemnified Parties&rdquo;) from and against any liabilities, damages, causes of action, suits, judgments,
liens, penalties, fines, losses, costs and expenses (including, without limitation, reasonable attorneys&rsquo; fees and other expenses
of litigation) (collectively &ldquo;Liabilities&rdquo;) resulting from claims or demands brought by third parties against an Indemnified
Party on account of any injury or death of persons, damage to property, or any other damage or loss arising out of or in connection with
the Agreement or the exercise or practice by or under authority of Licensee, its Affiliates or their Sublicensees, or third party wholesalers
or distributors, or physicians, hospitals or other healthcare providers who purchase a Licensed Product, of the rights granted hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>13.2</U></TD><TD STYLE="text-align: justify"><U>Conditions of Indemnification</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee shall have no responsibility
or obligation under Section 13.1 for any Liabilities to the extent caused by the gross negligence or willful misconduct by Licensor. Obligations
to indemnify, and hold harmless under Section 13.1 are subject to: (a) to the extent authorized by the Texas Constitution and the laws
of the State of Texas, and subject to the statutory duties of the Texas Attorney General, the Indemnified Party giving Licensee control
of the defense and settlement of the claim and demand; and (b) to the extent authorized by the Texas Constitution and the laws of the
State of Texas and subject to statutory duties of the Texas Attorney General, the Indemnified Party providing assistance reasonably requested
by Licensee, at Licensee&rsquo;s expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">14.</TD><TD STYLE="text-align: justify">Insurance</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>14.1</U></TD><TD STYLE="text-align: justify"><U>Insurance Requirements</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Prior to any Licensed Product being used
or Sold (including for the purpose of obtaining regulatory approvals), and prior to any Licensed Service being performed by Licensee,
an Affiliate, or by a Sublicensee, and for a period of five years after the Agreement expires or is terminated, Licensee shall, at its
sole cost and expense, procure and maintain commercial general liability insurance in commercially reasonable and appropriate amounts
for the Licensed Product being used or Sold or the Licensed Service being performed. Licensee shall use commercially reasonable efforts
to have Licensor, the university system it governs, its member institutions, Regents, officers, employees, students and agents named as
additional insureds. Such commercial general liability insurance shall provide, without limitation: (i)&nbsp;product liability coverage;
(ii)&nbsp;broad form contractual liability coverage for Licensee&rsquo;s indemnification under the Agreement; and (iii)&nbsp;coverage
for litigation costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>14.2</U></TD><TD STYLE="text-align: justify"><U>Evidence of Insurance and Notice of Changes</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Upon request by Licensor, Licensee shall
provide Licensor with written evidence of such insurance. Additionally, Licensee shall provide Licensor with written notice of at least
60 days prior to Licensee cancelling, not renewing, or materially changing such insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">15.</TD><TD STYLE="text-align: justify">Assignment</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Agreement may not be assigned by
Licensee without the prior written consent of Licensor, which consent will not be unreasonably withheld; except, however, that Licensee
shall be permitted to assign this Agreement without Licensee&rsquo;s consent to (i) any of its Affiliates or ii) a successor-in-interest
whether by way of stock sale, asset sale, merger, or otherwise. For any permitted assignment to be effective, (a) the Licensee must be
in good standing under this Agreement, (b) the assignee must assume in writing all of Licensee&rsquo;s interests, rights, duties and obligations
under the Agreement and agree to comply with all terms and conditions of the Agreement as if the assignee were an original Party to the
Agreement (c) provide written notice to the Licensor of such assignment no less than 15 days after completion of such assignment. Any
such assignment must be of all rights and obligations of Licensee, such that there is only one existing Licensee at any one time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">16.</TD><TD STYLE="text-align: justify">Governmental Markings</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>16.1</U></TD><TD STYLE="text-align: justify"><U>Patent Markings</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee agrees that all Licensed Products
Sold by Licensee, Affiliates, or Sublicensees will be legibly marked with the number of any applicable patent(s) licensed hereunder as
part of the Patent Rights in accordance with each country&rsquo;s patent marking laws, including Title&nbsp;35, U.S. Code, or if such
marking is not practicable, shall so mark the accompanying outer box or product insert for Licensed Products accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>16.2</U></TD><TD STYLE="text-align: justify"><U>Governmental Approvals and Marketing of Licensed Products
and or Licensed Services</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee will be responsible for obtaining
all necessary governmental approvals for the development, production, distribution, Sale, and use of any Licensed Product or performance
of any Licensed Service, at Licensee&rsquo;s expense, including, without limitation, any safety studies. Licensee will have sole responsibility
for any warning labels, packaging and instructions as to the use and the quality control for any Licensed Product or Licensed Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>16.3</U></TD><TD STYLE="text-align: justify"><U>Foreign Registration and Laws</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee agrees to register the Agreement
with any foreign governmental agency that requires such registration; and Licensee will pay all costs and legal fees in connection with
such registration. Licensee is responsible for compliance with all foreign laws affecting the Agreement or the Sale of Licensed Products
and Licensed Services to the extent there is no conflict with United States law, in which case United States law will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">17.</TD><TD STYLE="text-align: justify">Use of Name</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Licensee will not use the name, trademarks
or other marks of Licensor (or the name of the university system it governs, its member institutions, any of its Regents or employees)
without the advance written consent of Licensor. Licensor may use Licensee&rsquo;s name and logo for&nbsp;annual reports, brochures, website,
and internal reports without prior consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">18.</TD><TD STYLE="text-align: justify">Notices</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any notice or other communication of
the Parties required or permitted to be given or made under the Agreement will be in writing and will be deemed effective when sent in
a manner that provides confirmation or acknowledgement of delivery and received at the address set forth in Section 18 of the Patent License
Agreement (or as changed by written notice pursuant to this Section 18). Notices required under the Agreement may be delivered via E-mail
provided such notice is confirmed in writing as indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notices shall be provided to each Party
as specified in the &ldquo;Contact for Notice&rdquo; address set forth in Section 18 of the Patent License Agreement. Each Party shall
update the other Party in writing with any changes in such contact information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">19.</TD><TD STYLE="text-align: justify">General Provisions</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.1</U></TD><TD STYLE="text-align: justify"><U>Binding Effect</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Agreement is binding upon and inures
to the benefit of the Parties hereto, their respective executors, administrators, heirs, permitted assigns, and permitted successors in
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.2</U></TD><TD STYLE="text-align: justify"><U>Construction of Agreement</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Headings are included for convenience
only and will not be used to construe the Agreement. The Parties acknowledge and agree that both Parties substantially participated in
negotiating the provisions of the Agreement; therefore, both Parties agree that any ambiguity in the Agreement shall not be construed
more favorably toward one Party than the other Party, regardless of which Party primarily drafted the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.3</U></TD><TD STYLE="text-align: justify"><U>Intentionally left blank</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.4</U></TD><TD STYLE="text-align: justify"><U>Compliance with Laws</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee will comply with all applicable
federal, state and local laws and regulations, including, without limitation, all export laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.5</U></TD><TD STYLE="text-align: justify"><U>Governing Law</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Agreement will be construed and enforced
in accordance with laws of the U.S. and the State of Texas, without regard to choice of law and conflicts of law principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.6</U></TD><TD STYLE="text-align: justify"><U>Modification</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Any modification of the Agreement will
be effective only if it is in writing and signed by duly authorized representatives of both Parties. No modification will be made by email
communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.7</U></TD><TD STYLE="text-align: justify"><U>Severability</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If any provision hereof is held to be
invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and enforceable
substitute provision that most nearly reflects the original intent of the Parties, and all other provisions hereof shall remain in full
force and effect in such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as may
be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such other provisions
in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.8</U></TD><TD STYLE="text-align: justify"><U>Third Party Beneficiaries</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Nothing in the Agreement, express or implied,
is intended to confer any benefits, rights or remedies on any entity, other than the Parties and their permitted successors and assigns.
However, if there is a joint owner of any Patent Rights identified in Section 1 of the Patent License Agreement (other than Licensee),
then Licensee hereby agrees that the following provisions of these Terms and Conditions extend to the benefit of the co-owner identified
therein (excluding the Licensee to the extent it is a co-owner) as if such co-owner was identified in each reference to the Licensor:
the retained rights under clause (b) of Section 2.1; Section 11.3 (Licensor Disclaimers); Section 12 (Limitation of Liability); Section
13 (Indemnification); Section 14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.9</U></TD><TD STYLE="text-align: justify"><U>Waiver</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Neither Party will be deemed to have waived
any of its rights under the Agreement unless the waiver is in writing and signed by such Party. No delay or omission of a Party in exercising
or enforcing a right or remedy under the Agreement shall operate as a waiver thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.10</U></TD><TD STYLE="text-align: justify"><U>Sovereign Immunity</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Nothing in the Agreement shall be deemed
or treated as any waiver of Licensor&rsquo;s sovereign immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.11</U></TD><TD STYLE="text-align: justify"><U>Entire Agreement</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Agreement constitutes the entire Agreement
between the Parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements, representations and understandings
relative to such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><U>19.12</U></TD><TD STYLE="text-align: justify"><U>Claims Against Licensor for Breach of Agreement</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee acknowledges that any claim for
breach of the Agreement asserted by Licensee against Licensor shall be subject to Chapter 2260 of the Texas Government Code and that the
process provided therein shall be Licensee&rsquo;s sole and exclusive process for seeking a remedy for any and all alleged breaches of
the Agreement by Licensor or the State of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">-- END OF EXHIBIT A --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Patent Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: bottom; width: 12%; border: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="text-align: center; width: 20%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="vertical-align: bottom; width: 24%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 12%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 12%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7861 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/254,487 filed on 10/11/2021</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DRY FORMULATIONS OF ANTI-SARS-COV-2 VIRUS ANTIBODIES AND COMPOSITIONS AND METHODS OF USE THEREOF</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III (UT),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui (UT),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haiyue Xu (UT),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christopher Emig (Augmenta),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven J. Henry (Augmenta),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adela A. Vitug (Augmenta),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dale Christensen (TFF)</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, TFF Pharmaceuticals and Augmenta Bioworks, Inc.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooley LLP (TFF Pharma leading prosecution)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7822 CUI</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/232,099 filed on 8/11/2021</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Khaled AboulFotouh,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7779 CUI</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/232,091 filed on 8/11/2021</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DRY POWDER COMPOSITIONS OF OIL-IN-WATER (O/W) EMULSION ADJUVANTED VACCINES</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaeho Moon,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Khaled AboulFotouh,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haiyue Xu,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7752 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/239,333 filed on 8/31/2021</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed Release Niclosamide Formation</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III (UT),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zachary N. Warnken,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Miguel O. Jara</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Koleng (TFF),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, TFF Pharmaceuticals</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7714 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/158,280 filed on 3/8/2021</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dry Powder Formulations of Nucleic Acid Lipid Nanoparticles</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaeho Moon,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sawittree Sahakijpijarn,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haiyue Xu,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7715 CUI</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/232,076 filed on 8/11/2021</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DRY LIPOSOME ADJUVANT-CONTAINING VACCINES AND RELATED METHODS</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haiyue Xu,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Khaled AboulFotouh</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7626 WIL</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2021/042010 filed on 7/16/2021,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">claiming priority to 63/053,339</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed on 7/17/2020</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions for delivery of Remdesivir by inhalation</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaeho Moon,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sawittree Sahakijpijarn,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Koleng (TFF),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dale Christensen (TFF),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glenn Mattes (TFF)</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, TFF Pharmaceuticals</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 28; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; text-align: center; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7625 WIL</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/162,835 filed on 3/18/21</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions for delivery of drug combinations to treat lung disease</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jay I. Peters (UTHSC-SA),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tuangrat Praphawatvet,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sawittree Sahakijpijarn,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaeho Moon</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, University of Texas Health Science Center at San Antonio</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7574 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2021/025455 filed on 4/01/2021,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 17/220,833 filed on 4/01/2021,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">claiming priority to</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">63/003,793 filed on 4/01/2020</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions of Niclosamide</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hugh D. Smyth,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zachary N. Warnken,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Miguel O. Jara Gonzalez,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hyo-Jong Seo,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ashlee D. Brunaugh,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matthew Herpin</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7597 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/160,588 filed on 3/12/2021</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Methods to Prepare Dry Powder using Suspension-based Thin Film Freezing</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sawittree Sahakijpijarn,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaeho Moon,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John J. Koleng (TFF)</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, TFF Pharmaceuticals</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7572 WIL</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2021/028140 filed on 4/20/2021,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 17/235,771 filed on 4/20/2021,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to 63/012,792 filed on 4/20/20</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biologically Active Dry Powder Compositions And Method Of Their Manufacture And Use</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hugh D. Smyth,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hairui Zhang,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jieliang Wang,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haiyue Xu,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yajie Zhang.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Debadyuti Ghosh,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jasmim Leal,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Melissa Soto,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaeho Moon,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sawittree Sahakijpijarn</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7488 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2020/051388 filed on 9/18/2020</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">claiming priority to 62/902,095 filed on 9/18/2019</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions for delivery of cannabinoids by inhalation</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Robert O. Williams III, Chaeho Moon, John J. Koleng (TFF)</TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, TFF Pharmaceuticals</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; text-align: center; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7314 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">China (PRC) 201980055623.X filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mexico MX/a/2021/000796 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Australia 2019311086 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brazil BR1120210012907 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada 3,106,618 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">India 2021170031365 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Europe 19840589.6 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israel 280342 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 17/262,313 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Japan 2021-503813 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">South Korea 10-2021-7005060 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eurasia 202190331 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2019/043202 filed on 7/24/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to 62/702,674</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">filed on 7/24/2018</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions of surface-modified therapeutically active particles by ultra-rapid freezing</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chaeho Moon,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alan B. Watts,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John J. Koleng</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; text-align: center; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7149 CUI</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada 3,083,953 filed on 12/11/2018,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 16/771,648 filed on 12/11/2018,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2018/064837 filed on 12/11/2018,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to 62/597,037 filed on 12/11/2017</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dry Adjuvanted Immune Stimulating Compositions and Use Thereof for Mucosal Administration</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sachin G. Thakkar</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6677 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">China (PRC) 201580080517.9 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2015/048093 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Australia 2015393953 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada 2,983,427 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 15/570,828 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brazil BR 112017023351-7 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Japan 2017-557057 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Japan 2021-34347 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">India 201717040247 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Europe 15766292.5, Patent No 3288541, Registered in United Kingdom,
    Ireland France Patent No EP3288541,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Germany Patent No 602015058428.7,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Luxembourg Switzerland</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Monaco filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">South Korea 10-2017-7034565 filed on 09/02/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">claiming priority to</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">62/156,052 filed on 05/01/2015</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multidrug Brittle Matrix Compositions</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alan B. Watts,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jay I. Peters (UTHSC-SA),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Simone Carvalho</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, University of Texas Health Science Center at San Antonio</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; text-align: center; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6272 CUI</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 16/156,511 filed on 10/10/2018, divisional of 14/941,323 filed on
    11/13/2016,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2014/038475 filed on 5/16/2014,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to 61/824,181 filed on 5/16/2013</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dry Solid Aluminum Adjuvant-Containing Vaccines and Related Methods Thereof</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zhengrong Cui,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xinran Li</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5612 DOW</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 14/861,046 Filed on 9/22/2015 divisional of US 10/639,361, Patent
    No 9,175,906 filed on 8/12/2003,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2003/025338 filed on 8/12/2003,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Singapore 200504247-8, Patent No 112782 filed on 8/12/2003,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Japan 2004-566896, Patent No 4933732 filed on 8/12/2003</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug Particles From Freezing onto a Surface</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James E. Hitt (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brian D. Scherzer (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jonathan C. Evans (DOW)</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">N</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5408 JOH</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 16/839,957 filed on 4/3/2020,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 16/555,165, Patent No 10,660,850 filed on 8/29/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of 16/115,888, Patent No 10,434,062 filed on 8/29/2018,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CIP of 12/778,795, Patent No 10,092,512 filed on 5/12/2010</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions and Methods of Making Brittle-Matrix Particles Through Blister Pack Freezing</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Keith P. Johnston,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jasmine Tam (Rowe),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alan B. Watts,.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshua D. Engstrom.</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5312 JOH</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 12/371,573 filed on 2/13/2009,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Australia Patent No 2009214443 filed on 2/13/2009,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada Patent No 2,723,314 filed on 2/13/2009,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Europe 09709833.9, Patent No 2252275, Registered in Belgium, Sweden
    Patent No 09709833.9,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Norway, Netherlands, Switzerland, Denmark, United Kingdom, Ireland,
    Monaco, Finland, Luxembourg, Germany Patent No 602009049607.7,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">France, filed on 2/13/2009,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to US 61/028,218 filed on 2/13/2008</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary Delivery</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshua D. Engstrom,.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Keith P. Johnston,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">asmine Tam (Rowe),</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5254 JOH</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 17/154,610 filed on 1/21/2021,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 16/410,189, Patent No 10,898,437 filed on 5/13/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 15/479,137, Patent No 10,285,945 filed on 4/4/2017,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 14/603,211, Patent No 9,622,974, filed on 1/22/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of 12/665,386, Patent No 8,968,786, filed on 6/20/2008</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada 2,691,531, Patent No 2,691,531 filed on 12/22/2009,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Japan 2010-513468, Patent No 5658031, filed on 6/20/2008,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2008/067766 filed on 6/20/2008,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Europe 08771657.7, Patent No 2170283, Registered in France,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Germany Patent No 60 2008 058 694.4, Switzerland, United Kingdom, Denmark,
    Finland, Hungary, Iceland,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Netherlands, Norway, Sweden, Spain, Belgium, Ireland, Italy Patent
    No 502019000027264,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to 60/945,737 filed on 6/22/2007</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formation of Stable Submicron Protein Particles by Thin Film Freezing</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshua D. Engstrom,.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Keith P. Johnston,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: gray 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT Tech ID</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; text-align: center; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">App. No./</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Filing</P></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventor(s)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jointly <BR>
Owned? (Y/N; if Y, with whom?)</FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; vertical-align: bottom; border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prosecution <BR>
Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5175 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US 16/294,885, filed on 3/06/2019,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 14/621,337, Patent No 10,231,955 filed on 2/12/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 12/522,774, Patent No 9,044,391, filed on 1/10/2008,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada 3,027,598, Patent No 3,027,598, filed on 12/14/2018,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Divisional of Canada 2,678,455, Patent No 2,678,455, filed on 1/10/2008,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2008/050795 filed on 1/10/2008,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Europe 08780367.2, Patent No 2124898 filed on 1/10/2008,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United Kingdom 2124898 filed on 8/06/2009,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Spain 08780367.2, Patent No 2124898 filed on 8/06/2009,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">France 2124898, Patent No 2124898 filed on 8/06/2009</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Germany 08780367.2, Patent No 602008026819.5 filed on 8/06/2009</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to 60/884,383 filed on 1/10/2007</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhanced Delivery of Immunosuppressive Drug Compositions for Pulmonary Delivery</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jay I. Peters,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prapasri Sinswat,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jason T. McConville,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert L. Talbert Jr.,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Keith P. Johnston,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alan B. Watts,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">True L. Rogers (DOW)</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2802 WIL</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14/713,156, Patent No 9,724,344 filed on 5/15/2015,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continuation of 11/660,012, Patent No 9,061,027 filed on 8/15/2007,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/US2005/030543 filed on 8/26/2005</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Claiming priority to 60/605,179 filed on 8/27/2004</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhanced Delivery of Drug Compositions to Treat Life Threatening Infections</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nicholas S. Beck (DOW)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David S. Burgess,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ian B. Gillespie (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paula C. Garcia (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David A. Hayes (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Keith P. Johnston,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James E. Hitt (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jay I. Peters (UTHSC-SA),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">True L. Rogers,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jason T. McConville,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brian D. Scherzer (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert L. Talbert Jr.,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christopher J. Tucker (DOW),</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert O. Williams III,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Timothy J. Young</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y, University of Texas Health Science Center at San Antonio.&nbsp;&nbsp;.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parker Highlander PLLC</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Niclosamide Diligence Milestones</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Licensee by itself
or through its Affiliates and Sublicensees will use diligent efforts to make commercially available products or services that practice
an issued or pending claim of any patent or application listed under or claiming priority from an application listed under UT Tech ID
7574 WIL in the Patent Rights in Exhibit B, for example, oral or inhaled formulations of niclosamide (&ldquo;<B>Niclosamide Products</B>&rdquo;).
Without limiting the foregoing, Licensee will (a) maintain a reasonably funded, ongoing and active research, development, manufacturing,
regulatory, marketing or sales program required to make Niclosamide Products commercially available, and (b) by itself or through its
Affiliates and Sublicensees fulfill the Niclosamide Milestone Events specified in this Exhibit C and (c) use diligent and commercially
reasonable efforts to perform and complete the plans described in the annual report submitted pursuant to Section 4.2 (Annual Written
Progress Report). If the obligations under this Exhibit C are not fulfilled, Licensor may treat such failure as a breach in accordance
with Section 7.3(b), provided however if the breach is a result of not meeting the Niclosamide Milestone Events specified in this Exhibit
C, Licensor will work in good faith with Licensee to cure such breach by amending the PLA to change the Field of the exclusive license
to Patent Rights based on UT Tech ID 7574 WIL from &ldquo;All fields&rdquo; to &ldquo;dry powders manufactured by thin film freezing or
ultra-rapid freezing technology.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">With regard to
the Niclosamide Milestone Events specified in this Exhibit C, Licensee may at its election, extend the target date for fulfillment of
such milestone events by twelve (12) months upon written notice to Licensor and payment to Licensor of an amount equal to $10,000. Licensee
may invoke this clause only one time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If Licensee sublicenses
Patent Rights for the development of Niclosamide Products, and Sublicensee develops an alternate development plan within 24 months of
Amendment Effective Date, Licensor will renegotiate Niclosamide Milestone Events in good faith according to Sublicensee&rsquo;s reasonable
timeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="7" STYLE="width: 17%; border: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Niclosamide Diligence Milestones and deadlines</FONT></TD>
    <TD STYLE="width: 65%; border-top: gray 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Niclosamide Milestone Events</FONT></TD>
    <TD STYLE="width: 18%; border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deadlines</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.4pt">Manufacture dosage form under GMP or GLP conditions for
    a Niclosamide Product that is intended for oral administration.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.4pt">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 1, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 12.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Test a Niclosamide Product in humans that is administered orally.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 1, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 12.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND submission for a Niclosamide Product that is intended for oral administration.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 1, 2023</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 12.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiate appropriate clinical study for an orally available Niclosamide Product.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 1, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 12.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receive Regulatory Approval for a Niclosamide Product for oral administration. </FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 1, 2027</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: gray 1pt solid; padding-left: 12.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First sale of orally available Niclosamide Product.</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 1, 2028</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If Licensor or
a third party discovers that the Niclosamide Products are useful for an application for which Products have not been developed or are
not currently under development by Licensee by itself or through its Affiliates and Sublicensees, then Licensor shall give written notice
to the Licensee, except for information that is subject to restrictions of confidentiality with third parties.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Within ninety
(90) days following Licensee&rsquo;s receipt of Licensor&rsquo;s notification, Licensee shall give Licensor written notice stating whether
Licensee elects to develop Niclosamide Products for the application. If Licensee elects to develop and commercialize the proposed Niclosamide
Products for the new application, Licensee shall provide Licensor with a commercial development plan for the new application, including
proposed commercial milestones. Licensor and Licensee shall negotiate in good faith new diligence milestones for such application, which
shall be added to this Agreement by amendment.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If Licensee elects
not to develop and commercialize the proposed Niclosamide Products for use in the new application, Licensor may seek third parties to
develop and commercialize the proposed Niclosamide Products for the new application. If Licensor identifies a third party, it shall refer
such third party to Licensee. If the third party requests a sublicense under this Agreement, then Licensee shall report the request to
Licensor within thirty (30) days from the date of such written request. If Licensee does not grant a sublicense to such third party within
ninety (90) days of its request, then Licensee shall submit to Licensor a report specifying the license terms proposed by the third party
and written justification for the Licensee&rsquo;s refusal to grant the proposed sublicense. If Licensor, at is sole discretion, determines
that the terms of the sublicense proposed by the third party are reasonable under the totality of the circumstances, taking into account
the Niclosamide Products in development by Licensee or through its Affiliates and Sublicensees, then Licensor shall have the right to
grant such third party a non-exclusive license to use, sell, offer for sale, and import Niclosamide Products for such new application
in the Licensed Field on substantially the same terms as proposed to Licensee by the third party, providing royalty rates are at least
equal to those paid or required to be paid by Licensee under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee: TFF Pharmaceuticals, Inc.</FONT></TD><TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIAL</FONT></TD><TD STYLE="width: 40%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Patent License Agreement</FONT></TD></TR><TR STYLE="vertical-align: top"><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The University of Texas at Austin</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 37</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement No. PM2202501</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10q0322ex31-1_tffpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Glenn Mattes, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this Form 10-Q of TFF Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d- 15(f)) for the company and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the Company&rsquo;s most
recent quarter that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over
financial reporting; And</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TFF PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 11, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Glenn Mattes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glenn Mattes, Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>f10q0322ex31-2_tffpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Kirk Coleman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this Form 10-Q of TFF Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d- 15(f)) for the company and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the Company&rsquo;s most
recent quarter that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over
financial reporting; And</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TFF PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 11, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Kirk Coleman</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Kirk Coleman, Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">(Principal Financial Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>f10q0322ex32-1_tffpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S.C. 1350, AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report of TFF
Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), I, Glenn Mattes, the Chief Executive Officer, and Kirk Coleman, the Chief Financial
Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Glenn Mattes</I></FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;May 11, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glenn Mattes,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Kirk Coleman</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;May 11, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirk Coleman,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification is made solely for the purposes
of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 (L# 2(  A$! Q$!_\0
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MGCN(Q)$ZNAZ,IR#4E100I;PI#$@2-%"JHZ "I:1:"BDILDB11L[N%11DL3@
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MH[GVK9TCX?Z+=VK7LGB".ZMH_P#6-;E0JXZY;M4O_"':I]GLU33XOW.GQ"6
ML%69UF+M&2/48YZ5I:CIVJ:WI<]I9>'H=(%_*D<\DI4DQ+RV]5['[HYSR:J6
M,K2TYB(9?0CKRF]I&B>']&DBCL(;=9Y4\Q&9@SNO=@3VZ5K6.HV6HH[V5U#<
M*CE',3A@K#L<=Z\_LM'\0:=>Z8EQI9O4L[>XL?,BD"*T;D;&Y.0,<>HQ6WX$
MTN_TJ&]AN;(VEKN5;=)"C28 P067[RCL3S7++6[;N=D81BK15CL****@L***
J* "BBB@04444#"BBBBP!1110 4444 %%%% @HHHH&@HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>tffp-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 05:01:33 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://tffp.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:tffp="http://tffp.com/20220331" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20220331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20220331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20220331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20220331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedBalanceSheet" id="tffp_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals" id="tffp_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedIncomeStatement" id="tffp_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ShareholdersEquityType2or3" id="tffp_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedCashFlow" id="tffp_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/OrganizationandDescriptionofBusiness" id="tffp_r_OrganizationandDescriptionofBusiness">
        <link:definition>006 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LiquidityandManagementsPlans" id="tffp_r_LiquidityandManagementsPlans">
        <link:definition>007 - Disclosure - Liquidity and Management&#8217;s Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SummaryofSignificantAccountingPolicies" id="tffp_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/CommitmentsandContingencies" id="tffp_r_CommitmentsandContingencies">
        <link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LicenseandAgreements" id="tffp_r_LicenseandAgreements">
        <link:definition>010 - Disclosure - License and Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockBasedCompensation" id="tffp_r_StockBasedCompensation">
        <link:definition>011 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SubsequentEvents" id="tffp_r_SubsequentEvents">
        <link:definition>012 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/AccountingPoliciesByPolicy" id="tffp_r_AccountingPoliciesByPolicy">
        <link:definition>013 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables" id="tffp_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>014 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/CommitmentsandContingenciesTables" id="tffp_r_CommitmentsandContingenciesTables">
        <link:definition>015 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockBasedCompensationTables" id="tffp_r_StockBasedCompensationTables">
        <link:definition>016 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LiquidityandManagementsPlansDetails" id="tffp_r_LiquidityandManagementsPlansDetails">
        <link:definition>017 - Disclosure - Liquidity and Management&#8217;s Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails" id="tffp_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>018 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable" id="tffp_r_ScheduleofpotentialcommonstockequivalentsoutstandingTable">
        <link:definition>019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0cRffbuw4EmArolVL7JcutiDhHh5xiitTb/y8TaDQcUHL6I7rOA4HAM+CZSIX8sCdNA7WoMzgTreBxRK0VvULUeJI0bHvVrHP4bLHH5F4kzgTDLSh9T6rxNEwn7HryahL] CSR-->
      <link:roleType roleURI="http://tffp.com/role/CommitmentsandContingenciesDetails" id="tffp_r_CommitmentsandContingenciesDetails">
        <link:definition>020 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable" id="tffp_r_ScheduleoffutureminimumleasepaymentsTable">
        <link:definition>021 - Disclosure - Commitments and Contingencies (Details) - Schedule of future minimum lease payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LicenseandAgreementsDetails" id="tffp_r_LicenseandAgreementsDetails">
        <link:definition>022 - Disclosure - License and Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockBasedCompensationDetails" id="tffp_r_StockBasedCompensationDetails">
        <link:definition>023 - Disclosure - Stock Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" id="tffp_r_ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable">
        <link:definition>024 - Disclosure - Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable" id="tffp_r_ScheduleoffairvalueofemployeestockoptionsTable">
        <link:definition>025 - Disclosure - Stock Based Compensation (Details) - Schedule of fair value of employee stock options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofstockoptionactivityTable" id="tffp_r_ScheduleofstockoptionactivityTable">
        <link:definition>026 - Disclosure - Stock Based Compensation (Details) - Schedule of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="LiquidityAndManagementsPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LiquidityAndManagementsPlansAbstract"/>
  <xs:element name="ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumLeasePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
  <xs:element name="LicenseAndAgreementDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LicenseAndAgreementDisclosureAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract"/>
  <xs:element name="ScheduleOfFairValueOfEmployeeStockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="CondensedConsolidatedStatementsOfComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract"/>
  <xs:element name="OtherComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_OtherComprehensiveLossAbstract"/>
  <xs:element name="AssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_AssumptionsAbstract"/>
  <xs:element name="ReceivableDueFromCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ReceivableDueFromCollaborationAgreement"/>
  <xs:element name="ResearchAndDevelopmentTaxIncentiveReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ResearchAndDevelopmentTaxIncentiveReceivable"/>
  <xs:element name="AccruedCompensationLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_AccruedCompensationLiabilities"/>
  <xs:element name="ForeignCurrencyTranslationAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ForeignCurrencyTranslationAdjustments"/>
  <xs:element name="ForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ForeignCurrencyTranslationAdjustment"/>
  <xs:element name="IssuanceOfCommonStockForStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockForStockOptionExercises"/>
  <xs:element name="IssuanceOfCommonStockForStockOptionExercisesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
  <xs:element name="StockBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockBasedCompensation"/>
  <xs:element name="ReceivableDueFromCollaborationsAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ReceivableDueFromCollaborationsAgreement"/>
  <xs:element name="ResearchAndDevelopmentTaxIncentiveReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ResearchAndDevelopmentTaxIncentiveReceivables"/>
  <xs:element name="IncreaseDecreaseDeferredResearchGrantRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
  <xs:element name="ProceedsFromIssuanceOfCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ProceedsFromIssuanceOfCommonStockValue"/>
  <xs:element name="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
  <xs:element name="ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
  <xs:element name="EffectOfExchangeRateChangesOnCashAndCashEquivalent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
  <xs:element name="CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_CashlessExerciseOfWarrants"/>
  <xs:element name="LiquidityAndManagementsPlansTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LiquidityAndManagementsPlansTextBlock"/>
  <xs:element name="LiquidityandManagementsPlansTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_LiquidityandManagementsPlansTable"/>
  <xs:element name="LiquidityandManagementsPlansLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LiquidityandManagementsPlansLineItems"/>
  <xs:element name="LicenseAndAgreementDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LicenseAndAgreementDisclosureTextBlock"/>
  <xs:element name="CollaborativeArrangementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_CollaborativeArrangementsPolicyTextBlock"/>
  <xs:element name="ResearchAndDevelopmentTaxIncentivePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems"/>
  <xs:element name="StockBasedCompensationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockBasedCompensationExpenses"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionesExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
  <xs:element name="WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance"/>
  <xs:element name="WeightedAverageRemainingContractualTermOutstandingEndingBalance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance"/>
  <xs:element name="AggregateIntrinsicValueExercisables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_AggregateIntrinsicValueExercisables"/>
  <xs:element name="CashAndCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_CashAndCashEquivalents"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="ResearchAndDevelopmentTaxPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ResearchAndDevelopmentTaxPercentage"/>
  <xs:element name="AgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_AgreementDomain"/>
  <xs:element name="LicenseandAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_LicenseandAgreementsDetailsTable"/>
  <xs:element name="LicenseandAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LicenseandAgreementsDetailsLineItems"/>
  <xs:element name="MilestoneFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_MilestoneFee"/>
  <xs:element name="AgreementTremDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_AgreementTremDescription"/>
  <xs:element name="AgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_AgreementDescription"/>
  <xs:element name="PremarketingApprovals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_PremarketingApprovals"/>
  <xs:element name="InterstFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_InterstFee"/>
  <xs:element name="ReservedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ReservedShares"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="tffp_AgreementAxis"/>
  <xs:element name="April2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_April2019Member"/>
  <xs:element name="ClinicalTrialResearchAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ClinicalTrialResearchAgreementMember"/>
  <xs:element name="ContractManufacturingServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ContractManufacturingServicesMember"/>
  <xs:element name="January2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_January2021Member"/>
  <xs:element name="MasterConsultancyAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_MasterConsultancyAgreementMember"/>
  <xs:element name="MasterServicesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_MasterServicesAgreementMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockOptionsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>tffp-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 05:01:33 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedBalanceSheet" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedIncomeStatement" roleURI="http://tffp.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedCashFlow" roleURI="http://tffp.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivableDueFromCollaborationAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationAgreement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="tffp_ReceivableDueFromCollaborationAgreement" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_AccruedCompensationLiabilities" xlink:href="tffp-20220331.xsd#tffp_AccruedCompensationLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="tffp_AccruedCompensationLiabilities" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0cRffbuw4EmArolVL7JcutiDhHh5xiitTb/y8TaDQcUHL6I7rOA4HAM+CZSIX8sCdNA7WoMzgTreBxRK0VvULUeJI0bHvVrHP4bLHH5F4kzjSQ2z+J3PuhLOncAnZgsY1C3g+m0Nw2So=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20220331.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="tffp_ForeignCurrencyTranslationAdjustments" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensation" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tffp_StockBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivableDueFromCollaborationsAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationsAgreement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tffp_ReceivableDueFromCollaborationsAgreement" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20220331.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:href="tffp-20220331.xsd#tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20220331.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" order="4" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>tffp-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 05:01:33 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedBalanceSheet" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedIncomeStatement" roleURI="http://tffp.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ShareholdersEquityType2or3" roleURI="http://tffp.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedCashFlow" roleURI="http://tffp.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_OrganizationandDescriptionofBusiness" roleURI="http://tffp.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LiquidityandManagementsPlans" roleURI="http://tffp.com/role/LiquidityandManagementsPlans"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SummaryofSignificantAccountingPolicies" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_CommitmentsandContingencies" roleURI="http://tffp.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LicenseandAgreements" roleURI="http://tffp.com/role/LicenseandAgreements"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_StockBasedCompensation" roleURI="http://tffp.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SubsequentEvents" roleURI="http://tffp.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_AccountingPoliciesByPolicy" roleURI="http://tffp.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_CommitmentsandContingenciesTables" roleURI="http://tffp.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_StockBasedCompensationTables" roleURI="http://tffp.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleofpotentialcommonstockequivalentsoutstandingTable" roleURI="http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleoffutureminimumleasepaymentsTable" roleURI="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" roleURI="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleoffairvalueofemployeestockoptionsTable" roleURI="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleofstockoptionactivityTable" roleURI="http://tffp.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LiquidityandManagementsPlansDetails" roleURI="http://tffp.com/role/LiquidityandManagementsPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_CommitmentsandContingenciesDetails" roleURI="http://tffp.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LicenseandAgreementsDetails" roleURI="http://tffp.com/role/LicenseandAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_StockBasedCompensationDetails" roleURI="http://tffp.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#DocumentAndEntityInformation" roleURI="http://tffp.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivableDueFromCollaborationAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="tffp_ReceivableDueFromCollaborationAgreement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AccruedCompensationLiabilities" xlink:href="tffp-20220331.xsd#tffp_AccruedCompensationLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="tffp_AccruedCompensationLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract" xlink:href="tffp-20220331.xsd#tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_OtherComprehensiveLossAbstract" xlink:href="tffp-20220331.xsd#tffp_OtherComprehensiveLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="tffp_OtherComprehensiveLossAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20220331.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_OtherComprehensiveLossAbstract" xlink:to="tffp_ForeignCurrencyTranslationAdjustments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockForStockOptionExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercises" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustment" xlink:href="tffp-20220331.xsd#tffp_ForeignCurrencyTranslationAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_ForeignCurrencyTranslationAdjustment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensation" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tffp_StockBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivableDueFromCollaborationsAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationsAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tffp_ReceivableDueFromCollaborationsAgreement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20220331.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:href="tffp-20220331.xsd#tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20220331.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_CashlessExerciseOfWarrants" xlink:href="tffp-20220331.xsd#tffp_CashlessExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tffp_CashlessExerciseOfWarrants" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlans">
    <loc xlink:type="locator" xlink:label="tffp_LiquidityandManagementsPlansLineItems" xlink:href="tffp-20220331.xsd#tffp_LiquidityandManagementsPlansLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityandManagementsPlansTable" xlink:href="tffp-20220331.xsd#tffp_LiquidityandManagementsPlansTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_LiquidityandManagementsPlansLineItems" xlink:to="tffp_LiquidityandManagementsPlansTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock" xlink:href="tffp-20220331.xsd#tffp_LiquidityAndManagementsPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LiquidityandManagementsPlansLineItems" xlink:to="tffp_LiquidityAndManagementsPlansTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreements">
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementDisclosureAbstract" xlink:href="tffp-20220331.xsd#tffp_LicenseAndAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementDisclosureTextBlock" xlink:href="tffp-20220331.xsd#tffp_LicenseAndAgreementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseAndAgreementDisclosureAbstract" xlink:to="tffp_LicenseAndAgreementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_CollaborativeArrangementsPolicyTextBlock" xlink:href="tffp-20220331.xsd#tffp_CollaborativeArrangementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_CollaborativeArrangementsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0cRffbuw4EmArolVL7JcutiDhHh5xiitTb/y8TaDQcUHL6I7rOA4HAM+CZSIX8sCdNA7WoMzgTreBxRK0VvULUeJI0bHvVrHP4bLHH5F4kzg1ewkK86SUQyhpxCrcB0MqmUlLv/SgeSM=] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable">
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_StockOptionsMember" xlink:href="tffp-20220331.xsd#tffp_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tffp_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable">
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationExpenses" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" xlink:to="tffp_StockBasedCompensationExpenses" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable">
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AssumptionsAbstract" xlink:href="tffp-20220331.xsd#tffp_AssumptionsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="tffp_AssumptionsAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_AssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_AssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_AssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_AssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfStockOptionActivityAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="tffp-20220331.xsd#tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:href="tffp-20220331.xsd#tffp_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" xlink:href="tffp-20220331.xsd#tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance" xlink:href="tffp-20220331.xsd#tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AggregateIntrinsicValueExercisables" xlink:href="tffp-20220331.xsd#tffp_AggregateIntrinsicValueExercisables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_AggregateIntrinsicValueExercisables" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlansDetails">
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20220331.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_CashAndCashEquivalents" xlink:href="tffp-20220331.xsd#tffp_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LiquidityAndManagementsPlansAbstract" xlink:to="tffp_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SurplusNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SurplusNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LiquidityAndManagementsPlansAbstract" xlink:to="us-gaap_SurplusNotes" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxPercentage" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_ResearchAndDevelopmentTaxPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreementsDetails">
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsLineItems" xlink:href="tffp-20220331.xsd#tffp_LicenseandAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsTable" xlink:href="tffp-20220331.xsd#tffp_LicenseandAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_LicenseandAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_LicenseandAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_LicenseandAgreementsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementAxis" xlink:href="tffp-20220331.xsd#tffp_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_LicenseandAgreementsDetailsTable" xlink:to="tffp_AgreementAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementDomain" xlink:href="tffp-20220331.xsd#tffp_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tffp_AgreementAxis" xlink:to="tffp_AgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementDomain_0" xlink:href="tffp-20220331.xsd#tffp_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tffp_AgreementAxis" xlink:to="tffp_AgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ContractManufacturingServicesMember" xlink:href="tffp-20220331.xsd#tffp_ContractManufacturingServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_ContractManufacturingServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_MasterServicesAgreementMember" xlink:href="tffp-20220331.xsd#tffp_MasterServicesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_AgreementDomain" xlink:to="tffp_MasterServicesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_MasterConsultancyAgreementMember" xlink:href="tffp-20220331.xsd#tffp_MasterConsultancyAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_AgreementDomain" xlink:to="tffp_MasterConsultancyAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ClinicalTrialResearchAgreementMember" xlink:href="tffp-20220331.xsd#tffp_ClinicalTrialResearchAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_AgreementDomain" xlink:to="tffp_ClinicalTrialResearchAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_April2019Member" xlink:href="tffp-20220331.xsd#tffp_April2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tffp_April2019Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_January2021Member" xlink:href="tffp-20220331.xsd#tffp_January2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tffp_January2021Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_MilestoneFee" xlink:href="tffp-20220331.xsd#tffp_MilestoneFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_MilestoneFee" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementTremDescription" xlink:href="tffp-20220331.xsd#tffp_AgreementTremDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_AgreementTremDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementDescription" xlink:href="tffp-20220331.xsd#tffp_AgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_AgreementDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_PremarketingApprovals" xlink:href="tffp-20220331.xsd#tffp_PremarketingApprovals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_PremarketingApprovals" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_InterstFee" xlink:href="tffp-20220331.xsd#tffp_InterstFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_InterstFee" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherReceivables" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_ReservedShares" xlink:href="tffp-20220331.xsd#tffp_ReservedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tffp_ReservedShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfWeightedAverageCostInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfWeightedAverageCostInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_PercentageOfWeightedAverageCostInventory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="31" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>tffp-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 05:01:33 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20220331.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LiquidityAndManagementsPlansAbstract_lbl" xml:lang="en-US">Liquidity And Managements Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityAndManagementsPlansAbstract" xlink:to="tffp_LiquidityAndManagementsPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract_lbl" xml:lang="en-US">Schedule of potential common stock equivalents outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract" xlink:to="tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract_lbl" xml:lang="en-US">Schedule of future minimum lease payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:to="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementDisclosureAbstract" xlink:href="tffp-20220331.xsd#tffp_LicenseAndAgreementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseAndAgreementDisclosureAbstract_lbl" xml:lang="en-US">License And Agreement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseAndAgreementDisclosureAbstract" xlink:to="tffp_LicenseAndAgreementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract_lbl" xml:lang="en-US">Schedule of stock-based compensation expense stock options and warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract" xlink:to="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract_lbl" xml:lang="en-US">Schedule of fair value of employee stock options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:to="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfStockOptionActivityAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of stock option activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares, Outstanding, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Intrinsic Value, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivableDueFromCollaborationAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ReceivableDueFromCollaborationAgreement_lbl" xml:lang="en-US">Receivable due from collaboration agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivableDueFromCollaborationAgreement" xlink:to="tffp_ReceivableDueFromCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivable_lbl" xml:lang="en-US">Research and development tax incentive receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid assets and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Deferred research grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Deferred grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (see Note 4)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock; $0.001 par value, 45,000,000 shares authorized; 25,371,781 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Recorded research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract" xlink:href="tffp-20220331.xsd#tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract" xlink:to="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_OtherComprehensiveLossAbstract" xlink:href="tffp-20220331.xsd#tffp_OtherComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_OtherComprehensiveLossAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OtherComprehensiveLossAbstract" xlink:to="tffp_OtherComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustment" xlink:href="tffp-20220331.xsd#tffp_ForeignCurrencyTranslationAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ForeignCurrencyTranslationAdjustment_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustment" xlink:to="tffp_ForeignCurrencyTranslationAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockForStockOptionExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl" xml:lang="en-US">Issuance of common stock for stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl" xml:lang="en-US">Issuance of common stock for stock option exercises (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl" xml:lang="en-US">Issuance of common stock for warrant exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl" xml:lang="en-US">Issuance of common stock for warrant exercises (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensation" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_StockBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensation" xlink:to="tffp_StockBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20220331.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchases of equipment included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CashlessExerciseOfWarrants" xlink:href="tffp-20220331.xsd#tffp_CashlessExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CashlessExerciseOfWarrants" xlink:to="tffp_CashlessExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AccruedCompensationLiabilities" xlink:href="tffp-20220331.xsd#tffp_AccruedCompensationLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_AccruedCompensationLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AccruedCompensationLiabilities" xlink:to="tffp_AccruedCompensationLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20220331.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_ForeignCurrencyTranslationAdjustments_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustments" xlink:to="tffp_ForeignCurrencyTranslationAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivableDueFromCollaborationsAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationsAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_ReceivableDueFromCollaborationsAgreement_lbl" xml:lang="en-US">Receivable due from collaboration agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivableDueFromCollaborationsAgreement" xlink:to="tffp_ReceivableDueFromCollaborationsAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivables_lbl" xml:lang="en-US">Research and development tax incentive receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid assets and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20220331.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl" xml:lang="en-US">Proceeds from issuance of common stock for stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:href="tffp-20220331.xsd#tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock" xlink:href="tffp-20220331.xsd#tffp_LiquidityAndManagementsPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND MANAGEMENT&#8217;S PLANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityAndManagementsPlansTextBlock" xlink:to="tffp_LiquidityAndManagementsPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of potential common stock equivalents outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potential common stock equivalents outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Year Ending December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementDisclosureTextBlock" xlink:href="tffp-20220331.xsd#tffp_LicenseAndAgreementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_LicenseAndAgreementDisclosureTextBlock_lbl" xml:lang="en-US">LICENSE AND AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseAndAgreementDisclosureTextBlock" xlink:to="tffp_LicenseAndAgreementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense stock options and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationExpenses" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_StockBasedCompensationExpenses_lbl" xml:lang="en-US">Stock based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationExpenses" xlink:to="tffp_StockBasedCompensationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of employee stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AssumptionsAbstract" xlink:href="tffp-20220331.xsd#tffp_AssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AssumptionsAbstract_lbl" xml:lang="en-US">Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AssumptionsAbstract" xlink:to="tffp_AssumptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="tffp-20220331.xsd#tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" xlink:href="tffp-20220331.xsd#tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" xlink:to="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance" xlink:href="tffp-20220331.xsd#tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance" xlink:to="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AggregateIntrinsicValueExercisables" xlink:href="tffp-20220331.xsd#tffp_AggregateIntrinsicValueExercisables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AggregateIntrinsicValueExercisables_lbl" xml:lang="en-US">Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AggregateIntrinsicValueExercisables" xlink:to="tffp_AggregateIntrinsicValueExercisables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:href="tffp-20220331.xsd#tffp_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl" xml:lang="en-US">Number of Shares, Outstanding, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:to="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockOptionsMember" xlink:href="tffp-20220331.xsd#tffp_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockOptionsMember" xlink:to="tffp_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementAxis" xlink:href="tffp-20220331.xsd#tffp_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementAxis" xlink:to="tffp_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CashAndCashEquivalents" xlink:href="tffp-20220331.xsd#tffp_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CashAndCashEquivalents" xlink:to="tffp_CashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SurplusNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SurplusNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SurplusNotes_lbl" xml:lang="en-US">Working capital surplus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SurplusNotes" xlink:to="us-gaap_SurplusNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid assets and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxPercentage" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ResearchAndDevelopmentTaxPercentage_lbl" xml:lang="en-US">Research and development tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxPercentage" xlink:to="tffp_ResearchAndDevelopmentTaxPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development additional received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Short-term lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Assignment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0cRffbuw4EmArolVL7JcutiDhHh5xiitTb/y8TaDQcUHL6I7rOA4HAM+CZSIX8sCdNA7WoMzgTreBxRK0VvULUeJI0bHvVrHP4bLHH5F4kzisUwJAYxXIbbpl7v64oV9R6R1KQTVxxJg=] CSR-->
    <loc xlink:type="locator" xlink:label="tffp_MilestoneFee" xlink:href="tffp-20220331.xsd#tffp_MilestoneFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_MilestoneFee_lbl" xml:lang="en-US">Milestone fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MilestoneFee" xlink:to="tffp_MilestoneFee_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementTremDescription" xlink:href="tffp-20220331.xsd#tffp_AgreementTremDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AgreementTremDescription_lbl" xml:lang="en-US">Agreement term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementTremDescription" xlink:to="tffp_AgreementTremDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Research and development cost expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementDescription" xlink:href="tffp-20220331.xsd#tffp_AgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AgreementDescription_lbl" xml:lang="en-US">Agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementDescription" xlink:to="tffp_AgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_PremarketingApprovals" xlink:href="tffp-20220331.xsd#tffp_PremarketingApprovals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_PremarketingApprovals_lbl" xml:lang="en-US">Pre-marketing approvals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_PremarketingApprovals" xlink:to="tffp_PremarketingApprovals_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_InterstFee" xlink:href="tffp-20220331.xsd#tffp_InterstFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_InterstFee_lbl" xml:lang="en-US">Interest fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_InterstFee" xlink:to="tffp_InterstFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ReservedShares" xlink:href="tffp-20220331.xsd#tffp_ReservedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ReservedShares_lbl" xml:lang="en-US">Reserved shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReservedShares" xlink:to="tffp_ReservedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">IPO shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfWeightedAverageCostInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfWeightedAverageCostInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PercentageOfWeightedAverageCostInventory_lbl" xml:lang="en-US">Outstanding percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfWeightedAverageCostInventory" xlink:to="us-gaap_PercentageOfWeightedAverageCostInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl" xml:lang="en-US">Weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CollaborativeArrangementsPolicyTextBlock" xlink:href="tffp-20220331.xsd#tffp_CollaborativeArrangementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CollaborativeArrangementsPolicyTextBlock_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CollaborativeArrangementsPolicyTextBlock" xlink:to="tffp_CollaborativeArrangementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock_lbl" xml:lang="en-US">Research and Development Tax Incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock" xlink:to="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Earnings per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xml:lang="en-US">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_MasterServicesAgreementMember" xlink:href="tffp-20220331.xsd#tffp_MasterServicesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_MasterServicesAgreementMember_lbl" xml:lang="en-US">Master Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MasterServicesAgreementMember" xlink:to="tffp_MasterServicesAgreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tffp_MasterServicesAgreementMember_lbl0" xml:lang="en-US">Master Services Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MasterServicesAgreementMember" xlink:to="tffp_MasterServicesAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tffp_April2019Member" xlink:href="tffp-20220331.xsd#tffp_April2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_April2019Member_lbl" xml:lang="en-US">April 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_April2019Member" xlink:to="tffp_April2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_MasterConsultancyAgreementMember" xlink:href="tffp-20220331.xsd#tffp_MasterConsultancyAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_MasterConsultancyAgreementMember_lbl" xml:lang="en-US">Clinical Network Services Pty Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MasterConsultancyAgreementMember" xlink:to="tffp_MasterConsultancyAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ClinicalTrialResearchAgreementMember" xlink:href="tffp-20220331.xsd#tffp_ClinicalTrialResearchAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ClinicalTrialResearchAgreementMember_lbl" xml:lang="en-US">Clinical trial research agreement with Nucleus Network Pty Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ClinicalTrialResearchAgreementMember" xlink:to="tffp_ClinicalTrialResearchAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_January2021Member" xlink:href="tffp-20220331.xsd#tffp_January2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_January2021Member_lbl" xml:lang="en-US">January 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_January2021Member" xlink:to="tffp_January2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ContractManufacturingServicesMember" xlink:href="tffp-20220331.xsd#tffp_ContractManufacturingServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ContractManufacturingServicesMember_lbl" xml:lang="en-US">Contract manufacturing services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ContractManufacturingServicesMember" xlink:to="tffp_ContractManufacturingServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityandManagementsPlansTable" xlink:href="tffp-20220331.xsd#tffp_LiquidityandManagementsPlansTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LiquidityandManagementsPlansTable_lbl" xml:lang="en-US">Liquidity and Management&#8217;s Plans [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityandManagementsPlansTable" xlink:to="tffp_LiquidityandManagementsPlansTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityandManagementsPlansLineItems" xlink:href="tffp-20220331.xsd#tffp_LiquidityandManagementsPlansLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LiquidityandManagementsPlansLineItems_lbl" xml:lang="en-US">Liquidity and Managements Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityandManagementsPlansLineItems" xlink:to="tffp_LiquidityandManagementsPlansLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" xlink:to="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementDomain" xlink:href="tffp-20220331.xsd#tffp_AgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AgreementDomain_lbl" xml:lang="en-US">Agreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementDomain" xlink:to="tffp_AgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsTable" xlink:href="tffp-20220331.xsd#tffp_LicenseandAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseandAgreementsDetailsTable_lbl" xml:lang="en-US">License and Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseandAgreementsDetailsTable" xlink:to="tffp_LicenseandAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsLineItems" xlink:href="tffp-20220331.xsd#tffp_LicenseandAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseandAgreementsDetailsLineItems_lbl" xml:lang="en-US">License and Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_LicenseandAgreementsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_AccruedCompensationLiabilities_lbl0" xml:lang="en-US">Amount of accrued compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AccruedCompensationLiabilities" xlink:to="tffp_AccruedCompensationLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_AgreementDescription_lbl0" xml:lang="en-US">The description related to agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementDescription" xlink:to="tffp_AgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_CashlessExerciseOfWarrants_lbl0" xml:lang="en-US">Cashless exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CashlessExerciseOfWarrants" xlink:to="tffp_CashlessExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl0" xml:lang="en-US">Amount related to Conversion of Series A Preferred Stock (including accrued dividends) to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ForeignCurrencyTranslationAdjustment_lbl0" xml:lang="en-US">Foreign currency translation adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustment" xlink:to="tffp_ForeignCurrencyTranslationAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ForeignCurrencyTranslationAdjustments_lbl0" xml:lang="en-US">Foreign currency translation adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustments" xlink:to="tffp_ForeignCurrencyTranslationAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_InterstFee_lbl0" xml:lang="en-US">Interst fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_InterstFee" xlink:to="tffp_InterstFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_MilestoneFee_lbl0" xml:lang="en-US">Milestone fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MilestoneFee" xlink:to="tffp_MilestoneFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl0" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ReceivableDueFromCollaborationAgreement_lbl0" xml:lang="en-US">Receivable due from collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivableDueFromCollaborationAgreement" xlink:to="tffp_ReceivableDueFromCollaborationAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ReceivableDueFromCollaborationsAgreement_lbl0" xml:lang="en-US">Receivable due from collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivableDueFromCollaborationsAgreement" xlink:to="tffp_ReceivableDueFromCollaborationsAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivable_lbl0" xml:lang="en-US">Research and development tax incentive receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivables_lbl0" xml:lang="en-US">Research and development tax incentive receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ResearchAndDevelopmentTaxPercentage_lbl0" xml:lang="en-US">Research and development tax percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxPercentage" xlink:to="tffp_ResearchAndDevelopmentTaxPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl0" xml:lang="en-US">weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1" xml:lang="en-US">Number of options outstanding, including both vested and non-vested options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average exercise prices, outstanding, beginning balance (in Dollars per share).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_StockBasedCompensation_lbl0" xml:lang="en-US">Stock based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensation" xlink:to="tffp_StockBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_StockBasedCompensationExpenses_lbl0" xml:lang="en-US">Stock based compensation expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationExpenses" xlink:to="tffp_StockBasedCompensationExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:to="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CollaborativeArrangementsPolicyTextBlock_lbl0" xml:lang="en-US">CollaborativeArrangementsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CollaborativeArrangementsPolicyTextBlock" xlink:to="tffp_CollaborativeArrangementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_January2021Member_lbl0" xml:lang="en-US">January2021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_January2021Member" xlink:to="tffp_January2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl0" xml:lang="en-US">IssuanceOfCommonStockForStockOptionExercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionesExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:to="tffp_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseAndAgreementDisclosureTextBlock_lbl0" xml:lang="en-US">LicenseAndAgreementDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseAndAgreementDisclosureTextBlock" xlink:to="tffp_LicenseAndAgreementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockOptionsMember_lbl0" xml:lang="en-US">StockOptionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockOptionsMember" xlink:to="tffp_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl0" xml:lang="en-US">IncreaseDecreaseDeferredResearchGrantRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AggregateIntrinsicValueExercisables_lbl0" xml:lang="en-US">AggregateIntrinsicValueExercisables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AggregateIntrinsicValueExercisables" xlink:to="tffp_AggregateIntrinsicValueExercisables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ReceivableDueFromCollaborationAgreement_lbl1" xml:lang="en-US">ReceivableDueFromCollaborationAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivableDueFromCollaborationAgreement" xlink:to="tffp_ReceivableDueFromCollaborationAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_InterstFee_lbl1" xml:lang="en-US">InterstFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_InterstFee" xlink:to="tffp_InterstFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl1" xml:lang="en-US">ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AccruedCompensationLiabilities_lbl1" xml:lang="en-US">AccruedCompensationLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AccruedCompensationLiabilities" xlink:to="tffp_AccruedCompensationLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl2" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_MasterConsultancyAgreementMember_lbl0" xml:lang="en-US">MasterConsultancyAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MasterConsultancyAgreementMember" xlink:to="tffp_MasterConsultancyAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance_lbl0" xml:lang="en-US">WeightedAverageExercisePricesOutstandingOutstandingEndingBalance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" xlink:to="tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock_lbl0" xml:lang="en-US">LiquidityAndManagementsPlansTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityAndManagementsPlansTextBlock" xlink:to="tffp_LiquidityAndManagementsPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ForeignCurrencyTranslationAdjustment_lbl1" xml:lang="en-US">ForeignCurrencyTranslationAdjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustment" xlink:to="tffp_ForeignCurrencyTranslationAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AgreementAxis_lbl0" xml:lang="en-US">AgreementAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementAxis" xlink:to="tffp_AgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_MilestoneFee_lbl1" xml:lang="en-US">MilestoneFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MilestoneFee" xlink:to="tffp_MilestoneFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl1" xml:lang="en-US">ProceedsFromIssuanceOfCommonStockValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl0" xml:lang="en-US">IssuanceOfCommonStockForStockOptionExercisesShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl0" xml:lang="en-US">ProceedsFromIssuanceOfCommonStockForStockOptionExercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ResearchAndDevelopmentTaxPercentage_lbl1" xml:lang="en-US">ResearchAndDevelopmentTaxPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxPercentage" xlink:to="tffp_ResearchAndDevelopmentTaxPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance_lbl0" xml:lang="en-US">WeightedAverageRemainingContractualTermOutstandingEndingBalance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance" xlink:to="tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_MasterServicesAgreementMember_lbl1" xml:lang="en-US">MasterServicesAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MasterServicesAgreementMember" xlink:to="tffp_MasterServicesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_OtherComprehensiveLossAbstract_lbl0" xml:lang="en-US">OtherComprehensiveLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OtherComprehensiveLossAbstract" xlink:to="tffp_OtherComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock_lbl0" xml:lang="en-US">ResearchAndDevelopmentTaxIncentivePolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock" xlink:to="tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ClinicalTrialResearchAgreementMember_lbl0" xml:lang="en-US">ClinicalTrialResearchAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ClinicalTrialResearchAgreementMember" xlink:to="tffp_ClinicalTrialResearchAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationExpenses_lbl1" xml:lang="en-US">StockBasedCompensationExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationExpenses" xlink:to="tffp_StockBasedCompensationExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl0" xml:lang="en-US">EffectOfExchangeRateChangesOnCashAndCashEquivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AgreementDescription_lbl1" xml:lang="en-US">AgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementDescription" xlink:to="tffp_AgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ForeignCurrencyTranslationAdjustments_lbl1" xml:lang="en-US">ForeignCurrencyTranslationAdjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustments" xlink:to="tffp_ForeignCurrencyTranslationAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0" xml:lang="en-US">SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AgreementTremDescription_lbl0" xml:lang="en-US">AgreementTremDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementTremDescription" xlink:to="tffp_AgreementTremDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensation_lbl1" xml:lang="en-US">StockBasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensation" xlink:to="tffp_StockBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ReceivableDueFromCollaborationsAgreement_lbl1" xml:lang="en-US">ReceivableDueFromCollaborationsAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivableDueFromCollaborationsAgreement" xlink:to="tffp_ReceivableDueFromCollaborationsAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_April2019Member_lbl0" xml:lang="en-US">April2019Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_April2019Member" xlink:to="tffp_April2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AssumptionsAbstract_lbl0" xml:lang="en-US">AssumptionsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AssumptionsAbstract" xlink:to="tffp_AssumptionsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CashAndCashEquivalents_lbl0" xml:lang="en-US">CashAndCashEquivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CashAndCashEquivalents" xlink:to="tffp_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivables_lbl1" xml:lang="en-US">ResearchAndDevelopmentTaxIncentiveReceivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentiveReceivables" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ContractManufacturingServicesMember_lbl0" xml:lang="en-US">ContractManufacturingServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ContractManufacturingServicesMember" xlink:to="tffp_ContractManufacturingServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract_lbl0" xml:lang="en-US">CondensedConsolidatedStatementsOfComprehensiveLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract" xlink:to="tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_PremarketingApprovals_lbl0" xml:lang="en-US">PremarketingApprovals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_PremarketingApprovals" xlink:to="tffp_PremarketingApprovals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ReservedShares_lbl0" xml:lang="en-US">ReservedShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReservedShares" xlink:to="tffp_ReservedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ResearchAndDevelopmentTaxIncentiveReceivable_lbl1" xml:lang="en-US">ResearchAndDevelopmentTaxIncentiveReceivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="tffp_ResearchAndDevelopmentTaxIncentiveReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CashlessExerciseOfWarrants_lbl1" xml:lang="en-US">CashlessExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CashlessExerciseOfWarrants" xlink:to="tffp_CashlessExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl0" xml:lang="en-US">Research and Development Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SurplusNotes_lbl0" xml:lang="en-US">Surplus Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SurplusNotes" xlink:to="us-gaap_SurplusNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl0" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl0" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PercentageOfWeightedAverageCostInventory_lbl0" xml:lang="en-US">Percentage of Weighted Average Cost Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfWeightedAverageCostInventory" xlink:to="us-gaap_PercentageOfWeightedAverageCostInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl0" xml:lang="en-US">Component of Operating Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl1" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>tffp-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 05:01:33 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedBalanceSheet" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedIncomeStatement" roleURI="http://tffp.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ShareholdersEquityType2or3" roleURI="http://tffp.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ConsolidatedCashFlow" roleURI="http://tffp.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_OrganizationandDescriptionofBusiness" roleURI="http://tffp.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LiquidityandManagementsPlans" roleURI="http://tffp.com/role/LiquidityandManagementsPlans"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SummaryofSignificantAccountingPolicies" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_CommitmentsandContingencies" roleURI="http://tffp.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LicenseandAgreements" roleURI="http://tffp.com/role/LicenseandAgreements"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_StockBasedCompensation" roleURI="http://tffp.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SubsequentEvents" roleURI="http://tffp.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_AccountingPoliciesByPolicy" roleURI="http://tffp.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_CommitmentsandContingenciesTables" roleURI="http://tffp.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_StockBasedCompensationTables" roleURI="http://tffp.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleofpotentialcommonstockequivalentsoutstandingTable" roleURI="http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleoffutureminimumleasepaymentsTable" roleURI="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" roleURI="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleoffairvalueofemployeestockoptionsTable" roleURI="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_ScheduleofstockoptionactivityTable" roleURI="http://tffp.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LiquidityandManagementsPlansDetails" roleURI="http://tffp.com/role/LiquidityandManagementsPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_CommitmentsandContingenciesDetails" roleURI="http://tffp.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_LicenseandAgreementsDetails" roleURI="http://tffp.com/role/LicenseandAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#tffp_r_StockBasedCompensationDetails" roleURI="http://tffp.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20220331.xsd#DocumentAndEntityInformation" roleURI="http://tffp.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivableDueFromCollaborationAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="ReceivableDueFromCollaborationAgreement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="ResearchAndDevelopmentTaxIncentiveReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedCompensationLiabilities" xlink:href="tffp-20220331.xsd#tffp_AccruedCompensationLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="AccruedCompensationLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CondensedConsolidatedStatementsOfComprehensiveLossAbstract" xlink:href="tffp-20220331.xsd#tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="CondensedConsolidatedStatementsOfComprehensiveLossAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CondensedConsolidatedStatementsOfComprehensiveLossAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveLossAbstract" xlink:href="tffp-20220331.xsd#tffp_OtherComprehensiveLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherComprehensiveLossAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20220331.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveLossAbstract" xlink:to="ForeignCurrencyTranslationAdjustments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockForStockOptionExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForStockOptionExercises" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForStockOptionExercisesShares" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForStockOptionExercisesShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:href="tffp-20220331.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTranslationAdjustment" xlink:href="tffp-20220331.xsd#tffp_ForeignCurrencyTranslationAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ForeignCurrencyTranslationAdjustment" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensation" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="StockBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivableDueFromCollaborationsAgreement" xlink:href="tffp-20220331.xsd#tffp_ReceivableDueFromCollaborationsAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ReceivableDueFromCollaborationsAgreement" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentTaxIncentiveReceivables" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentiveReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ResearchAndDevelopmentTaxIncentiveReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20220331.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseDeferredResearchGrantRevenue" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20220331.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:href="tffp-20220331.xsd#tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20220331.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="EffectOfExchangeRateChangesOnCashAndCashEquivalent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessExerciseOfWarrants" xlink:href="tffp-20220331.xsd#tffp_CashlessExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CashlessExerciseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlans">
    <loc xlink:type="locator" xlink:label="LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20220331.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityandManagementsPlansTable" xlink:href="tffp-20220331.xsd#tffp_LiquidityandManagementsPlansTable"/>
    <loc xlink:type="locator" xlink:label="LiquidityandManagementsPlansLineItems" xlink:href="tffp-20220331.xsd#tffp_LiquidityandManagementsPlansLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndManagementsPlansAbstract" xlink:to="LiquidityandManagementsPlansTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandManagementsPlansTable" xlink:to="LiquidityandManagementsPlansLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndManagementsPlansTextBlock" xlink:href="tffp-20220331.xsd#tffp_LiquidityAndManagementsPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandManagementsPlansLineItems" xlink:to="LiquidityAndManagementsPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreements">
    <loc xlink:type="locator" xlink:label="LicenseAndAgreementDisclosureAbstract" xlink:href="tffp-20220331.xsd#tffp_LicenseAndAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LicenseAndAgreementDisclosureTextBlock" xlink:href="tffp-20220331.xsd#tffp_LicenseAndAgreementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndAgreementDisclosureAbstract" xlink:to="LicenseAndAgreementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborativeArrangementsPolicyTextBlock" xlink:href="tffp-20220331.xsd#tffp_CollaborativeArrangementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CollaborativeArrangementsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentTaxIncentivePolicyTextBlock" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentTaxIncentivePolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0cRffbuw4EmArolVL7JcutiDhHh5xiitTb/y8TaDQcUHL6I7rOA4HAM+CZSIX8sCdNA7WoMzgTreBxRK0VvULUeJI0bHvVrHP4bLHH5F4kzgloeTLAisLu7dNgU0/bp9bG61XNBEb+Fc=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="tffp-20220331.xsd#tffp_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationExpenses" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems" xlink:to="StockBasedCompensationExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:href="tffp-20220331.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssumptionsAbstract" xlink:href="tffp-20220331.xsd#tffp_AssumptionsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="AssumptionsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="tffp-20220331.xsd#tffp_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="tffp-20220331.xsd#tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:href="tffp-20220331.xsd#tffp_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionesExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_0" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" xlink:href="tffp-20220331.xsd#tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="WeightedAverageExercisePricesOutstandingOutstandingEndingBalance" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualTermOutstandingEndingBalance" xlink:href="tffp-20220331.xsd#tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="WeightedAverageRemainingContractualTermOutstandingEndingBalance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueExercisables" xlink:href="tffp-20220331.xsd#tffp_AggregateIntrinsicValueExercisables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="AggregateIntrinsicValueExercisables" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlansDetails">
    <loc xlink:type="locator" xlink:label="LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20220331.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalents" xlink:href="tffp-20220331.xsd#tffp_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndManagementsPlansAbstract" xlink:to="CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SurplusNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SurplusNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndManagementsPlansAbstract" xlink:to="us-gaap_SurplusNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tffp-20220331.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentTaxPercentage" xlink:href="tffp-20220331.xsd#tffp_ResearchAndDevelopmentTaxPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ResearchAndDevelopmentTaxPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreementsDetails">
    <loc xlink:type="locator" xlink:label="LicenseAndAgreementDisclosureAbstract" xlink:href="tffp-20220331.xsd#tffp_LicenseAndAgreementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LicenseandAgreementsDetailsTable" xlink:href="tffp-20220331.xsd#tffp_LicenseandAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LicenseandAgreementsDetailsLineItems" xlink:href="tffp-20220331.xsd#tffp_LicenseandAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndAgreementDisclosureAbstract" xlink:to="LicenseandAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="April2019Member" xlink:href="tffp-20220331.xsd#tffp_April2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="April2019Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2021Member" xlink:href="tffp-20220331.xsd#tffp_January2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="January2021Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ContractManufacturingServicesMember" xlink:href="tffp-20220331.xsd#tffp_ContractManufacturingServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ContractManufacturingServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="tffp-20220331.xsd#tffp_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsTable" xlink:to="AgreementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomain" xlink:href="tffp-20220331.xsd#tffp_AgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MasterServicesAgreementMember" xlink:href="tffp-20220331.xsd#tffp_MasterServicesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="MasterServicesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MasterConsultancyAgreementMember" xlink:href="tffp-20220331.xsd#tffp_MasterConsultancyAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="MasterConsultancyAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialResearchAgreementMember" xlink:href="tffp-20220331.xsd#tffp_ClinicalTrialResearchAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="ClinicalTrialResearchAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsTable" xlink:to="LicenseandAgreementsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneFee" xlink:href="tffp-20220331.xsd#tffp_MilestoneFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="MilestoneFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementTremDescription" xlink:href="tffp-20220331.xsd#tffp_AgreementTremDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="AgreementTremDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDescription" xlink:href="tffp-20220331.xsd#tffp_AgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="AgreementDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PremarketingApprovals" xlink:href="tffp-20220331.xsd#tffp_PremarketingApprovals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="PremarketingApprovals" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InterstFee" xlink:href="tffp-20220331.xsd#tffp_InterstFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="InterstFee" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherReceivables" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ReservedShares" xlink:href="tffp-20220331.xsd#tffp_ReservedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ReservedShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PercentageOfWeightedAverageCostInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfWeightedAverageCostInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_PercentageOfWeightedAverageCostInventory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:href="tffp-20220331.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="tffp-20220331.xsd#tffp_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060160032520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TFF PHARMACEUTICALS, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TFFP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,373,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001733413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4344737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1751 River Run<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Worth<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">76107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">438-6168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock: Par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060163244536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,414,170<span></span>
</td>
<td class="nump">$ 33,794,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ReceivableDueFromCollaborationAgreement', window );">Receivable due from collaboration agreement</a></td>
<td class="nump">1,776,583<span></span>
</td>
<td class="nump">1,628,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ResearchAndDevelopmentTaxIncentiveReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="nump">1,168,830<span></span>
</td>
<td class="nump">966,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid assets and other current assets</a></td>
<td class="nump">2,164,451<span></span>
</td>
<td class="nump">2,447,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">31,524,034<span></span>
</td>
<td class="nump">38,837,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,258,738<span></span>
</td>
<td class="nump">1,859,860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">33,782,772<span></span>
</td>
<td class="nump">40,697,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,028,779<span></span>
</td>
<td class="nump">1,493,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AccruedCompensationLiabilities', window );">Accrued compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">416,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Deferred research grant revenue</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,196,779<span></span>
</td>
<td class="nump">1,960,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.001 par value, 45,000,000 shares authorized; 25,371,781 shares issued and outstanding</a></td>
<td class="nump">25,372<span></span>
</td>
<td class="nump">25,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">105,256,670<span></span>
</td>
<td class="nump">104,078,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,687)<span></span>
</td>
<td class="num">(48,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(73,694,362)<span></span>
</td>
<td class="num">(65,318,360)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">31,585,993<span></span>
</td>
<td class="nump">38,737,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 33,782,772<span></span>
</td>
<td class="nump">$ 40,697,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AccruedCompensationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AccruedCompensationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ReceivableDueFromCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable due from collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ReceivableDueFromCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ResearchAndDevelopmentTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ResearchAndDevelopmentTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060160007176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,371,781<span></span>
</td>
<td class="nump">25,371,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,371,781<span></span>
</td>
<td class="nump">25,371,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158982008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="nump">$ 67,435<span></span>
</td>
<td class="nump">$ 24,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,261,604<span></span>
</td>
<td class="nump">5,278,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,246,195<span></span>
</td>
<td class="nump">2,647,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,507,799<span></span>
</td>
<td class="nump">7,925,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,440,364)<span></span>
</td>
<td class="num">(7,901,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">57,177<span></span>
</td>
<td class="nump">231,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="nump">15,499<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">64,362<span></span>
</td>
<td class="nump">246,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,376,002)<span></span>
</td>
<td class="num">$ (7,654,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, basic and diluted (in Shares)</a></td>
<td class="nump">25,371,781<span></span>
</td>
<td class="nump">23,140,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">$ (8,376,002)<span></span>
</td>
<td class="num">$ (7,654,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_OtherComprehensiveLossAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="nump">47,234<span></span>
</td>
<td class="num">(37,958)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Comprehensive loss</a></td>
<td class="num">$ (8,328,768)<span></span>
</td>
<td class="num">$ (7,692,533)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_OtherComprehensiveLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_OtherComprehensiveLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158356728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 22,535<span></span>
</td>
<td class="nump">$ 71,648,453<span></span>
</td>
<td class="num">$ (51,538)<span></span>
</td>
<td class="num">$ (34,279,648)<span></span>
</td>
<td class="nump">$ 37,339,802<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">22,534,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 2,140<span></span>
</td>
<td class="nump">28,021,424<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,023,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">2,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockForStockOptionExercises', window );">Issuance of common stock for stock option exercises</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">655,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">655,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockForStockOptionExercisesShares', window );">Issuance of common stock for stock option exercises (in Shares)</a></td>
<td class="nump">244,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises', window );">Issuance of common stock for warrant exercises</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">179,768<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">180,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares', window );">Issuance of common stock for warrant exercises (in Shares)</a></td>
<td class="nump">444,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,030,415<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,030,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(37,958)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(37,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,654,575)<span></span>
</td>
<td class="num">(7,654,575)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 25,364<span></span>
</td>
<td class="nump">101,535,068<span></span>
</td>
<td class="num">(89,496)<span></span>
</td>
<td class="num">(41,934,223)<span></span>
</td>
<td class="nump">59,536,713<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="nump">25,364,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 25,372<span></span>
</td>
<td class="nump">104,078,968<span></span>
</td>
<td class="num">(48,921)<span></span>
</td>
<td class="num">(65,318,360)<span></span>
</td>
<td class="nump">38,737,059<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">25,371,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,177,702<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,177,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">47,234<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">47,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,376,002)<span></span>
</td>
<td class="num">(8,376,002)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 25,372<span></span>
</td>
<td class="nump">$ 105,256,670<span></span>
</td>
<td class="num">$ (1,687)<span></span>
</td>
<td class="num">$ (73,694,362)<span></span>
</td>
<td class="nump">$ 31,585,993<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">25,371,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockForStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockForStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockForStockOptionExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockForStockOptionExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060159869240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,376,002)<span></span>
</td>
<td class="num">$ (7,654,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,177,702<span></span>
</td>
<td class="nump">1,030,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">77,028<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ReceivableDueFromCollaborationsAgreement', window );">Receivable due from collaboration agreement</a></td>
<td class="num">(147,880)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ResearchAndDevelopmentTaxIncentiveReceivables', window );">Research and development tax incentive receivable</a></td>
<td class="num">(108,097)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid assets and other current assets</a></td>
<td class="nump">237,646<span></span>
</td>
<td class="nump">534,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">192,211<span></span>
</td>
<td class="nump">521,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued compensation</a></td>
<td class="num">(416,910)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IncreaseDecreaseDeferredResearchGrantRevenue', window );">Deferred revenue</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="num">(24,315)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,246,302)<span></span>
</td>
<td class="num">(5,591,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(137,231)<span></span>
</td>
<td class="num">(476,128)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(137,231)<span></span>
</td>
<td class="num">(476,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ProceedsFromIssuanceOfCommonStockValue', window );">Net proceeds from issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,023,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises', window );">Proceeds from issuance of common stock for stock option exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">655,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock', window );">Proceeds from issuance of common stock for warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">180,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,859,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">3,031<span></span>
</td>
<td class="num">(37,330)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(7,380,502)<span></span>
</td>
<td class="nump">22,754,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">33,794,672<span></span>
</td>
<td class="nump">35,300,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">26,414,170<span></span>
</td>
<td class="nump">58,055,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of equipment included in accounts payable</a></td>
<td class="nump">338,674<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to Conversion of Series A Preferred Stock (including accrued dividends) to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IncreaseDecreaseDeferredResearchGrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IncreaseDecreaseDeferredResearchGrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ProceedsFromIssuanceOfCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ProceedsFromIssuanceOfCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ReceivableDueFromCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable due from collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ReceivableDueFromCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ResearchAndDevelopmentTaxIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ResearchAndDevelopmentTaxIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162005432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 1 &#8211; ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TFF Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated in the State of Delaware on January 24, 2018. The Company&#8217;s initial focus is on the development of inhaled dry
powder drugs to enhance the treatment of pulmonary diseases and conditions. In December 2019, the Company established a wholly-owned Australian
subsidiary, TFF Pharmaceuticals Australia Pty Ltd (&#8220;TFF Australia&#8221;), in order to conduct clinical research. TFF Pharmaceuticals,
Inc., along with TFF Australia, are collectively referred to as the &#8220;Company&#8221;. The Company is in the development stage and
is devoting substantially all of its efforts toward technology research and development and the human clinical trials of its initial product
candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">COVID-19</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this report, the COVID-19 pandemic
has had a relatively insignificant impact on the Company&#8217;s operations and has not caused the Company to forego, abandon or materially
delay any proposed activities. While the Company believes it has been able to effectively manage the disruption caused by the COVID-19
pandemic to date, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted
or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak
of COVID-19.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162672392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Management&#8217;s Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LiquidityandManagementsPlansLineItems', window );"><strong>Liquidity and Managements Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LiquidityAndManagementsPlansTextBlock', window );">LIQUIDITY AND MANAGEMENT&#8217;S PLANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 2 - LIQUIDITY AND MANAGEMENT&#8217;S PLANS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had cash and
cash equivalents of approximately $26,414,000 and a working capital of approximately $29,327,000. The Company has not generated revenues
from commercial operations since inception and has incurred recurring operating losses. The Company expects to continue incurring losses
for the foreseeable future and may need to raise additional capital to continue the pursuit of its product development.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to further increase its research
and development activities, which will increase the amount of cash utilized subsequent to March 31, 2022. Specifically, the Company expects
increased spending on research and development activities and higher payroll expenses as it increases its professional and scientific
staff and continues to prepare for anticipated manufacturing activities. If the Company encounters unforeseen delays or expenses, it has
the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and cash equivalents
will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of
issuance of these condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LiquidityAndManagementsPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LiquidityAndManagementsPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LiquidityandManagementsPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LiquidityandManagementsPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060163067240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;)
for interim financial statements and with Form 10-Q&#160;and Article&#160;10 of Regulation S-X&#160;of the United States Securities and
Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial
statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain
all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March&#160;31,
2022 and the results of operations, changes in stockholders&#8217; equity and cash flows for the periods presented. The results of operations
for the three months ended March&#160;31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any
future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December
31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and transactions
have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of TFF Australia, the Company&#8217;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars
using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using the average exchange
rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities is included as a separate
component of stockholders&#8217; equity in accumulated other comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its operating accounts in
financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&#8217;s cash is maintained
in checking accounts and money market funds with maturities of less than three months when purchased, which are readily convertible to
known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value. As of March 31, 2022
and December 31, 2021, the Company had cash in Australia of AUD$308,824 (US$231,447) and AUD$831,984 (US$604,944), respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into feasibility and material
transfer agreements (&#8220;Feasibility Agreements&#8221;) with third parties that provide the Company with funds in return for certain
research and development activities. Revenue from the Feasibility Agreements is recognized in the period during which the related qualifying
services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility Agreements have been met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Feasibility Agreements are on a best-effort
basis and do not require scientific achievement as a performance obligation. All fees received under the Feasibility Agreements are non-refundable.
The costs associated with the Feasibility Agreements are expensed as incurred and are reflected as a component of research and development
expense in the accompanying condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funds received from the Feasibility Agreements
are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility Agreements
are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of
providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying
services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company
records a grant receivable. During the three months ended March 31, 2022 and 2021, the Company rendered the related services and recognized
revenue and research and development expenses of $67,435 and $24,315, respectively. As of March 31, 2022 and December 31, 2021, the Company
had receivables due related to Feasibility Agreements of $55,435 and $11,996, respectively, which is included in prepaid assets and other
current assets in the accompanying condensed consolidated balance sheets, and deferred grant revenue of approximately $168,000 and $50,000,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Collaborative Arrangements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the nature and contractual
terms of arrangements and assesses whether an arrangement involves a joint operating activity pursuant to which the Company is an active
participant and is exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company is an
active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts
for such arrangement as a collaborative arrangement under Accounting Standards Codification (&#8220;ASC&#8221;) 808, <i>Collaborative
Arrangements</i>. ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition
matters subjected to other authoritative guidance, in certain cases by analogy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For arrangements determined to be within the scope
of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments
received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. This reflects
the joint risk sharing nature of these activities within a collaborative arrangement. The Company classifies payments owed or receivables
recorded as other current liabilities or prepaid expenses and other current assets, respectively, in the Company&#8217;s consolidated
balance sheets. Please refer to Note 5, &#8220;Joint Development Agreement&#8221; for additional details regarding the Company&#8217;s
joint development agreement (&#8220;JDA&#8221;) with Augmenta Bioworks, Inc. (&#8220;Augmenta&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If payments from the collaborative partner to
the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for
those payments within the scope of ASC 606, <i>Revenue from Contracts with Customers</i>. The Company does not currently have any collaborative
arrangements that are accounted for under ASC 606.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Tax Incentive</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to obtain a cash refund
from the Australian Taxation Office for eligible research and development expenditures under the Australian R&amp;D Tax Incentive Program
(the &#8220;Australian Tax Incentive&#8221;). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that
the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. During the
year ended December 31, 2021, the Company received its first cash refund under the Australian Tax Incentive, which was for expenditures
incurred during 2020. Therefore, the Company recorded amounts received, or that it expects to receive, for expenditures incurred during
2020 as other income in the condensed consolidated statements of operations during the period ended March 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company has determined that it has reasonable
assurance that it will receive the cash refund for eligible research and development expenditures, beginning with expenditures incurred
during the year ended December 31, 2021, the Company records the Australian Tax Incentive as a reduction to research and development expenses
as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company&#8217;s ongoing tax status,
or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information
at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for
the three months ended March 31, 2022 and 2021. In addition, the Company is also eligible to receive amounts from the United States Internal
Revenue Service (&#8220;IRS&#8221;) related to research and development tax credits for expenditures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research and development incentive receivable
represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development
tax incentive receivable of $1,168,830 and $966,646 as of March 31, 2022 and December 31, 2021, respectively, in the condensed consolidated
balance sheets. The Company has recorded other income of $57,177 and $231,278, in the condensed consolidated statements of operations
for the three months ended March 31, 2022 and 2021, respectively, related to refundable IRS and Australian research and development incentive
program payments for expenditures incurred during 2020. The Company recorded a reduction to research and development expenses of $108,098
during the three months ended March 31, 2022 for expenditures incurred during 2022 and $0 during the three months ended March 31, 2021
for expenditures incurred during 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basic and Diluted Earnings per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed
by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined
using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive
securities are anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2022 and
2021, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted
net loss per common share because inclusion thereof would be anti-dilutive:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,976,090</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,375,839</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,365,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,765,072</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>On
an as-converted basis</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial
statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation and
warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Accounting Standards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the three months ended March 31, 2022 that are of
significance or potential significance to the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162670168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 4 - COMMITMENTS AND CONTINGENCIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2018, the Company entered into a lease
agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018 and expires on October 31, 2022, as amended.
The lease has an additional one-year option for renewal, and the base rent is $36,000 per year. The Company has determined that the lease
agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The Company rents another
office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease as well. Short-term lease
expense for the three months ended March 31, 2022 and 2021 was approximately $21,000 and $15,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate future minimum lease payments required
under the operating leases are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -8.1pt; padding-left: 8.1pt">Year Ending December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Legal</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may be involved, from time to time,
in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes
and are not predictable with assurance. While management believes that such matters are currently insignificant, matters arising in the
ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its
business and financial condition. To the Company&#8217;s knowledge, neither the Company nor any of its properties are subject to any pending
legal proceedings.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162008376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseAndAgreementDisclosureAbstract', window );"><strong>License And Agreement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseAndAgreementDisclosureTextBlock', window );">LICENSE AND AGREEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 5 - LICENSE AND AGREEMENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2015, the University of Texas at Austin
(&#8220;UT&#8221;) granted to the Company&#8217;s former parent, LTI, an exclusive worldwide, royalty bearing license to the patent rights
for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide, royalty bearing license
to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all of its interest to the TFF platform,
including the patent license agreement with UT, at which time the Company paid UT an assignment fee of $100,000 in accordance with the
patent license agreement. In November 2018, the Company and UT entered into an amendment to the patent license agreement pursuant to which,
among other things, the Company&#8217;s exclusive patent rights to the TFF platform were expanded to all fields of use. The patent license
agreement requires the Company to pay royalties and milestone payments and conform to a variety of covenants and agreements, and in the
event of the Company&#8217;s breach of agreement, UT may elect to terminate the agreement. For the period ended December 31, 2018, the
Company did not achieve any of the milestones and, as such, was not required to make any milestone payments. During the ended December
31, 2019, the Company achieved one milestone by gaining IND approval on first indication of a licensed product on November 24, 2019 and
the Company satisfied the milestone payment of $50,000 and issuance of shares in accordance with the agreement. As of the date of these
condensed consolidated financial statements, the Company is in compliance with the patent license agreement as all required amounts have
been paid in accordance with the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2018, the Company entered into a master
services agreement and associated individual study contracts with ITR Canada, Inc. (&#8220;ITR&#8221;) to provide initial contract pre-clinical
research and development services for the Company&#8217;s drug product candidates. In January 2019, the Company cancelled all of the individual
study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba
Strategy Point Innovations (&#8220;SPI&#8221;)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits. The services related to the contract with
SPI were sub-contracted to ITR and others under substantially the same terms as the initial contract with ITR. Desire Ventures, LLC facilitates
the invoicing for the various affiliates. The accounts payable due in connection with this agreement was approximately $472,000 and $0
as of March 31, 2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded
research and development costs of approximately $1,585,000 and $1,812,000, respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2019, the Company entered into a master
services agreement with Irisys, LLC to provide contract manufacturing services for one of the Company&#8217;s drug product candidates,
Voriconazole. The accounts payable due in connection with this agreement was approximately $35,000 and $21,000 as of March 31, 2022 and
December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $446,000 and $494,000, respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, TFF Australia entered into a
master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to provide initial
contract clinical research and development services for the Company&#8217;s drug product candidates. The accounts payable due in connection
with this agreement was approximately AUD$179,000 (US$134,000) and AUD$138,000 (US$100,000) as of March 31, 2022 and December 31, 2021,
respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
AUD$347,000 (US$251,000) and AUD$705,000 (US$545,000), respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2020, TFF Australia entered into an amended
clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company&#8217;s drug candidates,
Tacrolimus. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of March 31,
2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $0 and AUD$244,000 (US$188,000), respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2020, the Company entered into a
licensing and collaboration agreement with UNION therapeutics A/S in which UNION acquired an option to obtain a worldwide exclusive license
for the TFF technology in combination with niclosamide. Pursuant to the terms of the license agreement, UNION can exercise its option
to obtain the license within 45 days after the complete data has been received by UNION from investigator-initiated trials. Upon exercise
of the option, UNION shall be responsible to pay all expenses incurred in the development of any licensed product. The Company will be
eligible to receive milestone payments upon the achievement of certain milestones in the development the licensed products, based on completion
of clinical trials, pre-marketing approvals and/or the receipt of at least $25,000,000 of grant funding. The Company will receive a single-digit
tiered royalty on net sales. The Company will also be entitled to receive sales-related milestone payments based on the commercial success
of the licensed products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2021, the Company entered into a master
services agreement with Experic to provide contract manufacturing services for one of the Company&#8217;s drug product candidates, Voriconazole.
The accounts payable due in connection with this agreement was approximately $87,000 and $313,000 as of March 31, 2022 and December 31,
2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
$318,000 and $196,000, respectively, pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2022, the Company entered into a Letter
of Intent with Synteract, Inc. to provide contract research and development services while negotiating a Master Services Agreement for
one of the Company&#8217;s drug product candidates, Voriconazole. The accounts payable due in connection with this agreement was approximately
$14,000 as of March 31, 2022. During the three months ended March 31, 2022, the Company recorded research and development costs of approximately
$226,000 pertaining to this agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Joint Development Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2020, the Company and Augmenta
entered into the JDA pursuant to which the Company and Augmenta (collectively the &#8220;Parties&#8221;) agreed to work jointly to develop
one or more novel commercial products incorporating Augmenta&#8217;s human derived monoclonal antibody for the treatment of patients with
COVID-19 and the Company&#8217;s patented Thin Film Freezing technology platform. Each party retains full ownership over its existing
assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties will share development costs with
each party funding its fifty-percent-share at specified times. In the event that one of the Parties fails to make its pro rata share payment,
the other party may terminate the JDA. In lieu of terminating the JDA, the non-defaulting party may elect to continue the JDA by paying
the delinquent amount and each party&#8217;s pro rata share of the JDA will automatically adjust by the amount paid. In addition, in the
event Augmenta experiences a default on its required payment, Augmenta will have the one-time right to elect to require the Company to
purchase Augmenta&#8217;s interest in the JDA (&#8220;Put Right&#8221;) for a one-time fee of $500,000. Upon exercise of the Put Right
and payment by the Company, Augmenta will grant the Company an exclusive, worldwide, royalty-free, transferable, sublicensable license
to the Augmenta antibody and Augmenta&#8217;s rights to the property developed under the JDA. The Company has determined that the likelihood
of the Put Right being exercised to be remote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JDA is within the scope of ASC 808 as the
Company and Augmenta are both active participants in the research and development activities and are exposed to significant risks and
rewards that are dependent on commercial success of the activities of the arrangement. The research and development activities are a unit
of account under the scope of ASC 808 and are not promises to a customer under the scope of ASC 606.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records its portion of the research
and development expenses as the related expenses are incurred. All payments received or amounts due from Augmenta for reimbursement of
shared costs are accounted for as an offset to research and development expense. During the three months ended March 31, 2022 and 2021,
the Company recorded research and development expenses of $147,880 and $76,200, respectively, and has recorded a receivable of $1,776,583
and $1,628,703 for reimbursement due from Augmenta as of March 31, 2022 and December 31, 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LicenseAndAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LicenseAndAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LicenseAndAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LicenseAndAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162666504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 6 &#8211; STOCK BASED COMPENSATION</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2018, the Company&#8217;s board of
directors approved its 2018 Stock Incentive Plan (&#8220;2018 Plan&#8221;). The 2018 Plan provides for the grant of non-qualified stock
options and incentive stock options to purchase shares of the Company&#8217;s common stock, the grant of restricted and unrestricted share
awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the 2018 Plan; however,
upon completion of the Company&#8217;s IPO the number of shares reserved for issuance under the 2018 Plan increased to 3,284,480, representing
15% of the Company&#8217;s outstanding shares of common stock calculated on a fully diluted basis upon the close of the IPO. All of the
Company&#8217;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the
Company&#8217;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible
to receive incentive awards under the 2018 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, the Company&#8217;s board of
directors approved its 2021 Stock Incentive Plan (&#8220;2021 Plan&#8221;), which was also approved by the stockholders of the Company
at the Company&#8217;s annual meeting of stockholders held on November 4, 2021. The 2021 Plan provides for the grant of non-qualified
stock options and incentive stock options to purchase shares of the Company&#8217;s common stock, the grant of restricted and unrestricted
share awards and grant of restricted stock units. The Company has 4,200,000 shares of its common stock reserved under the 2021 Plan. All
of the Company&#8217;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all
of the Company&#8217;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will
be eligible to receive incentive awards under the 2021 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the stock-based
compensation expense recorded in the Company&#8217;s results of operations during the three months ended March 31, 2022 and 2021 for stock
options and warrants:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three<br/> Months<br/> Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three<br/> Months<br/> Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205,809</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">67,279</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">971,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">963,136</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,177,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,030,415</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, there was approximately
$8,135,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected to
vest. This cost is expected to be recognized over a weighted-average period of 2.4 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records compensation expense for awards
with graded vesting using the straight-line method. The Company recognizes compensation expense over the requisite service period applicable
to each individual award, which generally equals the vesting term. The Company estimates the fair value of each option award using the
Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value stock options
using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite
service periods of the respective awards. The fair value of stock options issued was estimated using the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Three&#160;Months<br/> March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Weighted average exercise price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.90</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assumptions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;96%-97</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;1.79%-2.41</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate was obtained from
U.S. Treasury rates for the applicable periods. The Company&#8217;s expected volatility was based upon the historical volatility for industry
peers and used an average of those volatilities. The expected life of the Company&#8217;s options was determined using the simplified
method as a result of limited historical data regarding the Company&#8217;s activity for employee awards and the contractual term for
nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and does not expect to pay dividends
in the foreseeable future. The Company uses the closing stock price on the date of grant as the fair value of the common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock option activity
during the three months ended March 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term (In&#160;Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,893,839</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,932,413</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,749</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.09</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,976,090</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6.47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.87</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,435,685</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,411,441</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.24</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,196,095</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock options
is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock
for those stock options that had strike prices lower than the fair value of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Option Modification</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 21, 2022, one of the members of
the Company&#8217;s board of directors, Dr. Brian Windsor, resigned. As part of his resignation from the board of directors, modifications
were made to Dr. Windsor&#8217;s vested and non-vested stock option awards including acceleration of certain non-vested option awards
and the extension of the post-termination exercise period of certain stock option awards. During the three months ended March 31, 2022,
in accordance with ASC Topic 718, <i>Compensation&#8212;Stock Compensation,</i> the Company recorded a one-time, non-cash incremental
compensation expense net of the required reversal of previously recognized compensation attributed to non-vested shares in the amount
of approximately $339,000, which is included in general and administrative expense in the accompanying condensed consolidated statements
of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162004872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 7 &#8211; SUBSEQUENT EVENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has performed an evaluation of events
occurring subsequent to March 31, 2022 through the filing date of this Quarterly Report. Based on its evaluation, there are no events
that need to be disclosed.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158931528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;)
for interim financial statements and with Form 10-Q&#160;and Article&#160;10 of Regulation S-X&#160;of the United States Securities and
Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial
statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain
all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March&#160;31,
2022 and the results of operations, changes in stockholders&#8217; equity and cash flows for the periods presented. The results of operations
for the three months ended March&#160;31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any
future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December
31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and transactions
have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of TFF Australia, the Company&#8217;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars
using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using the average exchange
rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities is included as a separate
component of stockholders&#8217; equity in accumulated other comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its operating accounts in
financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&#8217;s cash is maintained
in checking accounts and money market funds with maturities of less than three months when purchased, which are readily convertible to
known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value. As of March 31, 2022
and December 31, 2021, the Company had cash in Australia of AUD$308,824 (US$231,447) and AUD$831,984 (US$604,944), respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into feasibility and material
transfer agreements (&#8220;Feasibility Agreements&#8221;) with third parties that provide the Company with funds in return for certain
research and development activities. Revenue from the Feasibility Agreements is recognized in the period during which the related qualifying
services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility Agreements have been met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Feasibility Agreements are on a best-effort
basis and do not require scientific achievement as a performance obligation. All fees received under the Feasibility Agreements are non-refundable.
The costs associated with the Feasibility Agreements are expensed as incurred and are reflected as a component of research and development
expense in the accompanying condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funds received from the Feasibility Agreements
are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility Agreements
are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of
providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying
services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company
records a grant receivable. During the three months ended March 31, 2022 and 2021, the Company rendered the related services and recognized
revenue and research and development expenses of $67,435 and $24,315, respectively. As of March 31, 2022 and December 31, 2021, the Company
had receivables due related to Feasibility Agreements of $55,435 and $11,996, respectively, which is included in prepaid assets and other
current assets in the accompanying condensed consolidated balance sheets, and deferred grant revenue of approximately $168,000 and $50,000,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_CollaborativeArrangementsPolicyTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Collaborative Arrangements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the nature and contractual
terms of arrangements and assesses whether an arrangement involves a joint operating activity pursuant to which the Company is an active
participant and is exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company is an
active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts
for such arrangement as a collaborative arrangement under Accounting Standards Codification (&#8220;ASC&#8221;) 808, <i>Collaborative
Arrangements</i>. ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition
matters subjected to other authoritative guidance, in certain cases by analogy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For arrangements determined to be within the scope
of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments
received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. This reflects
the joint risk sharing nature of these activities within a collaborative arrangement. The Company classifies payments owed or receivables
recorded as other current liabilities or prepaid expenses and other current assets, respectively, in the Company&#8217;s consolidated
balance sheets. Please refer to Note 5, &#8220;Joint Development Agreement&#8221; for additional details regarding the Company&#8217;s
joint development agreement (&#8220;JDA&#8221;) with Augmenta Bioworks, Inc. (&#8220;Augmenta&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If payments from the collaborative partner to
the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for
those payments within the scope of ASC 606, <i>Revenue from Contracts with Customers</i>. The Company does not currently have any collaborative
arrangements that are accounted for under ASC 606.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock', window );">Research and Development Tax Incentive</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Tax Incentive</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to obtain a cash refund
from the Australian Taxation Office for eligible research and development expenditures under the Australian R&amp;D Tax Incentive Program
(the &#8220;Australian Tax Incentive&#8221;). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that
the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. During the
year ended December 31, 2021, the Company received its first cash refund under the Australian Tax Incentive, which was for expenditures
incurred during 2020. Therefore, the Company recorded amounts received, or that it expects to receive, for expenditures incurred during
2020 as other income in the condensed consolidated statements of operations during the period ended March 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company has determined that it has reasonable
assurance that it will receive the cash refund for eligible research and development expenditures, beginning with expenditures incurred
during the year ended December 31, 2021, the Company records the Australian Tax Incentive as a reduction to research and development expenses
as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company&#8217;s ongoing tax status,
or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information
at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for
the three months ended March 31, 2022 and 2021. In addition, the Company is also eligible to receive amounts from the United States Internal
Revenue Service (&#8220;IRS&#8221;) related to research and development tax credits for expenditures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research and development incentive receivable
represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development
tax incentive receivable of $1,168,830 and $966,646 as of March 31, 2022 and December 31, 2021, respectively, in the condensed consolidated
balance sheets. The Company has recorded other income of $57,177 and $231,278, in the condensed consolidated statements of operations
for the three months ended March 31, 2022 and 2021, respectively, related to refundable IRS and Australian research and development incentive
program payments for expenditures incurred during 2020. The Company recorded a reduction to research and development expenses of $108,098
during the three months ended March 31, 2022 for expenditures incurred during 2022 and $0 during the three months ended March 31, 2021
for expenditures incurred during 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basic and Diluted Earnings per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed
by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined
using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive
securities are anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2022 and
2021, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted
net loss per common share because inclusion thereof would be anti-dilutive:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,976,090</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,375,839</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,365,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,765,072</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>On
an as-converted basis</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial
statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation and
warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Accounting Standards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the three months ended March 31, 2022 that are of
significance or potential significance to the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_CollaborativeArrangementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_CollaborativeArrangementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30885-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162003192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of potential common stock equivalents outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three&#160;Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,976,090</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,375,839</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,365,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,765,072</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>On
an as-converted basis</i></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060161912152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -8.1pt; padding-left: 8.1pt">Year Ending December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060159977528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of stock-based compensation expense stock options and warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three<br/> Months<br/> Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Three<br/> Months<br/> Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205,809</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">67,279</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">971,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">963,136</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,177,702</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,030,415</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of employee stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Three&#160;Months<br/> March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Weighted average exercise price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.90</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assumptions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;96%-97</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;1.79%-2.41</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term (In&#160;Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,893,839</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,932,413</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,749</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.09</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,976,090</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6.47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.87</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,435,685</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,411,441</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.24</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,196,095</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060161886184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity and Management&#8217;s Plans (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LiquidityAndManagementsPlansAbstract', window );"><strong>Liquidity And Managements Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,414,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SurplusNotes', window );">Working capital surplus</a></td>
<td class="nump">$ 29,327,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LiquidityAndManagementsPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LiquidityAndManagementsPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SurplusNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instruments issued by insurance entities (surplus notes) that are includable in surplus for statutory accounting purposes as prescribed or permitted by state laws and regulations that are liabilities of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 470<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6486086&amp;loc=d3e24387-158525<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SurplusNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158973352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Cash</a></td>
<td class="nump">$ 231,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,824<span></span>
</td>
<td class="nump">$ 604,944<span></span>
</td>
<td class="nump">$ 831,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development expenses</a></td>
<td class="nump">67,435<span></span>
</td>
<td class="nump">$ 24,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid assets and other current assets</a></td>
<td class="nump">55,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Deferred grant revenue</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ResearchAndDevelopmentTaxPercentage', window );">Research and development tax percentage</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income (expense)</a></td>
<td class="nump">$ 57,177<span></span>
</td>
<td class="nump">$ 231,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax incentive</a></td>
<td class="nump">1,168,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 966,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income (expense)</a></td>
<td class="nump">57,177<span></span>
</td>
<td class="nump">231,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development additional received</a></td>
<td class="nump">$ 108,098<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ResearchAndDevelopmentTaxPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ResearchAndDevelopmentTaxPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158895384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common stock equivalents outstanding</a></td>
<td class="nump">3,365,323<span></span>
</td>
<td class="nump">2,765,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common stock equivalents outstanding</a></td>
<td class="nump">389,233<span></span>
</td>
<td class="nump">389,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tffp_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common stock equivalents outstanding</a></td>
<td class="nump">2,976,090<span></span>
</td>
<td class="nump">2,375,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tffp_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tffp_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158675128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Short-term lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060162669608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of future minimum lease payments<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract', window );"><strong>Schedule of future minimum lease payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Year Ending December 31, 2022</a></td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060156873880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 24, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_MilestoneFee', window );">Milestone fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Research and development cost expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,000<span></span>
</td>
<td class="nump">$ 1,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_PremarketingApprovals', window );">Pre-marketing approvals</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Recorded research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,604<span></span>
</td>
<td class="nump">5,278,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_InterstFee', window );">Interest fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,776,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,628,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AgreementAxis=tffp_MasterServicesAgreementMember', window );">Master Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AgreementTremDescription', window );">Agreement term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company cancelled all of the individual
study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba
Strategy Point Innovations (&#8220;SPI&#8221;)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AgreementAxis=tffp_MasterConsultancyAgreementMember', window );">Clinical Network Services Pty Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AgreementDescription', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to provide initial
contract clinical research and development services for the Company&#8217;s drug product candidates. The accounts payable due in connection
with this agreement was approximately AUD$179,000 (US$134,000) and AUD$138,000 (US$100,000) as of March 31, 2022 and December 31, 2021,
respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
AUD$347,000 (US$251,000) and AUD$705,000 (US$545,000), respectively, pertaining to this agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AgreementAxis=tffp_ClinicalTrialResearchAgreementMember', window );">Clinical trial research agreement with Nucleus Network Pty Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AgreementDescription', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to provide a Phase I study of one of the Company&#8217;s drug candidates,
Tacrolimus. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of March 31,
2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $0 and AUD$244,000 (US$188,000), respectively, pertaining to this agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_ContractManufacturingServicesMember', window );">Contract manufacturing services [Member] | Master Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Recorded research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_April2019Member', window );">April 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Research and development cost expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,000<span></span>
</td>
<td class="nump">494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_January2021Member', window );">January 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Research and development cost expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,000<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_January2021Member', window );">January 2021 [Member] | Master Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,880<span></span>
</td>
<td class="nump">$ 76,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description related to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AgreementTremDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AgreementTremDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_InterstFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interst fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_InterstFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LicenseandAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LicenseandAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_MilestoneFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_MilestoneFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_PremarketingApprovals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_PremarketingApprovals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AgreementAxis=tffp_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AgreementAxis=tffp_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AgreementAxis=tffp_MasterConsultancyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AgreementAxis=tffp_MasterConsultancyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AgreementAxis=tffp_ClinicalTrialResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AgreementAxis=tffp_ClinicalTrialResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_ContractManufacturingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_ContractManufacturingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_April2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_April2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_January2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_January2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158896792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ReservedShares', window );">Reserved shares</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">1,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">IPO shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,284,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PercentageOfWeightedAverageCostInventory', window );">Outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ReservedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ReservedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>weighted-average period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfWeightedAverageCostInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of weighted average cost inventory present at the reporting date when inventory is valued using different valuation methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfWeightedAverageCostInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060160038152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationExpenses', window );">Stock based compensation expense</a></td>
<td class="nump">$ 1,177,702<span></span>
</td>
<td class="nump">$ 1,030,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationExpenses', window );">Stock based compensation expense</a></td>
<td class="nump">205,809<span></span>
</td>
<td class="nump">67,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationExpenses', window );">Stock based compensation expense</a></td>
<td class="nump">$ 971,893<span></span>
</td>
<td class="nump">$ 963,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockBasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockBasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060163250088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - Schedule of fair value of employee stock options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in Dollars per share)</a></td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AssumptionsAbstract', window );"><strong>Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AssumptionsAbstract', window );"><strong>Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.79%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AssumptionsAbstract', window );"><strong>Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.41%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140060158715048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - Schedule of stock option activity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ScheduleOfStockOptionActivityAbstract', window );"><strong>Schedule of stock option activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number of Shares, Outstanding, Outstanding ending balance | shares</a></td>
<td class="nump">2,893,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 6.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted-Average Remaining Contractual Term, Outstanding ending balance</a></td>
<td class="text">8 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding ending balance | $</a></td>
<td class="nump">$ 9,932,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Shares, Outstanding, Granted | shares</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Granted | $ / shares</a></td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockIssuedDuringPeriodSharesStockOptionesExercised', window );">Number of Shares, Outstanding, Exercised | shares</a></td>
<td class="num">(17,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Exercised | $ / shares</a></td>
<td class="nump">$ 11.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number of Shares, Outstanding, Outstanding ending balance | shares</a></td>
<td class="nump">2,976,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance', window );">Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 6.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance', window );">Weighted-Average Remaining Contractual Term, Outstanding ending balance</a></td>
<td class="text">7 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding ending balance | $</a></td>
<td class="nump">$ 4,435,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Outstanding, Exercisable | shares</a></td>
<td class="nump">1,411,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Exercisable | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">7 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AggregateIntrinsicValueExercisables', window );">Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 3,196,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AggregateIntrinsicValueExercisables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AggregateIntrinsicValueExercisables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ScheduleOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ScheduleOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise prices, outstanding, beginning balance (in Dollars per share).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockIssuedDuringPeriodSharesStockOptionesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockIssuedDuringPeriodSharesStockOptionesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>f10q0322_tffpharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:tffp="http://tffp.com/20220331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tffp-20220331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tffp:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tffp:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2019-11-24</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterConsultancyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tffp:January2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">tffp:ContractManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ProductOrServiceAxis">tffp:ContractManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tffp:AgreementAxis">tffp:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="aud">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-39102</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">TFF PHARMACEUTICALS, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">82-4344737</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">1751 River Run</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Fort Worth</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">76107</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(817)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">438-6168</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common stock: Par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">TFFP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">25373818</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">26414170</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">33794672</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <tffp:ReceivableDueFromCollaborationAgreement contextRef="c2" decimals="0" unitRef="usd">1776583</tffp:ReceivableDueFromCollaborationAgreement>
    <tffp:ReceivableDueFromCollaborationAgreement contextRef="c3" decimals="0" unitRef="usd">1628703</tffp:ReceivableDueFromCollaborationAgreement>
    <tffp:ResearchAndDevelopmentTaxIncentiveReceivable contextRef="c2" decimals="0" unitRef="usd">1168830</tffp:ResearchAndDevelopmentTaxIncentiveReceivable>
    <tffp:ResearchAndDevelopmentTaxIncentiveReceivable contextRef="c3" decimals="0" unitRef="usd">966646</tffp:ResearchAndDevelopmentTaxIncentiveReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c2" decimals="0" unitRef="usd">2164451</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c3" decimals="0" unitRef="usd">2447930</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">31524034</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">38837951</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">2258738</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">1859860</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">33782772</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">40697811</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" unitRef="usd">2028779</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">1493842</us-gaap:AccountsPayableCurrent>
    <tffp:AccruedCompensationLiabilities contextRef="c3" decimals="0" unitRef="usd">-416910</tffp:AccruedCompensationLiabilities>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">168000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">50000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="0" unitRef="usd">2196779</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">1960752</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">45000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">45000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">25371781</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">25371781</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">25371781</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">25371781</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">25372</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">25372</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">105256670</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">104078968</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c2" decimals="0" unitRef="usd">-1687</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c3" decimals="0" unitRef="usd">-48921</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">-73694362</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-65318360</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">31585993</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">38737059</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">33782772</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">40697811</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">67435</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">24315</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">5261604</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="usd">5278252</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">3246195</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="usd">2647415</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">8507799</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" unitRef="usd">7925667</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-8440364</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-7901352</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" unitRef="usd">57177</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c4" decimals="0" unitRef="usd">231278</us-gaap:OtherIncome>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="0" unitRef="usd">7185</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c4" decimals="0" unitRef="usd">15499</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">64362</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="0" unitRef="usd">246777</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-8376002</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">-7654575</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="0" unitRef="shares">25371781</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">23140607</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-8376002</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">-7654575</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <tffp:ForeignCurrencyTranslationAdjustments contextRef="c0" decimals="0" unitRef="usd">-47234</tffp:ForeignCurrencyTranslationAdjustments>
    <tffp:ForeignCurrencyTranslationAdjustments contextRef="c4" decimals="0" unitRef="usd">37958</tffp:ForeignCurrencyTranslationAdjustments>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c0" decimals="0" unitRef="usd">-8328768</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c4" decimals="0" unitRef="usd">-7692533</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:SharesOutstanding contextRef="c5" decimals="0" unitRef="shares">25371781</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="0" unitRef="usd">25372</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">104078968</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">-48921</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">-65318360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">38737059</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="0" unitRef="usd">1177702</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">1177702</us-gaap:ShareBasedCompensation>
    <tffp:ForeignCurrencyTranslationAdjustment contextRef="c11" decimals="0" unitRef="usd">47234</tffp:ForeignCurrencyTranslationAdjustment>
    <tffp:ForeignCurrencyTranslationAdjustment contextRef="c0" decimals="0" unitRef="usd">47234</tffp:ForeignCurrencyTranslationAdjustment>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="0" unitRef="usd">-8376002</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-8376002</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c13" decimals="0" unitRef="shares">25371781</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="0" unitRef="usd">25372</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="0" unitRef="usd">105256670</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">-1687</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" unitRef="usd">-73694362</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">31585993</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c17" decimals="0" unitRef="shares">22534874</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">22535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">71648453</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" unitRef="usd">-51538</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">-34279648</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">37339802</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c22" decimals="0" unitRef="shares">2140000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c22" decimals="0" unitRef="usd">2140</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c23" decimals="0" unitRef="usd">28021424</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c4" decimals="0" unitRef="usd">28023564</us-gaap:StockIssuedDuringPeriodValueOther>
    <tffp:IssuanceOfCommonStockForStockOptionExercisesShares contextRef="c22" decimals="0" unitRef="shares">244656</tffp:IssuanceOfCommonStockForStockOptionExercisesShares>
    <tffp:IssuanceOfCommonStockForStockOptionExercises contextRef="c22" decimals="0" unitRef="usd">245</tffp:IssuanceOfCommonStockForStockOptionExercises>
    <tffp:IssuanceOfCommonStockForStockOptionExercises contextRef="c23" decimals="0" unitRef="usd">655008</tffp:IssuanceOfCommonStockForStockOptionExercises>
    <tffp:IssuanceOfCommonStockForStockOptionExercises contextRef="c4" decimals="0" unitRef="usd">655253</tffp:IssuanceOfCommonStockForStockOptionExercises>
    <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares contextRef="c22" decimals="0" unitRef="shares">444751</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares>
    <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises contextRef="c22" decimals="0" unitRef="usd">444</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises>
    <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises contextRef="c23" decimals="0" unitRef="usd">179768</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises>
    <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises contextRef="c4" decimals="0" unitRef="usd">180212</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises>
    <us-gaap:ShareBasedCompensation contextRef="c23" decimals="0" unitRef="usd">1030415</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">1030415</us-gaap:ShareBasedCompensation>
    <tffp:ForeignCurrencyTranslationAdjustment contextRef="c24" decimals="0" unitRef="usd">-37958</tffp:ForeignCurrencyTranslationAdjustment>
    <tffp:ForeignCurrencyTranslationAdjustment contextRef="c4" decimals="0" unitRef="usd">-37958</tffp:ForeignCurrencyTranslationAdjustment>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="0" unitRef="usd">-7654575</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-7654575</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c26" decimals="0" unitRef="shares">25364281</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" unitRef="usd">25364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="0" unitRef="usd">101535068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" unitRef="usd">-89496</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" unitRef="usd">-41934223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">59536713</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-8376002</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">-7654575</us-gaap:ProfitLoss>
    <tffp:StockBasedCompensation contextRef="c0" decimals="0" unitRef="usd">1177702</tffp:StockBasedCompensation>
    <tffp:StockBasedCompensation contextRef="c4" decimals="0" unitRef="usd">1030415</tffp:StockBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">77028</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="0" unitRef="usd">1495</us-gaap:DepreciationDepletionAndAmortization>
    <tffp:ReceivableDueFromCollaborationsAgreement contextRef="c0" decimals="0" unitRef="usd">147880</tffp:ReceivableDueFromCollaborationsAgreement>
    <tffp:ResearchAndDevelopmentTaxIncentiveReceivables contextRef="c0" decimals="0" unitRef="usd">108097</tffp:ResearchAndDevelopmentTaxIncentiveReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" unitRef="usd">-237646</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c4" decimals="0" unitRef="usd">-534612</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" unitRef="usd">192211</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c4" decimals="0" unitRef="usd">521114</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedSalaries contextRef="c0" decimals="0" unitRef="usd">-416910</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <tffp:IncreaseDecreaseDeferredResearchGrantRevenue contextRef="c0" decimals="0" unitRef="usd">-118000</tffp:IncreaseDecreaseDeferredResearchGrantRevenue>
    <tffp:IncreaseDecreaseDeferredResearchGrantRevenue contextRef="c4" decimals="0" unitRef="usd">24315</tffp:IncreaseDecreaseDeferredResearchGrantRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-7246302</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="usd">-5591254</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">137231</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">476128</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-137231</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="0" unitRef="usd">-476128</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <tffp:ProceedsFromIssuanceOfCommonStockValue contextRef="c4" decimals="0" unitRef="usd">28023564</tffp:ProceedsFromIssuanceOfCommonStockValue>
    <tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="c4" decimals="0" unitRef="usd">-655253</tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
    <tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock contextRef="c4" decimals="0" unitRef="usd">-180212</tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="0" unitRef="usd">28859029</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent contextRef="c0" decimals="0" unitRef="usd">3031</tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent>
    <tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent contextRef="c4" decimals="0" unitRef="usd">-37330</tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-7380502</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="0" unitRef="usd">22754317</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">33794672</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c21" decimals="0" unitRef="usd">35300805</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">26414170</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c30" decimals="0" unitRef="usd">58055122</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c0" decimals="0" unitRef="usd">338674</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <tffp:CashlessExerciseOfWarrants contextRef="c4" decimals="0" unitRef="usd">416</tffp:CashlessExerciseOfWarrants>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 1 &#x2013; ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;TFF Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;)
was incorporated in the State of Delaware on January 24, 2018. The Company&#x2019;s initial focus is on the development of inhaled dry
powder drugs to enhance the treatment of pulmonary diseases and conditions. In December 2019, the Company established a wholly-owned Australian
subsidiary, TFF Pharmaceuticals Australia Pty Ltd (&#x201c;TFF Australia&#x201d;), in order to conduct clinical research. TFF Pharmaceuticals,
Inc., along with TFF Australia, are collectively referred to as the &#x201c;Company&#x201d;. The Company is in the development stage and
is devoting substantially all of its efforts toward technology research and development and the human clinical trials of its initial product
candidates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;COVID-19&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the date of this report, the COVID-19 pandemic
has had a relatively insignificant impact on the Company&#x2019;s operations and has not caused the Company to forego, abandon or materially
delay any proposed activities. While the Company believes it has been able to effectively manage the disruption caused by the COVID-19
pandemic to date, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted
or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak
of COVID-19.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <tffp:LiquidityAndManagementsPlansTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 2 - LIQUIDITY AND MANAGEMENT&#x2019;S PLANS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, the Company had cash and
cash equivalents of approximately $26,414,000 and a working capital of approximately $29,327,000. The Company has not generated revenues
from commercial operations since inception and has incurred recurring operating losses. The Company expects to continue incurring losses
for the foreseeable future and may need to raise additional capital to continue the pursuit of its product development.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company expects to further increase its research
and development activities, which will increase the amount of cash utilized subsequent to March 31, 2022. Specifically, the Company expects
increased spending on research and development activities and higher payroll expenses as it increases its professional and scientific
staff and continues to prepare for anticipated manufacturing activities. If the Company encounters unforeseen delays or expenses, it has
the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and cash equivalents
will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of
issuance of these condensed consolidated financial statements.&lt;/p&gt;</tffp:LiquidityAndManagementsPlansTextBlock>
    <tffp:CashAndCashEquivalents contextRef="c2" decimals="0" unitRef="usd">26414000</tffp:CashAndCashEquivalents>
    <us-gaap:SurplusNotes contextRef="c2" decimals="0" unitRef="usd">29327000</us-gaap:SurplusNotes>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited condensed consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;)
for interim financial statements and with Form 10-Q&#160;and Article&#160;10 of Regulation S-X&#160;of the United States Securities and
Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial
statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain
all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March&#160;31,
2022 and the results of operations, changes in stockholders&#x2019; equity and cash flows for the periods presented. The results of operations
for the three months ended March&#160;31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any
future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December
31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and transactions
have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The currency of TFF Australia, the Company&#x2019;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars
using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using the average exchange
rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities is included as a separate
component of stockholders&#x2019; equity in accumulated other comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains its operating accounts in
financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&#x2019;s cash is maintained
in checking accounts and money market funds with maturities of less than three months when purchased, which are readily convertible to
known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value. As of March 31, 2022
and December 31, 2021, the Company had cash in Australia of AUD$308,824 (US$231,447) and AUD$831,984 (US$604,944), respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into feasibility and material
transfer agreements (&#x201c;Feasibility Agreements&#x201d;) with third parties that provide the Company with funds in return for certain
research and development activities. Revenue from the Feasibility Agreements is recognized in the period during which the related qualifying
services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility Agreements have been met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Feasibility Agreements are on a best-effort
basis and do not require scientific achievement as a performance obligation. All fees received under the Feasibility Agreements are non-refundable.
The costs associated with the Feasibility Agreements are expensed as incurred and are reflected as a component of research and development
expense in the accompanying condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Funds received from the Feasibility Agreements
are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility Agreements
are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of
providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying
services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company
records a grant receivable. During the three months ended March 31, 2022 and 2021, the Company rendered the related services and recognized
revenue and research and development expenses of $67,435 and $24,315, respectively. As of March 31, 2022 and December 31, 2021, the Company
had receivables due related to Feasibility Agreements of $55,435 and $11,996, respectively, which is included in prepaid assets and other
current assets in the accompanying condensed consolidated balance sheets, and deferred grant revenue of approximately $168,000 and $50,000,
respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Collaborative Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers the nature and contractual
terms of arrangements and assesses whether an arrangement involves a joint operating activity pursuant to which the Company is an active
participant and is exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company is an
active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts
for such arrangement as a collaborative arrangement under Accounting Standards Codification (&#x201c;ASC&#x201d;) 808, &lt;i&gt;Collaborative
Arrangements&lt;/i&gt;. ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition
matters subjected to other authoritative guidance, in certain cases by analogy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For arrangements determined to be within the scope
of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments
received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. This reflects
the joint risk sharing nature of these activities within a collaborative arrangement. The Company classifies payments owed or receivables
recorded as other current liabilities or prepaid expenses and other current assets, respectively, in the Company&#x2019;s consolidated
balance sheets. Please refer to Note 5, &#x201c;Joint Development Agreement&#x201d; for additional details regarding the Company&#x2019;s
joint development agreement (&#x201c;JDA&#x201d;) with Augmenta Bioworks, Inc. (&#x201c;Augmenta&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If payments from the collaborative partner to
the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for
those payments within the scope of ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. The Company does not currently have any collaborative
arrangements that are accounted for under ASC 606.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Tax Incentive&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is eligible to obtain a cash refund
from the Australian Taxation Office for eligible research and development expenditures under the Australian R&amp;amp;D Tax Incentive Program
(the &#x201c;Australian Tax Incentive&#x201d;). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that
the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. During the
year ended December 31, 2021, the Company received its first cash refund under the Australian Tax Incentive, which was for expenditures
incurred during 2020. Therefore, the Company recorded amounts received, or that it expects to receive, for expenditures incurred during
2020 as other income in the condensed consolidated statements of operations during the period ended March 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As the Company has determined that it has reasonable
assurance that it will receive the cash refund for eligible research and development expenditures, beginning with expenditures incurred
during the year ended December 31, 2021, the Company records the Australian Tax Incentive as a reduction to research and development expenses
as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company&#x2019;s ongoing tax status,
or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information
at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for
the three months ended March 31, 2022 and 2021. In addition, the Company is also eligible to receive amounts from the United States Internal
Revenue Service (&#x201c;IRS&#x201d;) related to research and development tax credits for expenditures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The research and development incentive receivable
represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development
tax incentive receivable of $1,168,830 and $966,646 as of March 31, 2022 and December 31, 2021, respectively, in the condensed consolidated
balance sheets. The Company has recorded other income of $57,177 and $231,278, in the condensed consolidated statements of operations
for the three months ended March 31, 2022 and 2021, respectively, related to refundable IRS and Australian research and development incentive
program payments for expenditures incurred during 2020. The Company recorded a reduction to research and development expenses of $108,098
during the three months ended March 31, 2022 for expenditures incurred during 2022 and $0 during the three months ended March 31, 2021
for expenditures incurred during 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Earnings per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed
by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined
using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive
securities are anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the three months ended March 31, 2022 and
2021, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted
net loss per common share because inclusion thereof would be anti-dilutive:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&#160;Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&#160;Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,976,090&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,375,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,365,323&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,765,072&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;On
an as-converted basis&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of condensed consolidated financial
statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation and
warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There have been no recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the three months ended March 31, 2022 that are of
significance or potential significance to the Company.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited condensed consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;)
for interim financial statements and with Form 10-Q&#160;and Article&#160;10 of Regulation S-X&#160;of the United States Securities and
Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial
statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain
all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March&#160;31,
2022 and the results of operations, changes in stockholders&#x2019; equity and cash flows for the periods presented. The results of operations
for the three months ended March&#160;31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any
future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December
31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and transactions
have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The currency of TFF Australia, the Company&#x2019;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars
using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using the average exchange
rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities is included as a separate
component of stockholders&#x2019; equity in accumulated other comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains its operating accounts in
financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&#x2019;s cash is maintained
in checking accounts and money market funds with maturities of less than three months when purchased, which are readily convertible to
known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value. As of March 31, 2022
and December 31, 2021, the Company had cash in Australia of AUD$308,824 (US$231,447) and AUD$831,984 (US$604,944), respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash contextRef="c2" decimals="0" unitRef="aud">308824</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c2" decimals="0" unitRef="usd">231447</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c3" decimals="0" unitRef="aud">831984</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c3" decimals="0" unitRef="usd">604944</us-gaap:RestrictedCash>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into feasibility and material
transfer agreements (&#x201c;Feasibility Agreements&#x201d;) with third parties that provide the Company with funds in return for certain
research and development activities. Revenue from the Feasibility Agreements is recognized in the period during which the related qualifying
services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility Agreements have been met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Feasibility Agreements are on a best-effort
basis and do not require scientific achievement as a performance obligation. All fees received under the Feasibility Agreements are non-refundable.
The costs associated with the Feasibility Agreements are expensed as incurred and are reflected as a component of research and development
expense in the accompanying condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Funds received from the Feasibility Agreements
are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility Agreements
are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of
providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying
services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company
records a grant receivable. During the three months ended March 31, 2022 and 2021, the Company rendered the related services and recognized
revenue and research and development expenses of $67,435 and $24,315, respectively. As of March 31, 2022 and December 31, 2021, the Company
had receivables due related to Feasibility Agreements of $55,435 and $11,996, respectively, which is included in prepaid assets and other
current assets in the accompanying condensed consolidated balance sheets, and deferred grant revenue of approximately $168,000 and $50,000,
respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c0" decimals="0" unitRef="usd">67435</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c4" decimals="0" unitRef="usd">24315</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" unitRef="usd">55435</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" unitRef="usd">11996</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">168000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">50000</us-gaap:OtherLiabilitiesCurrent>
    <tffp:CollaborativeArrangementsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Collaborative Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers the nature and contractual
terms of arrangements and assesses whether an arrangement involves a joint operating activity pursuant to which the Company is an active
participant and is exposed to significant risks and rewards dependent on the commercial success of the activity. If the Company is an
active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity, the Company accounts
for such arrangement as a collaborative arrangement under Accounting Standards Codification (&#x201c;ASC&#x201d;) 808, &lt;i&gt;Collaborative
Arrangements&lt;/i&gt;. ASC 808 describes arrangements within its scope and considerations surrounding presentation and disclosure, with recognition
matters subjected to other authoritative guidance, in certain cases by analogy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For arrangements determined to be within the scope
of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments
received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. This reflects
the joint risk sharing nature of these activities within a collaborative arrangement. The Company classifies payments owed or receivables
recorded as other current liabilities or prepaid expenses and other current assets, respectively, in the Company&#x2019;s consolidated
balance sheets. Please refer to Note 5, &#x201c;Joint Development Agreement&#x201d; for additional details regarding the Company&#x2019;s
joint development agreement (&#x201c;JDA&#x201d;) with Augmenta Bioworks, Inc. (&#x201c;Augmenta&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If payments from the collaborative partner to
the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for
those payments within the scope of ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. The Company does not currently have any collaborative
arrangements that are accounted for under ASC 606.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tffp:CollaborativeArrangementsPolicyTextBlock>
    <tffp:ResearchAndDevelopmentTaxIncentivePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Tax Incentive&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is eligible to obtain a cash refund
from the Australian Taxation Office for eligible research and development expenditures under the Australian R&amp;amp;D Tax Incentive Program
(the &#x201c;Australian Tax Incentive&#x201d;). The Company recognizes the Australian Tax Incentive when there is reasonable assurance that
the cash refund will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. During the
year ended December 31, 2021, the Company received its first cash refund under the Australian Tax Incentive, which was for expenditures
incurred during 2020. Therefore, the Company recorded amounts received, or that it expects to receive, for expenditures incurred during
2020 as other income in the condensed consolidated statements of operations during the period ended March 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As the Company has determined that it has reasonable
assurance that it will receive the cash refund for eligible research and development expenditures, beginning with expenditures incurred
during the year ended December 31, 2021, the Company records the Australian Tax Incentive as a reduction to research and development expenses
as the Australian Tax Incentive is not dependent on the Company generating future taxable income, the Company&#x2019;s ongoing tax status,
or tax position. At each period end, management estimates the refundable tax offset available to the Company based on available information
at the time. This percentage of eligible research and development expenses reimbursable under the Australian Tax Incentive is 43.5% for
the three months ended March 31, 2022 and 2021. In addition, the Company is also eligible to receive amounts from the United States Internal
Revenue Service (&#x201c;IRS&#x201d;) related to research and development tax credits for expenditures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The research and development incentive receivable
represents amounts due in connection with the Australian Tax Incentive and from the IRS. The Company has recorded a research and development
tax incentive receivable of $1,168,830 and $966,646 as of March 31, 2022 and December 31, 2021, respectively, in the condensed consolidated
balance sheets. The Company has recorded other income of $57,177 and $231,278, in the condensed consolidated statements of operations
for the three months ended March 31, 2022 and 2021, respectively, related to refundable IRS and Australian research and development incentive
program payments for expenditures incurred during 2020. The Company recorded a reduction to research and development expenses of $108,098
during the three months ended March 31, 2022 for expenditures incurred during 2022 and $0 during the three months ended March 31, 2021
for expenditures incurred during 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tffp:ResearchAndDevelopmentTaxIncentivePolicyTextBlock>
    <tffp:ResearchAndDevelopmentTaxPercentage contextRef="c0" decimals="3" unitRef="pure">0.435</tffp:ResearchAndDevelopmentTaxPercentage>
    <tffp:ResearchAndDevelopmentTaxPercentage contextRef="c4" decimals="3" unitRef="pure">0.435</tffp:ResearchAndDevelopmentTaxPercentage>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c31" decimals="0" unitRef="usd">1168830</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c32" decimals="0" unitRef="usd">966646</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:OtherIncome contextRef="c33" decimals="0" unitRef="usd">57177</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c34" decimals="0" unitRef="usd">231278</us-gaap:OtherIncome>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c33" decimals="0" unitRef="usd">108098</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c34" decimals="0" unitRef="usd">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Earnings per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed
by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding for the period, determined
using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods presented, all potentially dilutive
securities are anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the three months ended March 31, 2022 and
2021, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of diluted
net loss per common share because inclusion thereof would be anti-dilutive:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&#160;Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&#160;Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,976,090&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,375,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,365,323&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,765,072&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;On
an as-converted basis&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&#160;Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&#160;Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,976,090&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,375,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;389,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,365,323&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,765,072&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;On
an as-converted basis&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c35" decimals="INF" unitRef="shares">2976090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c36" decimals="INF" unitRef="shares">2375839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c37" decimals="INF" unitRef="shares">389233</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c38" decimals="INF" unitRef="shares">389233</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="INF" unitRef="shares">3365323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c4" decimals="INF" unitRef="shares">2765072</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of condensed consolidated financial
statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation and
warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There have been no recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the three months ended March 31, 2022 that are of
significance or potential significance to the Company.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 4 - COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2018, the Company entered into a lease
agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018 and expires on October 31, 2022, as amended.
The lease has an additional one-year option for renewal, and the base rent is $36,000 per year. The Company has determined that the lease
agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The Company rents another
office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease as well. Short-term lease
expense for the three months ended March 31, 2022 and 2021 was approximately $21,000 and $15,000, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Approximate future minimum lease payments required
under the operating leases are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -8.1pt; padding-left: 8.1pt"&gt;Year Ending December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Legal&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company may be involved, from time to time,
in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes
and are not predictable with assurance. While management believes that such matters are currently insignificant, matters arising in the
ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its
business and financial condition. To the Company&#x2019;s knowledge, neither the Company nor any of its properties are subject to any pending
legal proceedings.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense contextRef="c39" decimals="0" unitRef="usd">36000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" unitRef="usd">21000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="0" unitRef="usd">15000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -8.1pt; padding-left: 8.1pt"&gt;Year Ending December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c2" decimals="0" unitRef="usd">21000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <tffp:LicenseAndAgreementDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 5 - LICENSE AND AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2015, the University of Texas at Austin
(&#x201c;UT&#x201d;) granted to the Company&#x2019;s former parent, LTI, an exclusive worldwide, royalty bearing license to the patent rights
for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide, royalty bearing license
to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all of its interest to the TFF platform,
including the patent license agreement with UT, at which time the Company paid UT an assignment fee of $100,000 in accordance with the
patent license agreement. In November 2018, the Company and UT entered into an amendment to the patent license agreement pursuant to which,
among other things, the Company&#x2019;s exclusive patent rights to the TFF platform were expanded to all fields of use. The patent license
agreement requires the Company to pay royalties and milestone payments and conform to a variety of covenants and agreements, and in the
event of the Company&#x2019;s breach of agreement, UT may elect to terminate the agreement. For the period ended December 31, 2018, the
Company did not achieve any of the milestones and, as such, was not required to make any milestone payments. During the ended December
31, 2019, the Company achieved one milestone by gaining IND approval on first indication of a licensed product on November 24, 2019 and
the Company satisfied the milestone payment of $50,000 and issuance of shares in accordance with the agreement. As of the date of these
condensed consolidated financial statements, the Company is in compliance with the patent license agreement as all required amounts have
been paid in accordance with the agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2018, the Company entered into a master
services agreement and associated individual study contracts with ITR Canada, Inc. (&#x201c;ITR&#x201d;) to provide initial contract pre-clinical
research and development services for the Company&#x2019;s drug product candidates. In January 2019, the Company cancelled all of the individual
study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba
Strategy Point Innovations (&#x201c;SPI&#x201d;)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits. The services related to the contract with
SPI were sub-contracted to ITR and others under substantially the same terms as the initial contract with ITR. Desire Ventures, LLC facilitates
the invoicing for the various affiliates. The accounts payable due in connection with this agreement was approximately $472,000 and $0
as of March 31, 2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded
research and development costs of approximately $1,585,000 and $1,812,000, respectively, pertaining to this agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2019, the Company entered into a master
services agreement with Irisys, LLC to provide contract manufacturing services for one of the Company&#x2019;s drug product candidates,
Voriconazole. The accounts payable due in connection with this agreement was approximately $35,000 and $21,000 as of March 31, 2022 and
December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $446,000 and $494,000, respectively, pertaining to this agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2020, TFF Australia entered into a
master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to provide initial
contract clinical research and development services for the Company&#x2019;s drug product candidates. The accounts payable due in connection
with this agreement was approximately AUD$179,000 (US$134,000) and AUD$138,000 (US$100,000) as of March 31, 2022 and December 31, 2021,
respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
AUD$347,000 (US$251,000) and AUD$705,000 (US$545,000), respectively, pertaining to this agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2020, TFF Australia entered into an amended
clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company&#x2019;s drug candidates,
Tacrolimus. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of March 31,
2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $0 and AUD$244,000 (US$188,000), respectively, pertaining to this agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 12, 2020, the Company entered into a
licensing and collaboration agreement with UNION therapeutics A/S in which UNION acquired an option to obtain a worldwide exclusive license
for the TFF technology in combination with niclosamide. Pursuant to the terms of the license agreement, UNION can exercise its option
to obtain the license within 45 days after the complete data has been received by UNION from investigator-initiated trials. Upon exercise
of the option, UNION shall be responsible to pay all expenses incurred in the development of any licensed product. The Company will be
eligible to receive milestone payments upon the achievement of certain milestones in the development the licensed products, based on completion
of clinical trials, pre-marketing approvals and/or the receipt of at least $25,000,000 of grant funding. The Company will receive a single-digit
tiered royalty on net sales. The Company will also be entitled to receive sales-related milestone payments based on the commercial success
of the licensed products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2021, the Company entered into a master
services agreement with Experic to provide contract manufacturing services for one of the Company&#x2019;s drug product candidates, Voriconazole.
The accounts payable due in connection with this agreement was approximately $87,000 and $313,000 as of March 31, 2022 and December 31,
2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
$318,000 and $196,000, respectively, pertaining to this agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2022, the Company entered into a Letter
of Intent with Synteract, Inc. to provide contract research and development services while negotiating a Master Services Agreement for
one of the Company&#x2019;s drug product candidates, Voriconazole. The accounts payable due in connection with this agreement was approximately
$14,000 as of March 31, 2022. During the three months ended March 31, 2022, the Company recorded research and development costs of approximately
$226,000 pertaining to this agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Joint Development Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 2, 2020, the Company and Augmenta
entered into the JDA pursuant to which the Company and Augmenta (collectively the &#x201c;Parties&#x201d;) agreed to work jointly to develop
one or more novel commercial products incorporating Augmenta&#x2019;s human derived monoclonal antibody for the treatment of patients with
COVID-19 and the Company&#x2019;s patented Thin Film Freezing technology platform. Each party retains full ownership over its existing
assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Parties will share development costs with
each party funding its fifty-percent-share at specified times. In the event that one of the Parties fails to make its pro rata share payment,
the other party may terminate the JDA. In lieu of terminating the JDA, the non-defaulting party may elect to continue the JDA by paying
the delinquent amount and each party&#x2019;s pro rata share of the JDA will automatically adjust by the amount paid. In addition, in the
event Augmenta experiences a default on its required payment, Augmenta will have the one-time right to elect to require the Company to
purchase Augmenta&#x2019;s interest in the JDA (&#x201c;Put Right&#x201d;) for a one-time fee of $500,000. Upon exercise of the Put Right
and payment by the Company, Augmenta will grant the Company an exclusive, worldwide, royalty-free, transferable, sublicensable license
to the Augmenta antibody and Augmenta&#x2019;s rights to the property developed under the JDA. The Company has determined that the likelihood
of the Put Right being exercised to be remote.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The JDA is within the scope of ASC 808 as the
Company and Augmenta are both active participants in the research and development activities and are exposed to significant risks and
rewards that are dependent on commercial success of the activities of the arrangement. The research and development activities are a unit
of account under the scope of ASC 808 and are not promises to a customer under the scope of ASC 606.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records its portion of the research
and development expenses as the related expenses are incurred. All payments received or amounts due from Augmenta for reimbursement of
shared costs are accounted for as an offset to research and development expense. During the three months ended March 31, 2022 and 2021,
the Company recorded research and development expenses of $147,880 and $76,200, respectively, and has recorded a receivable of $1,776,583
and $1,628,703 for reimbursement due from Augmenta as of March 31, 2022 and December 31, 2021, respectively.&lt;/p&gt;</tffp:LicenseAndAgreementDisclosureTextBlock>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c40" decimals="0" unitRef="usd">100000</us-gaap:DebtInstrumentFeeAmount>
    <tffp:MilestoneFee contextRef="c41" decimals="0" unitRef="usd">50000</tffp:MilestoneFee>
    <tffp:AgreementTremDescription contextRef="c42">the Company cancelled all of the individual
study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba
Strategy Point Innovations (&#x201c;SPI&#x201d;)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits.</tffp:AgreementTremDescription>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c43" decimals="0" unitRef="usd">472000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c44" decimals="0" unitRef="usd">0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:OtherExpenses contextRef="c0" decimals="0" unitRef="usd">1585000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c4" decimals="0" unitRef="usd">1812000</us-gaap:OtherExpenses>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">35000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">21000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:OtherExpenses contextRef="c45" decimals="0" unitRef="usd">446000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c46" decimals="0" unitRef="usd">494000</us-gaap:OtherExpenses>
    <tffp:AgreementDescription contextRef="c47">to provide initial
contract clinical research and development services for the Company&#x2019;s drug product candidates. The accounts payable due in connection
with this agreement was approximately AUD$179,000 (US$134,000) and AUD$138,000 (US$100,000) as of March 31, 2022 and December 31, 2021,
respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately
AUD$347,000 (US$251,000) and AUD$705,000 (US$545,000), respectively, pertaining to this agreement.</tffp:AgreementDescription>
    <tffp:AgreementDescription contextRef="c48">to provide a Phase I study of one of the Company&#x2019;s drug candidates,
Tacrolimus. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of March 31,
2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development
costs of approximately $0 and AUD$244,000 (US$188,000), respectively, pertaining to this agreement.</tffp:AgreementDescription>
    <tffp:PremarketingApprovals contextRef="c49" decimals="0" unitRef="usd">25000000</tffp:PremarketingApprovals>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c50" decimals="0" unitRef="usd">87000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c51" decimals="0" unitRef="usd">313000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:OtherExpenses contextRef="c52" decimals="0" unitRef="usd">318000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c53" decimals="0" unitRef="usd">196000</us-gaap:OtherExpenses>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c54" decimals="0" unitRef="usd">14000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c55" decimals="0" unitRef="usd">226000</us-gaap:ResearchAndDevelopmentExpense>
    <tffp:InterstFee contextRef="c0" decimals="0" unitRef="usd">500000</tffp:InterstFee>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c56" decimals="0" unitRef="usd">147880</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c57" decimals="0" unitRef="usd">76200</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherReceivables contextRef="c2" decimals="0" unitRef="usd">1776583</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c3" decimals="0" unitRef="usd">1628703</us-gaap:OtherReceivables>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 6 &#x2013; STOCK BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2018, the Company&#x2019;s board of
directors approved its 2018 Stock Incentive Plan (&#x201c;2018 Plan&#x201d;). The 2018 Plan provides for the grant of non-qualified stock
options and incentive stock options to purchase shares of the Company&#x2019;s common stock, the grant of restricted and unrestricted share
awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the 2018 Plan; however,
upon completion of the Company&#x2019;s IPO the number of shares reserved for issuance under the 2018 Plan increased to 3,284,480, representing
15% of the Company&#x2019;s outstanding shares of common stock calculated on a fully diluted basis upon the close of the IPO. All of the
Company&#x2019;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the
Company&#x2019;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible
to receive incentive awards under the 2018 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2021, the Company&#x2019;s board of
directors approved its 2021 Stock Incentive Plan (&#x201c;2021 Plan&#x201d;), which was also approved by the stockholders of the Company
at the Company&#x2019;s annual meeting of stockholders held on November 4, 2021. The 2021 Plan provides for the grant of non-qualified
stock options and incentive stock options to purchase shares of the Company&#x2019;s common stock, the grant of restricted and unrestricted
share awards and grant of restricted stock units. The Company has 4,200,000 shares of its common stock reserved under the 2021 Plan. All
of the Company&#x2019;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all
of the Company&#x2019;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will
be eligible to receive incentive awards under the 2021 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the stock-based
compensation expense recorded in the Company&#x2019;s results of operations during the three months ended March 31, 2022 and 2021 for stock
options and warrants:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&lt;br/&gt; Months&lt;br/&gt; Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&lt;br/&gt; Months&lt;br/&gt; Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;205,809&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;67,279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;971,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;963,136&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,177,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,030,415&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, there was approximately
$8,135,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected to
vest. This cost is expected to be recognized over a weighted-average period of 2.4 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records compensation expense for awards
with graded vesting using the straight-line method. The Company recognizes compensation expense over the requisite service period applicable
to each individual award, which generally equals the vesting term. The Company estimates the fair value of each option award using the
Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company estimated the fair value stock options
using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite
service periods of the respective awards. The fair value of stock options issued was estimated using the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Three&#160;Months&lt;br/&gt; March&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assumptions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;96%-97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;1.79%-2.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The risk-free interest rate was obtained from
U.S. Treasury rates for the applicable periods. The Company&#x2019;s expected volatility was based upon the historical volatility for industry
peers and used an average of those volatilities. The expected life of the Company&#x2019;s options was determined using the simplified
method as a result of limited historical data regarding the Company&#x2019;s activity for employee awards and the contractual term for
nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and does not expect to pay dividends
in the foreseeable future. The Company uses the closing stock price on the date of grant as the fair value of the common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes stock option activity
during the three months ended March 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (In&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,893,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,932,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,749&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11.09&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,976,090&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.87&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,435,685&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,411,441&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.24&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,196,095&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate intrinsic value of stock options
is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock
for those stock options that had strike prices lower than the fair value of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Option Modification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective March 21, 2022, one of the members of
the Company&#x2019;s board of directors, Dr. Brian Windsor, resigned. As part of his resignation from the board of directors, modifications
were made to Dr. Windsor&#x2019;s vested and non-vested stock option awards including acceleration of certain non-vested option awards
and the extension of the post-termination exercise period of certain stock option awards. During the three months ended March 31, 2022,
in accordance with ASC Topic 718, &lt;i&gt;Compensation&#x2014;Stock Compensation,&lt;/i&gt; the Company recorded a one-time, non-cash incremental
compensation expense net of the required reversal of previously recognized compensation attributed to non-vested shares in the amount
of approximately $339,000, which is included in general and administrative expense in the accompanying condensed consolidated statements
of operations.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <tffp:ReservedShares contextRef="c58" decimals="0" unitRef="shares">1630000</tffp:ReservedShares>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c58" decimals="0" unitRef="shares">3284480</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:PercentageOfWeightedAverageCostInventory contextRef="c59" decimals="2" unitRef="pure">0.15</us-gaap:PercentageOfWeightedAverageCostInventory>
    <tffp:ReservedShares contextRef="c60" decimals="0" unitRef="shares">4200000</tffp:ReservedShares>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&lt;br/&gt; Months&lt;br/&gt; Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Three&lt;br/&gt; Months&lt;br/&gt; Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;205,809&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;67,279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;971,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;963,136&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,177,702&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,030,415&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <tffp:StockBasedCompensationExpenses contextRef="c61" decimals="0" unitRef="usd">205809</tffp:StockBasedCompensationExpenses>
    <tffp:StockBasedCompensationExpenses contextRef="c62" decimals="0" unitRef="usd">67279</tffp:StockBasedCompensationExpenses>
    <tffp:StockBasedCompensationExpenses contextRef="c63" decimals="0" unitRef="usd">971893</tffp:StockBasedCompensationExpenses>
    <tffp:StockBasedCompensationExpenses contextRef="c64" decimals="0" unitRef="usd">963136</tffp:StockBasedCompensationExpenses>
    <tffp:StockBasedCompensationExpenses contextRef="c0" decimals="0" unitRef="usd">1177702</tffp:StockBasedCompensationExpenses>
    <tffp:StockBasedCompensationExpenses contextRef="c4" decimals="0" unitRef="usd">1030415</tffp:StockBasedCompensationExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c2" decimals="0" unitRef="usd">8135000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm contextRef="c0">P2Y4M24D</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Three&#160;Months&lt;br/&gt; March&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assumptions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;96%-97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;1.79%-2.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">6.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c0" decimals="2" unitRef="usdPershares">5.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c65" decimals="2" unitRef="pure">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c66" decimals="2" unitRef="pure">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c65" decimals="4" unitRef="pure">0.0179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c66" decimals="4" unitRef="pure">0.0241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (In&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,893,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,932,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,749&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11.09&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,976,090&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.87&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,435,685&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,411,441&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.24&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,196,095&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber contextRef="c3" decimals="0" unitRef="shares">2893839</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
    <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">6.48</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
    <tffp:SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="c0">P8Y18D</tffp:SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="0" unitRef="usd">9932413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c0" decimals="0" unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">6.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <tffp:StockIssuedDuringPeriodSharesStockOptionesExercised contextRef="c0" decimals="0" unitRef="shares">17749</tffp:StockIssuedDuringPeriodSharesStockOptionesExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">11.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber contextRef="c2" decimals="0" unitRef="shares">2976090</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
    <tffp:WeightedAverageExercisePricesOutstandingOutstandingEndingBalance contextRef="c0" decimals="2" unitRef="usdPershares">6.47</tffp:WeightedAverageExercisePricesOutstandingOutstandingEndingBalance>
    <tffp:WeightedAverageRemainingContractualTermOutstandingEndingBalance contextRef="c0">P7Y10M13D</tffp:WeightedAverageRemainingContractualTermOutstandingEndingBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c2" decimals="0" unitRef="usd">4435685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c2" decimals="0" unitRef="shares">1411441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P7Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <tffp:AggregateIntrinsicValueExercisables contextRef="c2" decimals="0" unitRef="usd">3196095</tffp:AggregateIntrinsicValueExercisables>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">339000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 7 &#x2013; SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has performed an evaluation of events
occurring subsequent to March 31, 2022 through the filing date of this Quarterly Report. Based on its evaluation, there are no events
that need to be disclosed.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <tffp:AccruedCompensationLiabilities
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c9"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c11"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c12"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ForeignCurrencyTranslationAdjustment
      contextRef="c9"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ForeignCurrencyTranslationAdjustment
      contextRef="c10"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ForeignCurrencyTranslationAdjustment
      contextRef="c12"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c9"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c10"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c24"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c25"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:IssuanceOfCommonStockForStockOptionExercises
      contextRef="c24"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:IssuanceOfCommonStockForStockOptionExercises
      contextRef="c25"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises
      contextRef="c24"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises
      contextRef="c25"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c22"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c24"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c25"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ForeignCurrencyTranslationAdjustment
      contextRef="c22"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ForeignCurrencyTranslationAdjustment
      contextRef="c23"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ForeignCurrencyTranslationAdjustment
      contextRef="c25"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ReceivableDueFromCollaborationsAgreement
      contextRef="c4"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ResearchAndDevelopmentTaxIncentiveReceivables
      contextRef="c4"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="c4"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ProceedsFromIssuanceOfCommonStockValue
      contextRef="c0"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises
      contextRef="c0"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock
      contextRef="c0"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c4"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <tffp:CashlessExerciseOfWarrants
      contextRef="c0"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001733413</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MRP%4 IV?D>8W1NVR8\9G98R*LDM?"D]J^P+\OE'*'&]L ^5)]?@_4$L#!!0
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M+H#VUTK9%\<-KOX[E?T%4$L#!!0    ( +J JU0\3 BWGP0  )4/   8
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M!?^)L@<L)XKO3!OUPA4T96:XA;Z9"2T _Z\Y5V\3O4'5B4__!U!+ P04
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MI,7ACK.(YR9 ?[\50GT_,:\VJK=KBW\!4$L#!!0    ( +J JU1 5NW+_P4
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MMN@3K+U"%^CKXSWZ^:=?KN8:@)CAYGDWZ6T[*9F8-$2?1:VW"GV$*8NW_>=
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M<\<LVUOH]D&+G;W(70FM166;6T8+)HT!?%\+H5\?S 3]_P*6_P)02P,$%
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M5!#Z.9,?!M/DC$V&]'CBVI.Q@=;22(>S&9K^29I:^E[N;$FI+4OI4L6@%9]
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M)IVGVK2U81"0%CLTC>L(#Y@NJK,7I5Y!6\P?K@?D42C4=>V8C =?=$J%061
M0[,PG))#V9]61*ST:+*26N%THX3<*A^:7FP:FO[=T+U8 "N)].;01[7IS6N<
M981#QQPDCS!-)<=-U#>7OV-8UX[0*&0 <>%#%,K(;:!)0F5S*<1^YOT,.B.R
MGO*^%MS(-@J+8D2",O884^6M5EE,2:X,SO$,0"Y#XV[XW(0>'=V)&!OK>/-[
MBGEJKL=NM_NX6#9WZN%X\V6":E\KC!HM<YB.AV=O^N2:V[YY"+:*-^S*!MS7
M<5G@ TDZ/H#WN;5A_\ .ND^NQ3]02P,$%     @ NH"K5'B0K&]I$   :#
M !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R]6VUO&[D1_KZ_@G#30U+(
MLBSY+9<70'&2JZ]-XD9.KT71#]0N)3'9)75+KA7WUW=>R%VN+=DQ4!0XQ))V
M2<X,9YYY9LA[N;'U-[=2RHOO56G<J[V5]^N?#PY<OE*5=$.[5@:>+&Q=20]?
MZ^6!6]=*%C2H*@_&H]')026UV7O]DGZ[K%^_M(TOM5&7M7!-5<GZYHTJ[>;5
MWN%>_.&S7JX\_G#P^N5:+M5,^2_KRQJ^';2S%+I2QFEK1*T6K_:FAS^_.<+W
MZ86_:[5QR6>!FLRM_89?+HI7>R,42)4J]SB#A#_7ZER5)4X$8OP>YMQKE\2!
MZ><X^WO2'7292Z?.;?F;+OSJU=[9GBC40C:E_VPW?U9!GV.<+[>EHW_%AM\]
MFNR)O''>5F$P2%!IPW_E]V"'9,#9:,> <1@P)KEY(9+RK?3R]<O:;D2-;\-L
M^(%4I=$@G#:X*3-?PU,-X_SK&6^&L LQTTNC%SJ7QHMIGMO&>&V6XM*6.M?*
MO3SPL!Z..LC#W&]X[O&.N2?B@S5^Y<0[4ZBB/_X Y&R%'4=AWXSOG?"#K(=B
M<C@0X]%X?,]\DU;Y"<TWV3'?%BW%OZ9SYVMPEG_?L\!1N\ 1+7"TR[I?/GR8
M?OZG^/1>S"Y^^7CQ_N)\^O%*3,_//WWY>'7Q\1=Q^>FO%^<7[V;;K'O_W!\_
M7;T3$[$O?GP1\48Z[7"O+VOEE/&2(N-JI41C9%-HKPJ16]@MX_B3 [,4$G]>
M:"--KF69.1BF("Z]$RMYK<1<*2, $=:RAO<T1EINZP+>5N#,?D7?@YG7M89)
MUB48>JF,JF59WN!SM?8\UH,L7PP),L-U2-III6KP2_'TIS^<C<>C%[],IY?T
M\?#%LPR "09Z>*/JA!2)D-(4+ >&L3@<[?^-?IK67N>E@A]PB<]JV91LCMG^
M/_"7NY+,5-[4VJ.7P 39N^_Y2IJE$N>VJK0CF(H2SMZ=1P&'%$QU >J7-P.<
M]D845ACKT<!>HL'*$E1@A"6H O$6UGIX!]:JU>^-1M/.;P1J+E!C:4P#:F[;
ME:&X8#O:M38X75 &Q%Q+<X-R'9Z^<( B!F 7AY!4M$WT!F[4C_M#:NJ@4(8*
MT93%5X P?F94KIQ#K'F*$VE'#F%-2>!C4/D2= 43U_@ I*E!0_=,>(O>A>Y*
M<W8+KZW3_JZ"0I+3 %CD*T2+#-&";(HOP4P V/0&9+::#.X&@K?2H0L"YN;?
M5K8L5.V"L01N@;^A27+I5F(!R<S11N"<,(^VA8MBJF)(,;5UJ2P.\JM:*5$Q
M0BI$R$YDP2+7BMPD6DZ#J;0I(!(PDT6MP]1@LKA>7&'1E.@A+@=;W2A9"_*;
MFVS1^*:.4I.H[C$ D&ZX6]FF!,]$924%,(SYVAA.N11UY ?=U.V$V<Y@9;>'
M<;7R=B V*PU606, =I1-T0'%;8^><E!\5FM;>W"M-N+_TMJ$[,#6?@MFK>:J
MSH+!#X< BRT\@77/6VDC2CYLD"!B%@.J,>P 5^_?B\N5!"?/50/  YX]@#C-
MAZ2QAI<VX'+ES;[=&)C;-7.G"PW1,J"ATP:34JDEH EL*N $;)XL&?CRZ/=Q
M/?+U6AHG<_:Y#J=5J8%%R("V>:KA$,T%+,:(<XA!9?(;UCE^"5JTH@RV[4%&
M$AF:$"V3Z*$INMKA!E"P+&7MNG7;I<#_;!13.J>"3C!JKLN P. /I&,9E &8
M^#*<#>.L6>,P)E!$%8&Z)A@'(=1B :Q02"^4!-^:RY*R%=-@W-TA.-&6X+T-
M +>$Z)8$>]< KNW2&2\-,6^;)<2,3W"#P2*(!,OUQ(6%FMPW87EPP[A<P+T=
MUM&N"Q: 0RD<IF>8+T-GL0;!%$;? W6<QYNJ8=4LAJ/ P;5:(2<'ARJM@\T[
M1W/@^O3A'8R^EB7%PE6"R5@?8&IPY.L=9K4^"UFC"RAXSVO?L-*1%>#F4K"8
M-!QPD;!_+H"$:S!;-FO,'&ZM<B"U"LU3:4R.5UN @[94NU9*0">,CI7*O_6$
MQ.4!L17J4W\#7UDT!G"?< YB,K(#L"Q "&ZW-'V<WZR0*S4 \U!)%"FV(7XB
MP$-(@N]X/0=JXFWVS0 @"%FU0(*B#IC3T%A])]=W>9TFAA#\BIX%Q@#3)!R_
MUNX;B0K;B-/ MC7@^--^]J14E.%Z$2_CKX<]   N&$(CW1]B;U_>/IF,S@9G
MXR/Q],OLR1C&'QV=/F,6!@_/X(?G9_SP9'0T>'YT]&R V6RMJ&8K;S <KY5I
M%/S-+:C0(G*W.B91@)Z(!0L%7)?B@=-VA,R, F@!:L@E; RC=J1M[Y-!T_9Q
M9'(QG^FZ$!!-M-6PQ1[ROKW6A>J9@]YE]]!8OH)S&,I".>PN<B3D"F1DE*X
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M/+6E2[<V#(JN;(_NV=JP-DMEM1K0(PPG"Y0AX<@N#+MG[^/C7D*02L!/M?9
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MW.0 (]'LLBY&T3QZH=) D)J4:LG2(&"-UTB]RI<L?K@H)%.00DX[.Y>2E@*
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M\^:-F)>RIH.$AI^6I1AK51:.!&@<Z!JLH\4X]T[F.73$?(G[J<ZGQ!+"0Z[
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MD"N\ -9'75<G,)KS)$[97.,MS98\M]F2V_9V.A6/!H=H%Q=4W=7*AAHUU,_
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MB8SWZ'0'+/UMLPF,TFT\XDLN^9+:?>)%F57WTA;.B^]CV9R2:E6'[F&M4H[
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M^OK=T>1M!QW:;TO@V@8.B[4F/M/K I#><M3L'CD4*C-U$@G"*<":+/B]>X]
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MH@M&]-6U_1&]:EO_A:3](MSUA?FP]14_4W;.OU50=96Y\Q_TFZ?-SR'G_E>
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MC"VP\BL#EJX4M%J$)UPUAF28$ "M0,=R#5[#^3AT#9^C18OF<6@D0CFERTP
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M#=H00/N5,?XT"0GZIRO_ U!+ P04    " "Z@*M4:%D(,-P#  # "   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R55FUSXC80_NY?L>,FG63&^!4P
M3H$9R%VOUYEK,\FU]Z'3#\)>0!/;<B4!X=]W)8-#4\*T'\ K>5\>/;NK]7@G
MY+-:(VIXJ<I:3=RUULU=$*A\C153OFBPIC=+(2NF:2E7@6HDLL(:5640A^$P
MJ!BOW>G8[CW(Z5AL=,EK?)"@-E7%Y'Z.I=A-W,@];CSRU5J;C6 Z;M@*GU#_
MUCQ(6@6=EX)76"LN:I"XG+BSZ&X^-/I6X7>..W4B@SG)0HAGL_A<3-S0 ,(2
M<VT\,'IL\1[+TC@B&'\=?+I=2&-X*A^]_VC/3F=9,(7WHOS&"[V>N",7"ERR
M3:D?Q>XG/)QG8/SEHE3V'W:M;AJ[D&^4%M7!F!!4O&Z?[.7 PXG!*'S'(#X8
MQ!9W&\BB_, TFXZEV($TVN3-"/:HUIK \=HDY4E+>LO)3D^?M,B?84[G*N!>
M5)1KQ2Q=-U_9HD1U.PXTA3'*07YP.6]=QN^X3."+J/5:P<>ZP.*?]@'!ZS#&
M1XSS^*+#+TSZD$0>Q&$<7_"7=&=.K+_DO3.OF<1>>^8'MJ<2TS"3DM4KM/(?
MLX72DNKESPO!^EVPO@W6?R\8M5&Q*1'$$I0AN[>P@?-3LO'%R-@J@&C,I@)6
M%[!C!IA6Y])P,;#IYCO5L!PG+K6K0KE%=_IU+1'!_CM$:[ZVO':2\TB*=F%B
M%[BEIFTL)U=$_L ;A1E)P]2+T\SYA#5*5EI55E!M<L.::3+(TL@;90EDP\2+
MDJ%S!9$7I:F7AC$8.4Q"KQ\-X *_@X[?P7_F=\FXA"TK-W:%55.*/;YA]1R1
M%R-<(K(M=.>;[7U**ML2(RND?*+,.26TD3Q'0YF?A?]66YG40L$TGD*_@H$?
MA\Y,T4798G8^4GWDQG(K2F*XY'I/W%[WLA2N7U]JE!7<\!KVE$-U2T$3YY&K
MY][28.4UO4>E09IXD9]FU[W8[T>G'@J^Y052/O<<RP)"/PSA^E*6AEV6AO^O
M"P[I:&]E.LZYM%QT>3XMOVRJ!4H3Y4AV[T3Z7&O):9[DSJ\;K305+J]7P#3\
MS.H-C20XW#$0F^KU1HFM=K\_@I$?#DC.O"R)J7(3YY-)'3$6A:$7$DLFP?#]
M=Z,XBG\X/IU[5N<T;TCM)J+B[V=P"U'D4Q.]U7R#Y[4U#W"R=.B%%,'"22'U
M1RG)?:^?#+SA:$ 9M 5GKNPS]A%!IA_EVM06H4W]N$\R-6=F_)YOQ.!DJE0H
M5W9V*KJX-K5N!TRWVXWG63N57M7;V4YX5D0\E+@DT]!/J>-D.R_;A1:-G5$+
MH6GB67%-GQ@HC0*]7PJACPL3H/MHF?X-4$L#!!0    ( +J JU0A#ZYM$P(
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M"64(LKKEJ@>"[G6;LZ9"-DWZ=B?;5&!J@GR_H50<!PJ@;7P7?P%02P,$%
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MON]6W6A>]:]P^M=/Y[\!4$L#!!0    ( +J JU1_/=]I1P$  -@0   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T RSDJZD1<
MS<;MQ!L@6'XB4$([&;W[(;C C\QB-J9G1=J&TW?UA'#\,DWF:]NYJNY==&^;
MSJ6J\K[_T-KEE6DSM[*]Z<:3P@YMYL?E4.H^RV]9:33'<:*'UQGJ='R=&5T>
MO?G/1%L4=6X^;?[=FL[_,5C_V.'F*F.\BB[94!J?*GUOYFVGIP>MQLDJ.E]3
M-9ROI'3H((8@#A^TAJ!U^* -!&W"!VTA:!L^*(&@)'S0#H)VX8/V$+0/'W2
MH$/X((I1QEA T@)K 5H3<DT"O"8$FP2(34@V"3";$&T2H#8AVR3 ;4*X28#<
MA'23 +L)\28!>C/JS0+T9M2;!>C-BX]M 7HSZLT"]&;4FP7HS:@W"]";46\6
MH#>CWOQ.O9U_-,;-/<\UWO].JOWXKIFOGY;/S04[$\X:?F2<?@%02P,$%
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MA'8MC%3VX,^Z/S6S3U!+ 0(4 Q0    ( +J JU0'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " "Z@*M4/$P(MY\$  "5#P  &
M    @(&N%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MNH"K5%(YQB>*!0  :1L  !@              ("!@QH  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( +J JU1 5NW+_P4  !<8   8
M          " @4,@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "Z@*M4_$F?.J\$   4"@  &               @(%X)@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ NH"K5+^<'])1!   ?@D
M !@              ("!72L  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( +J JU1XD*QO:1   &@P   8              " @>0O  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "Z@*M4H0TR;>,$
M  !K"@  &0              @(&#0   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( +J JU3]%N*"B@T  &DI   9              "
M@9U%  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ NH"K
M5*.0?<2>"0  ,!H  !D              ("!7E,  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "Z@*M4%-!OX&T"   R!0  &0
M        @($S70  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( +J JU2\4RS5_A   /(U   9              " @==?  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ NH"K5$K<6*R! @  104
M !D              ("!#'$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "Z@*M4;P"<9C4"  #&!   &0              @('$<P
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +J JU1H60@P
MW ,  , (   9              " @3!V  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ NH"K5"$/KFT3 @  :00  !D
M ("!0WH  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "Z
M@*M4'T^\-KX#  "2#0  &0              @(&-?   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +J JU0?''I=O@(  ($)   9
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M970R-"YX;6Q02P$"% ,4    " "Z@*M4.AMM/LP"  !>"0  &0
M    @(&\D@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M +J JU3=KXG7+P,  *4*   9              " @;^5  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ NH"K5#3.D.G# P  ! \  !D
M             ("!)9D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " "Z@*M492AN-1@#  "*$0  #0              @ $?G0  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +J JU27BKL<P    !,"   +
M      "  6*@  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +J JU0&)2_R\@(
M  (3   /              "  4NA  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "Z@*M4?SW?:4<!  #8$   &@              @ %JI   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "Z@*M4VG)9V'@!  "Q
M$0  $P              @ 'II0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    (P C &P)  "2IP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>167</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Unaudited Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Liquidity and Management???s Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LiquidityandManagementsPlans</Role>
      <ShortName>Liquidity and Management???s Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - License and Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LicenseandAgreements</Role>
      <ShortName>License and Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/CommitmentsandContingencies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensation</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Liquidity and Management???s Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LiquidityandManagementsPlansDetails</Role>
      <ShortName>Liquidity and Management???s Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/LiquidityandManagementsPlans</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Commitments and Contingencies (Details) - Schedule of future minimum lease payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of future minimum lease payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - License and Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LicenseandAgreementsDetails</Role>
      <ShortName>License and Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/LicenseandAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable</Role>
      <ShortName>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Stock Based Compensation (Details) - Schedule of fair value of employee stock options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable</Role>
      <ShortName>Stock Based Compensation (Details) - Schedule of fair value of employee stock options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10q0322_tffpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Stock Based Compensation (Details) - Schedule of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofstockoptionactivityTable</Role>
      <ShortName>Stock Based Compensation (Details) - Schedule of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="f10q0322_tffpharma.htm">f10q0322_tffpharma.htm</File>
    <File>f10q0322ex10-1_tffpharma.htm</File>
    <File>f10q0322ex31-1_tffpharma.htm</File>
    <File>f10q0322ex31-2_tffpharma.htm</File>
    <File>f10q0322ex32-1_tffpharma.htm</File>
    <File>tffp-20220331.xsd</File>
    <File>tffp-20220331_cal.xml</File>
    <File>tffp-20220331_def.xml</File>
    <File>tffp-20220331_lab.xml</File>
    <File>tffp-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="224">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10q0322_tffpharma.htm": {
   "axisCustom": 1,
   "axisStandard": 7,
   "contextCount": 67,
   "dts": {
    "calculationLink": {
     "local": [
      "tffp-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tffp-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10q0322_tffpharma.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tffp-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tffp-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tffp-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 246,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 19,
    "http://tffp.com/20220331": 17,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 40
   },
   "keyCustom": 39,
   "keyStandard": 128,
   "memberCustom": 7,
   "memberStandard": 10,
   "nsprefix": "tffp",
   "nsuri": "http://tffp.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://tffp.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Commitments and Contingencies",
     "role": "http://tffp.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tffp:LicenseAndAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - License and Agreements",
     "role": "http://tffp.com/role/LicenseandAgreements",
     "shortName": "License and Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tffp:LicenseAndAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Stock Based Compensation",
     "role": "http://tffp.com/role/StockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Subsequent Events",
     "role": "http://tffp.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://tffp.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://tffp.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://tffp.com/role/StockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Liquidity and Management\u2019s Plans (Details)",
     "role": "http://tffp.com/role/LiquidityandManagementsPlansDetails",
     "shortName": "Liquidity and Management\u2019s Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://tffp.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding",
     "role": "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c39",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://tffp.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c39",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Commitments and Contingencies (Details) - Schedule of future minimum lease payments",
     "role": "http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of future minimum lease payments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c40",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - License and Agreements (Details)",
     "role": "http://tffp.com/role/LicenseandAgreementsDetails",
     "shortName": "License and Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c40",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c60",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:ReservedShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Stock Based Compensation (Details)",
     "role": "http://tffp.com/role/StockBasedCompensationDetails",
     "shortName": "Stock Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c60",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:ReservedShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:StockBasedCompensationExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants",
     "role": "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable",
     "shortName": "Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:StockBasedCompensationExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Stock Based Compensation (Details) - Schedule of fair value of employee stock options",
     "role": "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable",
     "shortName": "Stock Based Compensation (Details) - Schedule of fair value of employee stock options",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Stock Based Compensation (Details) - Schedule of stock option activity",
     "role": "http://tffp.com/role/ScheduleofstockoptionactivityTable",
     "shortName": "Stock Based Compensation (Details) - Schedule of stock option activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "role": "http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://tffp.com/role/ConsolidatedIncomeStatement",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://tffp.com/role/ShareholdersEquityType2or3",
     "shortName": "Unaudited Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "role": "http://tffp.com/role/ConsolidatedCashFlow",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "tffp:StockBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Organization and Description of Business",
     "role": "http://tffp.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tffp:LiquidityAndManagementsPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Liquidity and Management\u2019s Plans",
     "role": "http://tffp.com/role/LiquidityandManagementsPlans",
     "shortName": "Liquidity and Management\u2019s Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tffp:LiquidityAndManagementsPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://tffp.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_tffpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 18,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://tffp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r136",
      "r137",
      "r144",
      "r145",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r263",
      "r265",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r136",
      "r137",
      "r144",
      "r145",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r263",
      "r265",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r107",
      "r121",
      "r122",
      "r140",
      "r141",
      "r226",
      "r262",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r107",
      "r121",
      "r122",
      "r140",
      "r141",
      "r226",
      "r262",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r115",
      "r120",
      "r121",
      "r122",
      "r123",
      "r136",
      "r137",
      "r142",
      "r144",
      "r145",
      "r157",
      "r158",
      "r159",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r263",
      "r265",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r115",
      "r120",
      "r121",
      "r122",
      "r123",
      "r136",
      "r137",
      "r142",
      "r144",
      "r145",
      "r157",
      "r158",
      "r159",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r263",
      "r265",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_AccruedCompensationLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued compensation.",
        "label": "AccruedCompensationLiabilities",
        "negatedLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationLiabilities",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_AggregateIntrinsicValueExercisables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AggregateIntrinsicValueExercisables",
        "terseLabel": "Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "AggregateIntrinsicValueExercisables",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementAxis",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_AgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description related to agreement.",
        "label": "AgreementDescription",
        "terseLabel": "Agreement description"
       }
      }
     },
     "localname": "AgreementDescription",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_AgreementTremDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementTremDescription",
        "terseLabel": "Agreement term, description"
       }
      }
     },
     "localname": "AgreementTremDescription",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_April2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April2019Member",
        "terseLabel": "April 2019 [Member]"
       }
      }
     },
     "localname": "April2019Member",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_AssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AssumptionsAbstract",
        "terseLabel": "Assumptions"
       }
      }
     },
     "localname": "AssumptionsAbstract",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_CashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CashAndCashEquivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LiquidityandManagementsPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_CashlessExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants.",
        "label": "CashlessExerciseOfWarrants",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "CashlessExerciseOfWarrants",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ClinicalTrialResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ClinicalTrialResearchAgreementMember",
        "terseLabel": "Clinical trial research agreement with Nucleus Network Pty Ltd. [Member]"
       }
      }
     },
     "localname": "ClinicalTrialResearchAgreementMember",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_CollaborativeArrangementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CollaborativeArrangementsPolicyTextBlock",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsPolicyTextBlock",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tffp_CondensedConsolidatedStatementsOfComprehensiveLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CondensedConsolidatedStatementsOfComprehensiveLossAbstract",
        "terseLabel": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "CondensedConsolidatedStatementsOfComprehensiveLossAbstract",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_ContractManufacturingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ContractManufacturingServicesMember",
        "terseLabel": "Contract manufacturing services [Member]"
       }
      }
     },
     "localname": "ContractManufacturingServicesMember",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related to Conversion of Series A Preferred Stock (including accrued dividends) to common stock.",
        "label": "ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock",
        "negatedLabel": "Proceeds from issuance of common stock for warrant exercises"
       }
      }
     },
     "localname": "ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "EffectOfExchangeRateChangesOnCashAndCashEquivalent",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalent",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ForeignCurrencyTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency translation adjustment.",
        "label": "ForeignCurrencyTranslationAdjustment",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAdjustment",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ForeignCurrencyTranslationAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency translation adjustments.",
        "label": "ForeignCurrencyTranslationAdjustments",
        "negatedLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAdjustments",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_IncreaseDecreaseDeferredResearchGrantRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseDeferredResearchGrantRevenue",
        "negatedLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseDeferredResearchGrantRevenue",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_InterstFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interst fee.",
        "label": "InterstFee",
        "terseLabel": "Interest fee"
       }
      }
     },
     "localname": "InterstFee",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_IssuanceOfCommonStockForStockOptionExercises": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfCommonStockForStockOptionExercises",
        "terseLabel": "Issuance of common stock for stock option exercises"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForStockOptionExercises",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_IssuanceOfCommonStockForStockOptionExercisesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfCommonStockForStockOptionExercisesShares",
        "terseLabel": "Issuance of common stock for stock option exercises (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForStockOptionExercisesShares",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises",
        "terseLabel": "Issuance of common stock for warrant exercises"
       }
      }
     },
     "localname": "IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares",
        "terseLabel": "Issuance of common stock for warrant exercises (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "tffp_January2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2021Member",
        "terseLabel": "January 2021 [Member]"
       }
      }
     },
     "localname": "January2021Member",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_LicenseAndAgreementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Agreement Disclosure [Abstract]"
       }
      }
     },
     "localname": "LicenseAndAgreementDisclosureAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_LicenseAndAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LicenseAndAgreementDisclosureTextBlock",
        "terseLabel": "LICENSE AND AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAndAgreementDisclosureTextBlock",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tffp_LicenseandAgreementsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Agreements (Details) [Line Items]"
       }
      }
     },
     "localname": "LicenseandAgreementsDetailsLineItems",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_LicenseandAgreementsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Agreements (Details) [Table]"
       }
      }
     },
     "localname": "LicenseandAgreementsDetailsTable",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_LiquidityAndManagementsPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity And Managements Plans [Abstract]"
       }
      }
     },
     "localname": "LiquidityAndManagementsPlansAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_LiquidityAndManagementsPlansTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LiquidityAndManagementsPlansTextBlock",
        "terseLabel": "LIQUIDITY AND MANAGEMENT\u2019S PLANS"
       }
      }
     },
     "localname": "LiquidityAndManagementsPlansTextBlock",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LiquidityandManagementsPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tffp_LiquidityandManagementsPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Managements Plans [Abstract]"
       }
      }
     },
     "localname": "LiquidityandManagementsPlansLineItems",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LiquidityandManagementsPlans"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_LiquidityandManagementsPlansTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Management\u2019s Plans [Table]"
       }
      }
     },
     "localname": "LiquidityandManagementsPlansTable",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LiquidityandManagementsPlans"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_MasterConsultancyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MasterConsultancyAgreementMember",
        "terseLabel": "Clinical Network Services Pty Ltd. [Member]"
       }
      }
     },
     "localname": "MasterConsultancyAgreementMember",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_MasterServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MasterServicesAgreementMember",
        "terseLabel": "Master Services [Member]",
        "verboseLabel": "Master Services Agreement [Member]"
       }
      }
     },
     "localname": "MasterServicesAgreementMember",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_MilestoneFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone fee.",
        "label": "MilestoneFee",
        "terseLabel": "Milestone fee"
       }
      }
     },
     "localname": "MilestoneFee",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_OtherComprehensiveLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherComprehensiveLossAbstract",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveLossAbstract",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_PremarketingApprovals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PremarketingApprovals",
        "terseLabel": "Pre-marketing approvals"
       }
      }
     },
     "localname": "PremarketingApprovals",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsFromIssuanceOfCommonStockForStockOptionExercises",
        "negatedLabel": "Proceeds from issuance of common stock for stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockForStockOptionExercises",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ProceedsFromIssuanceOfCommonStockValue": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "ProceedsFromIssuanceOfCommonStockValue",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockValue",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ReceivableDueFromCollaborationAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable due from collaboration agreement.",
        "label": "ReceivableDueFromCollaborationAgreement",
        "terseLabel": "Receivable due from collaboration agreement"
       }
      }
     },
     "localname": "ReceivableDueFromCollaborationAgreement",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ReceivableDueFromCollaborationsAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable due from collaboration agreement.",
        "label": "ReceivableDueFromCollaborationsAgreement",
        "negatedLabel": "Receivable due from collaboration agreement"
       }
      }
     },
     "localname": "ReceivableDueFromCollaborationsAgreement",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ResearchAndDevelopmentTaxIncentivePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ResearchAndDevelopmentTaxIncentivePolicyTextBlock",
        "terseLabel": "Research and Development Tax Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentivePolicyTextBlock",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tffp_ResearchAndDevelopmentTaxIncentiveReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax incentive receivable.",
        "label": "ResearchAndDevelopmentTaxIncentiveReceivable",
        "terseLabel": "Research and development tax incentive receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveReceivable",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ResearchAndDevelopmentTaxIncentiveReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax incentive receivable.",
        "label": "ResearchAndDevelopmentTaxIncentiveReceivables",
        "negatedLabel": "Research and development tax incentive receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveReceivables",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_ResearchAndDevelopmentTaxPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax percentage.",
        "label": "ResearchAndDevelopmentTaxPercentage",
        "terseLabel": "Research and development tax percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxPercentage",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tffp_ReservedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ReservedShares",
        "terseLabel": "Reserved shares"
       }
      }
     },
     "localname": "ReservedShares",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of employee stock options [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfEmployeeStockOptionsAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum lease payments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of potential common stock equivalents outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPotentialCommonStockEquivalentsOutstandingAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock-based compensation expense stock options and warrants [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockBasedCompensationExpenseStockOptionsAndWarrantsAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_ScheduleOfStockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "nsuri": "http://tffp.com/20220331",
     "xbrltype": "stringItemType"
    },
    "tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted-average period",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm",
        "terseLabel": "Weighted-average period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber",
        "periodEndLabel": "Number of Shares, Outstanding, Outstanding ending balance",
        "periodStartLabel": "Number of Shares, Outstanding, Outstanding ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise prices, outstanding, beginning balance (in Dollars per share).",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice",
        "terseLabel": "Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "tffp_SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tffp_StockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation.",
        "label": "StockBasedCompensation",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "StockBasedCompensation",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsLineItems",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and warrants [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_StockBasedCompensationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation expenses.",
        "label": "StockBasedCompensationExpenses",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenses",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tffp_StockIssuedDuringPeriodSharesStockOptionesExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "StockIssuedDuringPeriodSharesStockOptionesExercised",
        "negatedLabel": "Number of Shares, Outstanding, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionesExercised",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "tffp_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockOptionsMember",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingLineItems",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of potential common stock equivalents outstanding [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpotentialcommonstockequivalentsoutstandingTable",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tffp_WeightedAverageExercisePricesOutstandingOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePricesOutstandingOutstandingEndingBalance",
        "terseLabel": "Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePricesOutstandingOutstandingEndingBalance",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "tffp_WeightedAverageRemainingContractualTermOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingContractualTermOutstandingEndingBalance",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding ending balance"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermOutstandingEndingBalance",
     "nsuri": "http://tffp.com/20220331",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r215"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r242",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts payable due"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r22",
      "r24",
      "r26",
      "r27",
      "r192"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r23",
      "r27",
      "r30",
      "r31",
      "r32",
      "r60",
      "r61",
      "r62",
      "r184",
      "r209",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r10",
      "r215"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r165",
      "r166",
      "r167",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential common stock equivalents outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r6",
      "r58",
      "r96",
      "r99",
      "r105",
      "r111",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r178",
      "r185",
      "r193",
      "r213",
      "r215",
      "r240",
      "r250"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r15",
      "r58",
      "r111",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r178",
      "r185",
      "r193",
      "r213",
      "r215"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r59",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r5",
      "r48"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r48",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r195"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r243",
      "r255"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r124",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r215"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.001 par value, 45,000,000 shares authorized; 25,371,781 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Assignment fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development tax incentive"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r46",
      "r95"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r160",
      "r161",
      "r163",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r36",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r73",
      "r75",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r190",
      "r191",
      "r246",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense (in Dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r30",
      "r31",
      "r32",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r84",
      "r112",
      "r138",
      "r139",
      "r165",
      "r166",
      "r167",
      "r173",
      "r174",
      "r189",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r209",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable",
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "auth_ref": [
      "r194",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.",
        "label": "Foreign Currency Disclosure [Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r114",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid assets and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expenses"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r58",
      "r100",
      "r111",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r179",
      "r185",
      "r186",
      "r193",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r58",
      "r111",
      "r193",
      "r215",
      "r241",
      "r253"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r44",
      "r47"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r28",
      "r29",
      "r32",
      "r34",
      "r47",
      "r58",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r71",
      "r72",
      "r76",
      "r96",
      "r98",
      "r101",
      "r104",
      "r106",
      "r111",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r191",
      "r193",
      "r244",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r28",
      "r29",
      "r32",
      "r71",
      "r72",
      "r182",
      "r187"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r96",
      "r98",
      "r101",
      "r104",
      "r106"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Year Ending December 31, 2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r25",
      "r30",
      "r35",
      "r170",
      "r175",
      "r176",
      "r196",
      "r199",
      "r201",
      "r245",
      "r258"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r39",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Research and development cost expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "General and administrative (in Dollars)"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement",
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Component of Operating Income [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "OtherIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r215"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Deferred research grant revenue",
        "verboseLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet",
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Research and development additional received",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails",
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PercentageOfWeightedAverageCostInventory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of weighted average cost inventory present at the reporting date when inventory is valued using different valuation methods.",
        "label": "Percentage of Weighted Average Cost Inventory",
        "terseLabel": "Outstanding percentage"
       }
      }
     },
     "localname": "PercentageOfWeightedAverageCostInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid assets and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid assets and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r28",
      "r29",
      "r32",
      "r42",
      "r58",
      "r63",
      "r71",
      "r72",
      "r96",
      "r98",
      "r101",
      "r104",
      "r106",
      "r111",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r177",
      "r181",
      "r183",
      "r187",
      "r188",
      "r191",
      "r193",
      "r248"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedCashFlow",
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r113",
      "r215",
      "r249",
      "r254"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r143",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r143",
      "r210",
      "r212",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and Development Arrangement [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r169",
      "r225",
      "r275"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Recorded research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement",
      "http://tffp.com/role/LicenseandAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]",
        "verboseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LicenseandAgreementsDetails",
      "http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandwarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r5",
      "r53",
      "r239",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r139",
      "r215",
      "r252",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r112",
      "r165",
      "r166",
      "r167",
      "r173",
      "r174",
      "r189",
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r33",
      "r58",
      "r93",
      "r94",
      "r97",
      "r102",
      "r103",
      "r107",
      "r108",
      "r109",
      "r111",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r193",
      "r248"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of potential common stock equivalents outstanding"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of employee stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense stock options and warrants"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Prices, Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Number of Shares, Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Intrinsic Value, Outstanding ending balance",
        "periodStartLabel": "Intrinsic Value, Outstanding ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Prices, Outstanding, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Prices, Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r54",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r21",
      "r30",
      "r31",
      "r32",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r84",
      "r112",
      "r138",
      "r139",
      "r165",
      "r166",
      "r167",
      "r173",
      "r174",
      "r189",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r209",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable",
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r84",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Sale of common stock, net of offering costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "IPO shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r12",
      "r13",
      "r58",
      "r110",
      "r111",
      "r193",
      "r215"
     ],
     "calculation": {
      "http://tffp.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet",
      "http://tffp.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SurplusNotes": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instruments issued by insurance entities (surplus notes) that are includable in surplus for statutory accounting purposes as prescribed or permitted by state laws and regulations that are liabilities of the issuer.",
        "label": "Surplus Notes",
        "terseLabel": "Working capital surplus"
       }
      }
     },
     "localname": "SurplusNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/LiquidityandManagementsPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ScheduleofpotentialcommonstockequivalentsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r74",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://tffp.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30885-110895"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "470",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486086&loc=d3e24387-158525"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r276": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r277": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r278": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r279": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r280": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r281": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r282": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001213900-22-025580-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-025580-xbrl.zip
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MK(H/=SXXQICY$P-6/?]YQ SS7%'Q__T<6('-SM6?/_!_*,K/8Q88ZL!U N8
MUP?L1_"!OPA7K[ _0^OI[R<7_/O* Q#R1/T <N$#7_7GOFM.SW\VK2?5#Z8V
M^_O)$![]J.K52: ^6 "$>L.>U7MW;#@:_T!3>\RSAB?T*X3@ _[WYTG9!3ZI
M8\-[M)R/*CY:_:0B[!7#MA[AHP% RSQXQX?)S'M0_GVVF W2[SZT6>7.>&0H
MZI)[X M7 G?R$1<6?_;=('#'],FS908C!++ZT\G<[BN^]1>#+R?!)[7O>B;S
M^$J_V,;@NUH#8'W7MLSH2[DN_UZ7WY^<__=_Z:WJ)P'W'/0?YL#?-C(E/+,H
MW1+I^N??;JX?KB[5WD/WX:KW\X=^!CFW]N[>U<6W^^N'ZZN>VKVY5*_^]^*W
M[LVO5^K%[=>OU[W>]>W-C@'ZW?!'H!H$+OS^\O3B%"[I9N-LET#LG/Z?;^^_
MJC];/SXZKG,3CN&G RZJ?@3W;/CWDP&H3"CI_GX":L7'2W< SS@!":ESO5KY
MY\\?4K\]?]7(6H(GKF/\_03TDH]#ZP<S*X$7LBS\_3,T/%C4GMZSB>L%N)6S
M=J/U:1:;ZC^_=>\?KNZ__%N]O[J[O7]0[[[=][YU;Q[4AUL5SL\#'!)%KZNW
M]ZK>?&>^5V\_JP^_7:F)HQ4=J^[% WZMG]4;KYI*GUU/#49,C9"LWL'/75.]
M<DQ0QDL0T005OC*&!T9(PHII3"M39G@5YF01E;\%7G()/SLY_VIX@Y%:U[7R
MQ^NSY0\,^]_PJL_PB7]RCGK=_$E[0R?O]OY5;Z^T8!D:MI\I6<ABM=#028F6
MQKQH>;COWO2N48 <94MIV1)$:%8G7+@,/3#_.3SK_Z\2N!M;Z_15$^3"'8\M
M'_T[ZM"RF>J$XS[S/A:7N5<.V&G3S_#;&_KIR3G8CI7ZF5[-D+@'C$AA:J'%
M-&MLX6>9Z+7&CZIA@^ Y47UO /)G#*;0?P _IW],'D\^'"XR%G-5.=:Y9X^6
MC_(@N(%OB"D?/G]6[W[KWG_M7EQ]>[B^Z'[I:>JU,Q!'<9:K=K.M=U<_C$%
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M!S=QC(N8>@4'EJY$U>W<3ONK$^X5,"\I0R-GSD28M6I_FFEF'/[I+RHP\\?
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MGR(?$LJ:)Q2@ZY&1%(?OX0N7/'V(GP ,"R SO _^AP@:@"T[!/TE0!H"SP
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M1JC"2<T$EXEV3_NAT :J=AHYFKG?G;O9HDQ24GKG<):<,S #E"* .IN=@TG
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M$7=M>6L]WE6MT8AWU>D<_-'?P>%OKW;XMYBW?.O <7^$O\ NTX0,R/=5*CR
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MZ>A4J-I*&21V(<,Y<4A!1'!GF19.'? DG4@Q1P]9T%PEXD1"=MX^>Z;H;'"
M<_@VQ2+-#;/<IB;UT;OZL];*?73-D!K0Q>&QJ4^^X;73Y8'TZ=L8X+?927UX
MLN%0_=SW/IP+-RK_-_E2RP%SH% 7'1YXP+,624KREX*HY*C*&D.XVO3% \:
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M^E801;3D&0)A:(-"*K(2J 8W,3*0P)3QY4=N.=I3E6'DE@= )-18OYB&#;]
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M7G8^2#'YA8;G+%6N&$WH,I K*@%PF488&1C^B ^U1=8U[.P!7PX+XE9_?X9
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MX*8E6SR?II_>6)4_->#\W,2;F,A_<#XF>HZ!H"0*D02US 4;!3LE]H=18D7
M<FX]-E(Q>=3*B(- =B#F.LLT'93/$$M((K>)Z_ *@H-VEZ2A-J"1DJ^80L/
M1T0^+:I@@6Q*G0G.>#^Z*"@369L+G[H#3DWH.@U:QH/FR_0-Z4@#EU*'DV+
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MP<@726#Z; #6@$))>WP#7%"B\J2&.<FE\(T-U>+17Z$R8-1FZ5R[S*641/@
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M44Z.Y^AP?A!7A[PV?I@(<\$0[G]1>2OK\,!/IZT0]E\#OU.D+"D\I5Z/8>A
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MFKG+H/ EOL0D:T\:=TGNJGHM3O.9HBDADZVU<78]3*V:0R05R")BE5(@2?X
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M!N3U=?79[P[76 ]0N&._P1P4Q )HE]T&[=*@71JT2X-V<=$NNPW:Y>FB79[
MAL+_>T\/Z?_OYX./!^>B=\\O\R C5A>ZPS54UF/WU(G[@MO/>0HHP:P^@CS[
MQ@;85!MA,K@F+\60-QAQ$[3C.,"5RJ%,21^%<1E0,QMC@]\YT@Y73:DU."IZ
M_D@&7=&+(A/Q,FU"5SA -N]-3.3)WF+05QE=<?W]11QA),X-Q_/.1D"?JS"3
M=Q=_64P:;I%GLV3V_?-)MMGJ+A0&WI?#,.8)79T<&HM$-*32#@91C*47TT*>
MBD&1A3%)>9RC.31&%OE\Y,5B=_/OU4P52:D,LS?QNH6+L^K]0^=.RG.9N1F1
M,9QD,N?1WLSCZ(;KGW;G +LG.;?6HIZ96SQ,H<*\E*"VUL)U[N5\9<? (4Q7
M,E<^0-3Y"0^NH<[XG\)+<Z3.,&/<;M$@<T[0" 9E8PP7C\2$P+Z9KD:#YR&^
MJ-I6"<"A8[CS1MLLG"PO!NH9>$,JDZ')LO+1EP@;'*.YN$&[M2:,YX"-+%0%
M$Q+&J8:QI]%>I3M6:X;_E%Y:LX1P1+:V%YY;;,696'ZO'YI=!0G"Q=S,[K*S
MVR<T$>@_L5_>_=S52SBHF2DMW[K48GUH@_ !!_23%Z;BBY=^DSF[(>>,J>]E
M(T11.N598'\N8D];(D$'/NE<ST$Q!7UX12FM$V]*-8+A_]*Q 9U%,KZ !9AY
M$451/,S*1" GID["WL99E%A0,\SEN-W*T-Y5P+G,&TOQ;\S_!;.AXR#;Z ?"
M?"KT?NY\#:-%7TXBSU\-0X)\'S,:4%#V[!!_N_N<U*<X#+\G<(R)YQA4J*.]
M"]#"($B!G, ^KI4OIWT@@-F!8Z%LG^54S 6^[(VA9[ZG537]8#R/JS&V:0(&
M?*EJ4XW^P/,ZZ0]<?W$2;]0HDS79O>AVL/)?D8:(L[S#S(TG-VQN-2H?CD!U
M8P82FH\2SN_GJ^! AGD$FAN 4N<S@NG[*.+Z7 5:/(0S '(!K(0,5DM[U0UF
MC$EIIKPD,A4E,:YSI)7@484.%4,86,H,A&'MT-8$=AQ8#2G7JZ2M"HS!,68V
M5(<=GN ,O&6)H$-TNX4'8<PDP3/O!4Q250+87F2=,Z>DVTN<Q47BHZ\_B.,)
MG6;?XV.5T=8$39N@:1,T?;E!T][&;<*F6TW8].F&39_<[E-C0T [EZ%?=PB>
MR)3J!<6^/K#RI6*H7#UE>[9NH\?-O*-/"]:,&];8 UWDLD9"IY3.N*DB(U)Y
MK\S;I/U&U4=4"E!BDJ<M0LF>*;<,I4WGQC> ,S7F)SD]4D/R@JV0&3FH"ZOH
M%##MFX 3M'$MN<G!C^!4>O(#FLQSQ%X_H,ER+O65&- O801&!9Q>3+'MFL/V
M$).@RZ-:OF_&HXUES+WU9H21QD#F6I-R/=\Y'M$:WP?SG9 O2/DU9W4S@0_P
MDB'8^,D5[A+HXLPL89Z7YVDX4$0HFN%0M4=,%[K1=LNT2L%31%<@)P9,NN]X
M44D$$O:=AO%EHC<M:HL:QDT%SB @')7<YDYUYW#+%^O%FB&Y9?J^W4()0A8.
M9 C6B?L#KGQ,W)?0HPM,ZI?!![$V6*<3-31[B0<YS) F'W+&W5&L*]YW12-Q
M8;QXPH<SR(7;Z,0+X4[YW8^*@+@0$+""/E^\&Q[EK^M#.[8DO].?04'9O*5&
MX-I@'3D(T0;L"$HHQ8L[\*O_C39TY&' KY'U)LZ*E.R!VAZU6[C3XASC^U(<
M5JZK]_+&:HST#:D<HA\;7D/=07Z*5 ;D<@P*$H14_L5K-F-JA[Q(,<0+HJ(2
MU'TIB0B2"!C D UC+\+1H#D/U%-?\"+N!1SWQB$EML9Y5A#-34F62>YFEBL;
M2S/.FJ'BSD *C!"//_!$)"6=),AZHIW'""6BR(< :2E80= Z-087SDQT*9'<
MD]8AMLNH"\_4&0\SDB85YM";X4YW6^7ISZ@K!9""TWF"R"U8$Y*"+S3Y HY$
MT%>E57P8.!CU=$I+$3DU0R/-1-CI$64/QG!PGQXF3IRE;JBJ ]71#"AD(X/$
M>AE,#JHU';X1!1/V\!@B%BN)9#1E!EB8J%QQA&*O\7(DYDX3.]@=E)!O4E\6
MR#':L$H;VXM0VTE)*]@J$H]HF]($](]V/W_MGJ'EG?#Q?3\M0)GT@G$8AZ91
M/X)/&)@")>U%ZXIF0J:*D:4RIH*&U% JR+G3-9@[24Z$KMTBI]<+7L'E;;BZ
M_;JF8Y[@!,*6.#NB.'=TNSJAT;>K,VCN6R]ANQ@*D_E&C&IZOA'3N=F*(5+E
MDAECFWT,*P:4;\F,$8]DQ8#V+9LQHFS%D 'AWZT!L7&5I-_J+ A>8MJ$$*MC
M03A+*8DW3M4>;.0%IV4VV@EWY(LOKRI]D+(EC(CR^BN[:,*XXEY2!S421(.?
MB#1-CX5$E(D.U]@>@+?H:&)Q$87CD-G!.H9A'"V8B<8<!;CWX4JF X[$H1TR
MR1:,+>S<\/_FQE0QC?-2C(OLE[$^=Z)\4SF?;)T%S@JZ%F8S1+ BTR*.\3<V
M@T)\JH<QO&%(W$,I(T]Y,1#=9$$\GBG>,_ RUA6S6P-R.LTH2<?NJN&HKW1E
M.FN)L;..:)Z0!$F["(.D&,#189X@M5ME 6$[@,U"MMI@!#V!A.*LE&:&I"13
MKCR!)6'%Z=K1P"_;K?)H&"VL7GAC('E<#0T>1IYGS5%4AF!R@6++E-U# SM#
M' ?BX'^SLV=#_NT6OSWIH8P@%C/P)(-H#=>-W)!]C%^3,4ERE3%$EFG?%9'[
M0JY3QXHUXU)RJ#Z@\@,MI/7?Q]\>]+&E!UX3FWW3A&&;,&P3AFW"L.4P['83
MAGW&8=A'VG:LZ3U_F=8>9M$Y%?I%Y*6+I2'.2PQTDQ,54:>3]TBICF[RXTJ<
M@DKGASF>F!E"447%#H8<FJT\153-C '8W*0JI,-#'\$9@\L0+1SMX\,WF\SQ
MALG^1(=WW1.XQA(52 +3-$D5+[%"!NI[W7MNURE]3">4=1#JAF$FT'49QNP'
M5D<D\EU0I\C8+5VQ ?H#)1L/0RB9E"47L5MV]CWH\($JB>B*G>'^!4\\-0-B
M^>U3296D,D09P+:C\TO(>9OC4873A_D&? 3("O$VPWZ#'=2^B6"=1U,]6^7_
M0<LENG9B[Z_K;:EW<*(B)Q2"]O%Z_&]0I#JV@1C_F?R7CB *;%U]P3)]PZ(%
M13QB/2$S6_B!T105"OIB0NDC5 X+!( .UUBTH$:FK#1G<ZMNK8:6H"/?04VN
M0;LU*N!!%:_Y+.:%H3'&/:&\?"%F@Z#FY0MP"9(:IC:SCL+1P%WAQ 9@L'%#
M[@X7)P-T4;1;68&<72$1/\<$Y>$LE@%Z06C>^"E&C7$5=#_Y%L82-A@UW^K+
M*+F@]V%Z8\Y Q^0L;BJ02*J,/=$TR'H 0/YQ!+2/1(H+&<N47'CDX<E(=FC%
M;&^)O4^GXF<X((-BV=G:[FYCD+X+Q_0P4 ,Y]J;8"-*;0]=96S$8"=9G>O<5
M*9ZP],V*'\;5%A>_Q:1I['V3Y(F2Z#B+,<X32#<MC_0>*7;=;@@=R;RAB@6"
MPB 9G"03,%G8J:9<@!@&HT.+=A\;Z177"J_[M/^3H4C"N_K36IDD]WM5*,6/
MR>2@D<EY,OFC0MG19BM=0C4;<1;)#&"O()YM![!3C93?;E:NX2X2/P(_L&R$
M29%QC+4J=VQ6!4BO(+$( WH<,RSY(WVOL-N>%^!I%3DX/-\QL,B$SK+$IXQ
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M)5-QEI085US^ :Y.)5,+? E"F-TL+!=FG(-%L1A)BU4J(\+">C@0(=_;+0N
MK.(?NZ)W3;9*;1>N0@8L![A;!$2G$$EB6F)/$[GKY^+;"'N/W[@ -P.WXI"(
M^V8KH2O.<)TG2"9QJN%*UX<],9H%9A?Z!J^[5WP][VV]W=C<W-S=?4W$6(%
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M.:G[=1,G:N)$39RHB1-5XD1;39SHF<:)&D/Q6D-Q*:#T)Y5:](F\!RL4#3@
M,RY '*BE\D0SKC-K6RE*4,Q:&_RE&$P=#K^!EY*M"-U UPT>HMA*)/^T2=UR
M_=36-9\@.SC\3DA,BU(J)==6L,KHG<#?3=7IJ5N/E!U2!E3$F"SUGG"H9">1
M<:+#+5B"<+:3V!4"ACN .&,LEXQIXW^:#4J470=! NVBK\,?)?A0S/BEP=*6
ML\(\UM3==CHW=3")Y%Q(.(E*^PP<7U>IL&L%[UGRK"G^.QA0.@9DF(@R>W!
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M3UUQGO!FK :"WGKN\&6)<]0W'"&<LFP(D<A>X)TF2+#N/677AFE>2$- 9GN
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MDAB/,HJ.$V-=E97V67JXL#)5*A<]_#)0CK<8#/=0<L0 88JE"KT#R1E/7/T
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M:KVQ^!DXD56MN@C\>?]XX 1XKI3TD^)7NZ6ZKB@^?=X"DQ9%Y A4<\60A)/
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M=!KXTX#_?0". 5)&PB@>SA*Q\U*E4HA-KQ#$FLC76E2.OA<JYX$-&)Z''_*
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M;,!SG %HN< 9Y B;@>^-'.2_ VL#[.4)_CF_'1:N2$^M6+9D+WVS7&PYO^T
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M;,O8;\K8YPTQUHM05&99FJ$LS>0(Y:4$B8$*0X&'.V;7!FN7<0T6"HQQT9=
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MI$@GE+@NFY?6$TN;!<FM! M-"Z6F31$>G$?ETC#30T39V%3;]Y4.K 6VZAQ
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M,>QHPJU66/#RKP4BR%SLO&J%Z*,@"U&[ORW/#$AQ__P;,0UE3/X#4$L#!!0
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M7N6I B^$4DP\^5-:WF_]2);_#U!+ P04    " "Z@*M4"W$_'>0(  #'40
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M75W2!U(3*/V_[>29I064@E"Z>A09'DS=.;24;C9O:/,'-#RZV,$^6^WRKM3
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M),JHW\>M.)KPYIAQ8D<EV,_^'U!+ P04    " "Z@*M4O8Q\#;E/  "Z^P,
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M$)Y 43$:X7QX*2,6Y(/+G[IDL!'4/$?*Q3)YNXR2R62BML.K?]@2B@H(CEC
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MK6G6^<&!0E(\8 +H+3#%\CW#90Y3+EJ8:OH^&DM2=6<5TRZ$H3N&QLM9V**
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M.(\=2.NL;[ZPH .#^/'JVV:6C>UWJIMLX3Q.7<-+4Q X;Q5/(A3BO2S4C K
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MJXB^K"?2KEUX),0/UT'T 0'>*"6_=#R/OH( Q4G.UD]ID5*8QO[]CIXO1!.
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ML5D0*,UU5JL^/0V:L)FM0U>#>:,J;[PR\RHDY__1W[\=_[/ELHS9+9_%F\Y
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MQ5KH?H]>P'*$92]K7VWMBIZ+7:Y.!:8JIDE+LSI:M-GX63D&9'I$(4"&B8[
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M6'20,:D#U/*;%F'V]-QC%'@X3K)Z,X6D5.H%S69QTE+LIG<)\6-Q1HTV1K^
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M$SD>HA@&"X(B^36+O>0[@#8T\5WSRR7=RBP6+E!4H24T2K?\6X"^,)AYZ(^
MKO9ZP\.FPN>A3+:HLY?;\*=M$TDUWX0BCL_(IL;,AC+8&!;@IEQI>'QD-P,
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M9#)Y=N@JIDJ1%'GB![1V":OTFE#V!>W.8+6 ^V%%];P!:]<G)[(;;".2S"
MD%067K\VH1POX"JL9./L<3)^N7605PZQ)_ZN@AWRU5'M_5U"TC[HO*&_@4DW
MY6'VP\M5<@2P+*J=E"+U@993&FHO<CLU3&DQ*1XJA)BL#-N^##Q*?>W0#=[]
M* NO7_M1CA>0$]7EA'.]0F1!8Y>WQ'WTE^R&R' @@H9RN'W("]7R1<\D\93^
M+)%MPTDI ZX?FU(9'P#'8$M:T5/83 LSRB/W"V%"1:#]<G9E7 $;@-TB=OAW
M8! *S-Y&)S>0R"$/LQ_&5,F11$P F0?I&XF=[@"*J0"T+Q95S95$5$#3 203
M#G=!0T-%D6Q##*PG9]DB$Q*1M,XSR,F#30LA5#E"LEE2"EVQ)^9D>^5:$-??
M]?![<6+B8E0B1BWIB(C"J?%T:]$UA2-&POI4*#NK@MP7A]C G^0^5T=E0T3:
MP+(H][SX'[:.<P"QE4'MD<65,B61E<8<19&N"R7"NNBWL"[VPNJ\KW.!KBOZ
MXSV9NH]U;[L$196"V8\(OI(CB9RT54K$-(7;ZCT9$W>#'1,B_*@ W$-Y%7B3
M"$U;(B,F;.QZOF'_BM= $6,IV%Z%]^6,2>35.ILA7#;&2"+(:"V?#* ^I&>S
M*T\$T#Y/(2J!D<NN6I:N W'T+0#KB6T4F9 (I'4V0E0>$V0&A.K&^<5LBOV6
M[QD*P'HBCR(3$GETGHI(2+E^,I?L(5KKTOM2@+V(ILM9D4A&8W8A;#[$)H!L
MT-#PC>;1Z?P9HE+ ?0K1JGB3%"##U#Z4/VW[\901Q%[DL?_[?U!+ 0(4 Q0
M   ( +J JU24M/?*EIP  !23!0 6              "  0    !F,3!Q,#,R
M,E]T9F9P:&%R;6$N:'1M4$L! A0#%     @ NH"K5&K,(<J_CP  "RL% !P
M             ( !RIP  &8Q,'$P,S(R97@Q,"TQ7W1F9G!H87)M82YH=&U0
M2P$"% ,4    " "Z@*M4'"V-BT,'  #_+0  '               @ '#+ $
M9C$P<3 S,C)E>#,Q+3%?=&9F<&AA<FUA+FAT;5!+ 0(4 Q0    ( +J JU0,
MGXBI3P<  "$N   <              "  4 T 0!F,3!Q,#,R,F5X,S$M,E]T
M9F9P:&%R;6$N:'1M4$L! A0#%     @ NH"K5!;^B2"0!   :Q4  !P
M         ( !R3L! &8Q,'$P,S(R97@S,BTQ7W1F9G!H87)M82YH=&U02P$"
M% ,4    " "Z@*M4VY%,F^\*  "7"P  #0              @ &30 $ :6UA
M9V5?,# Q+FIP9U!+ 0(4 Q0    ( +J JU3?@K@7)PX  +:"   1
M      "  :U+ 0!T9F9P+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( +J JU0+
M<3\=Y @  ,=1   5              "  0-: 0!T9F9P+3(P,C(P,S,Q7V-A
M;"YX;6Q02P$"% ,4    " "Z@*M44,A2:?0A   'WP$ %0
M@ $:8P$ =&9F<"TR,#(R,#,S,5]D968N>&UL4$L! A0#%     @ NH"K5+V,
M? VY3P  NOL# !4              ( !084! '1F9G M,C R,C S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( +J JU1R%B!*CR(  .0! @ 5              "
M 2W5 0!T9F9P+3(P,C(P,S,Q7W!R92YX;6Q02P4&      L "P#R @  [_<!
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
